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 Proper placentation is critical for normal fetal growth, development, and 
fitness throughout gestation.  This research examines the central hypothesis that Dlx3 
and the gene targets of Dlx3 help to direct normal placental labyrinth morphogenesis 
in the mouse placenta.  Further, misregulation of key features of this gene network 
appears to be correlated with changes in gene expression associated with the 
pathophysiology of preeclampsia (PE).  
 Yeast-two hybrid screening of a placental cDNA library identified Smad6 as a 
binding partner of Dlx3.   Investigation using immunoprecipitation assays mapped the 
Smad6 interaction domain to Dlx3 residues 80-163.  Further, studies indicate Smad6 
has the ability to repress Dlx3 transcriptional activity on the human glycoprotein 
hormone α subunit promoter in JEG3 cells likely through allosteric interference. 
Gene profiling using Affymetrix microarray was performed on RNA from 
wildtype and Dlx3-/- placentas and identified 401 genes that were differentially 
expressed following the loss of Dlx3, including expression of matrix metalloproteinase 
(MMP-) 9, an extracellular matrix (ECM) remodeler.  Analysis of cultured media 
using Western blot and zymography from Dlx3 +/+, +/-, and -/- placental explants 
corroborated these findings.  Using luciferase reporter gene analysis and DNA binding 
studies, Dlx3 was shown to bind and transactivate a 1.9kb portion of the mouse MMP-
9 gene promoter in a dose dependent manner in JEG3 cells.   Further siRNA-mediated 
reduction of Dlx3 resulted in decreased human MMP-9 protein levels and activity.  
Consistent with this result, chromatin immunoprecipitation (ChIP) assays revealed 
Dlx3 is capable of binding to the human MMP-9 gene promoter.  Lastly, Dlx3 and 
MMP-9 were both coordinately misregulated in a mouse model of preeclampsia.  
These studies indicate the potential role for the interaction between Dlx3 and MMP-9 
during placental development and potentially the causal pathophysiology of PE.  
Analysis of fetal weights during gestation revealed a potential intrauterine 
growth retardation (IUGR) phenotype in Dlx3+/- animals.  Analysis of Dlx3+/- 
placentas throughout gestation found evidence for an accumulation of reactive oxygen 
species (ROS) likely leading to a high apoptotic index in these placentas relative to 
controls.  Antioxidant therapy using the superoxide dismutase mimetic, Tempol, 
resulted in amelioration of ROS and a rescue of the IUGR phenotype.  Tempol 
treatment also rescued a subset of Dlx3-/- embryos 3 days beyond their normally 
identified embryonic demise.  Additionally, micro computer tomography (micro-CT) 
and histological analyses of Dlx3+/+ and +/- placentas identified important changes in 
maternal spiral arteries associated with Dlx3+/- which were reversed by antioxidant 
supplementation.  These findings support the conclusion that loss of a single Dlx3 
allele is detrimental to fetal growth in utero.  Antioxidant therapy rescued fetal growth 
abnormalities due to oxidative stress suggesting potential treatment for pregnancy 
complications associated with placental insufficiency. 
Together, these studies provide evidence for the novel role of Dlx3 in the 
regulation of an important gene network during placental development.  This includes 
Dlx3-dependent regulation of a key MMP linked to placental ECM remodeling.  Both 
Dlx3 and MMP-9 are misregulated in a mouse model of PE indicating involvement in 
pregnancy complications.  Additionally, these studies characterize a new IUGR model 
due to haploinsufficiency at the Dlx3 locus.  Studies also provide support for the 
possible benefits of gestational antioxidant therapy in controlling ROS accumulation 
that can occur during abnormal placentation as observed in the Dlx3 mouse model.  
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2 
1 Introduction 
The placenta is the first functional organ formed in the mammalian embryo 
and is essential for fetal growth and survival throughout gestation.   This collection of 
extra-embryonic membranes serves as the main site of exchange for a variety of 
materials between mother and fetus including gases, nutrients, hormones, growth 
factors and waste products of metabolism.   Both fetal circulation and maternal blood 
flow contribute to normal placental perfusion.  Maternal contributions to proper 
placental development are affected by nutrition, age, and body mass index (BMI), to 
name a few.  Improper placentation, regardless of the cause, could lead to a multitude 
of placental disease conditions including intrauterine growth retardation (IUGR), 
placental insufficiency, preeclampsia and possibly fetal death.  Thus, this important 
interface functions to meet fetal metabolic demands to maintain fetal fitness and 
normal growth during gestation.  
The Office of Rare Diseases (ORD) of the National Institute of Health (NIH) 
lists placental disease conditions as a “rare disease.”  By definition this identifies less 
than 200,000 people each year in the United States affected by placental disease.   
Despite this “rare disease” designation, health care costs associated with pregnancy-
associated diseases including pathologies within the placenta are substantial.  For 
example, a population survey examining 17,415 patients carrying singleton 
pregnancies (single placentas) found the incidence of defective placental maturation 
was 5.7%, and was associated with fetal mortality in 2.3% of cases. In control patients 
displaying normally developed placentas, fetal mortality due to placental pathologies 
occurred in only 0.033% of cases 1; a ~70 fold decrease in fetal mortality.  These 
findings indicate the importance of proper placentation to facilitate the appropriate 
growth trajectory and health of the fetus and mother.  
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2 Placental Development in the Mouse 
 Placental development is likely best understood in the mouse, since this 
species has been the focus of numerous genetic studies due to the relative ease of 
genetic manipulation in this model animal.  Recent work from the laboratories of 
James Cross, Janet Rossant and colleagues have described the developing mouse 
placenta in great detail providing the field of placentology key insights into the genetic 
and molecular mechanisms of productive and successful fetal and maternal 
communication throughout gestation.  The following sections of this dissertation 
provide an overview of murine placental development. 
 
2.1 Placental Establishment Timeline 
 In mice, the placenta begins developing at embryonic day (E) 3.5 in the 
blastocyst when the trophectoderm is separated from the inner cell mass 2 3 essentially 
creating a two compartment embryo; the inner cell mass contributing to development 
of the embryo proper while the trophectoderm contributes to the placenta.  Several 
trophoblast cell populations or lineages emerge from the trophoectoderm during 
establishment of the placenta.   During the peri-implantation period trophoblast giant 
cells differentiate emerging from the outer trophectoderm layer of the blastocyst.  
After implantation, trophoblast giant cells, derived from the mural trophectoderm, line 
the embryonic cavity, where they form part of the parietal yolk sac.  These giant cells 
are referred to as ‘primary’ or ‘parietal’ giant cells, named for their time of 
differentiation 4.  A second wave of trophoblast giant cells differentiates after 
implantation occurs.  These cells are known as ‘secondary’ trophoblast giant cells or 
polar trophoblast cells, again based on the timing of differentiation and their 
directional invasive function during formation of the fetal-maternal interface 2,4.  
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Secondary giant cells also form a discontinuous border towards the maternal decidua 
and line the maternal vascular canals that deliver maternal blood into the fetal-
maternal interface 4.   
At E8.5 the extraembryonic mesoderm (allantois) fuses with the chorion 
derived from the trophectoderm defining the chorioallantoic attachment in the murine 
placenta 2 5.  At this point, the vascular portion of the placenta commences formation.  
The chorion begins to fold to form not only dense villus structures, but also additional 
space and surface area for fetal blood vessels to grow from the allantois 5.  From this 
point throughout the remainder of gestation, branching morphogenesis of the fetal villi 
continue to create a vast and intricate vascular network within the placenta. In the 
mouse, the fetal-maternal interface, termed the labyrinth, is structurally supported by 
the spongiotrophoblast cells of the junctional zone, which are derived from the 
ectoplacental cone and largely serves as the interface between fetal tissues and the 
maternal decidua.  The labyrinth is formed by the proliferation and migration of polar 
trophoblasts to the mesometral side of the uterus 2 5 6.  The full establishment of the 
labyrinth reflects the key compartment where exchange of maternal and fetal 
components occurs during gestation. 
Concurrent with the formation of vasculature within the labyrinth, chorionic 
trophoblast cells begin to differentiate into two labyrinth cell types, 
syncytiotrophoblast and cytotrophoblast cells.  Both cell types play integral roles in 
the vascularization of the placenta. Syncytiotrophoblast cells are multinucleated, 
formed by the fusion of cytotrophoblast cells, and function as the cellular layer 
adjacent to the fetal capillary endothelium.  Meanwhile, the mononuclear 
cytotrophoblast cells line maternal blood sinuses that form within the labyrinth.  The 
villi, which are composed of an outer epithelial layer derived from syncytiotrophoblast 
cells and an inner core of stromal cells and blood vessels, are bathed in maternal blood 
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spaces, allowing for direct contact between maternal circulation and fetal trophoblasts 
7 6.  As gestation progresses, the vasculature within the labyrinth continue to expand to 
meet the growing metabolic needs of the growing fetus 5. The mechanisms associated 
with normal placentation are clearly regulated by numerous factors including specific 
gene networks, hormones, growth factors and many other key determinants.  A wide 
variety of these factors have been shown to be of great importance for proper 
placentation and the establishment of the fetal-maternal interface in the mouse largely 
due to extensive genetic studies taking advantage of naturally occurring mutations and 
experimentally defined gene disruption studies.  A disruption in the formation of this 
critical communication between fetus and mother has the possibility of creating 
devastating effects on fetal fitness. 
 
3 Genetic Factors Influencing Placental Development 
 Numerous knockout models have led to the discovery of the involvement of 
specific genes in normal placental development.  The following sections provide 
important examples of these types of genetic knockout studies; however, due to space 
constraints, these are not an exhaustive list of examples of gene knockouts affecting 
placental function.  Spongiotrophoblast cells of the junctional zone border the 
labyrinth and the outer giant cells.  Maternal blood supply passes through this layer via 
large arterial sinuses to bath the fetal blood vessels of the labyrinth 8.  The survival and 
growth of the spongiotrophoblast cells depend on the basic helix-loop-helix (bHLH) 
factor Mash-2 9.  In the absence of Mash-2, the spongiotrophoblast layer within the 
mouse placenta is greatly reduced, leading to midgestation embryonic lethality due to 
placental failure associated with a lack of spongiotrophoblasts and reduced trophoblast 
layers within the labyrinth 10.  In addition to Mash-2, hypoxia-inducible factor 1β 
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(HIF1β) serves an essential function in the development and maintenance of 
spongiotrophoblasts.  HIF1β forms a heterodimer with HIF1α and induces target 
genes under low oxygen tension; targeted deletion of HIF1β in mice reduces the size 
of the spongiotrophoblast layer.  These findings indicate low oxygen levels within the 
developing placenta are important for maintenance and function of spongiotrophoblast 
11.   
Secondary trophoblast giant cells also develop from precursors of the 
ectoplacental cone and require the action of bHLH proteins heart- and neural crest 
derivatives-expressed protein (Hand1) 1 and I-mfa.  Both proteins have been shown to 
increase in expression during giant cell differentiation in vitro 12,13.  Analyses of 
homologous genetic deletions of these genes in mice demonstrate a total reduction of 
giant cells due to decreased proliferation 13 14.  Additionally, both factors are able to 
antagonize the activity of Mash-2 through two different mechanisms.  I-mfa directly 
binds to Mash-2, while Hand1 competes for other bHLH binding partners; both 
mechanisms result in a decrease in Mash-2 transcriptional activity 15 13.  Members of 
the inhibitors of DNA binding (Id) family may also play a role in trophoblast giant cell 
formation.  These proteins have a HLH dimerization domain, but lack the basic 
domain required for DNA-binding.  Both Id-1 and Id-2 proteins are present in the 
chorion but absent from trophoblast giant cells 16.  More specifically, overexpression 
of Id-1 in Rcho-1 trophoblast stem cells inhibits giant cell differentiation in this in 
vitro model 12.  In addition to its’ role in differentiation of trophoblast giant cells 
outlined above, Hand1 is expressed in numerous developing tissues including heart, 
limbs, neural crest derivatives and extra-embryonic membranes and Hand1 knockout 
embryos die at E8.5, due to numerous developmental defects, mainly involving a 
failure of vascular growth and remodeling within the yolk sac.  Despite the 
observation that placental angiogenic genes such as vascular endothelial growth factor 
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(VEGF) and Angiotensin1 (Ang1) were expressed normally, Hand1 mutant yolk sacs 
lacked proper distribution of smooth muscle cells that provide structural support to 
vasculature 17.  This study provides an important example of the critical function of 
Hand1 during yolk sac vascular development.  These findings support the conclusion 
that genes like Hand1 serve multiple functions within the establishment of the 
placenta.   
The Ets winged helix-turn-helix family of transcription factors have been 
identified in trophoblast tissues as early as day 6.5 and are also expressed in many 
other cell types in the developing mouse embryos, including limb buds and embryonic 
skin.  Targeted deletion of Ets-2 resulted in embryonic lethality at E8.5 due to a defect 
in both the migration and differentiation of trophoblast cells and deficient expression 
of matrix metalloproteinase-9 (MMP-9) 18 19.  MMP-9 functions in a variety of 
physiological and pathophysiological processes, including placental development, 
wound healing, angiogenesis, inflammation and metastasis 20.  Most relevant, MMP-9 
is expressed in extravillous trophoblast cells during trophoblast invasion in the 
beginning stages of gestation, where it helps degrade and remodel extracellular matrix 
(ECM) within the uterine endometrium associated with implantation 21. Further 
discussion of the role MMP-9 plays in placentation is described in sections of Chapter 
1 below.  Similar to the Ets-2 null mouse, the Distal less (Dlx) 3 null mouse dies 
between E9.5 and 10 as a result of poor differentiation of the spongiotrophoblast and 
labyrinth layers and an overall decrease in vascularization within the placental 
labyrinth 22 23.  Dlx3 is the focus of this dissertation and will also be discussed in more 
detail in a later section; briefly, Dlx3 is a member of a larger class of homeodomain-
containing transcription factors involved in many aspects of embryonic and placental 
development.    
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Together, these findings indicate the involvement of multiple genes and or 
gene networks in the systematic interplay responsible for normal placental cell lineage 
commitment and proliferation as well as important features of vascular development 
within the maternal-fetal interface.  The key use of knockout mouse models have 
aided greatly in our more global understanding of how single gene deletions can 
contribute to placental insufficiency.  There is a strong likelihood that these types of 
models will serve to better support our understanding of the many molecular 
determinants that give rise to this complex tissue.  For the purposes of this dissertation 
placental insufficiency is defined as improper placental development resulting in a 
decreased fetal growth trajectory. 
  
4 Signaling In Placental Development 
The inner cell mass of the developing embryo provides important positive 
signaling for trophoblast cell proliferation and differentiation 8 6.  Early studies by 
Gardner and colleagues have shown that transplantation of an inner cell mass into a 
trophectodermal vesicle can result in normal development 24.  These important early 
studies provided the initial framework for how cell-cell interactions within the 
blastocyst regulate key developmental decisions.  Additional evidence for the 
important communication between the trophectoderm and the inner cell mass comes 
from the failure of cultured extra-embryonic ectoderm and ectoplacental cone tissues 
to proliferate and form trophoblast giant cells in the absence of signaling from an inner 
cell mass 25 26.  These findings, led to speculation that the trophoectodermal cells, 
which surround the inner cell mass, and the early extraembryonic ectoderm facilitate 
the proliferation and differentiation of trophoblast lineages.  Initial signaling arises 
from the inner cell mass and as cells migrate away from the signaling source, they 
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then differentiate to form the ectoplacental cone and trophoblast giant cells.  This 
section of Chapter 1 seeks to provide important examples of these signaling 
relationships and how these signaling pathways regulate trophoblast cell function. 
 
4.1 Fibroblast growth factor (FGF) as a signaling molecule 
 Recent work has focused on fibroblast growth factor (FGF) as a pathway 
involved in the signaling between the inner cell mass and trophoblast differentiation.   
More specifically, out of the 23 FGF family members found in vertebrates, the 
experiments highlighted below focus on Fgf4 since this family member appears to 
play a crucial role in trophoblast lineage determination.  Fgf4 null mouse embryos die 
at implantation and are characterized by poor development of all trophoblast cell 
lineages 27.  Fgf4 is expressed within the inner cell mass at the preimplantation 
blastocyst and expression continues throughout the epiblast following implantation 28 
29.  Interestingly, embryonic stem cells derived from the inner cell mass of Fgf4 
homozygous null embryos can be readily isolated and cultured 30.  This finding 
indicates the mechanisms associated with the embryonic lethality of the Fgf4-/- mouse 
model might result from a failure of trophoblast cell lineage differentiation and/or 
proliferation.  The most persuasive evidence supporting the important role of Fgf 
signaling in trophoblast proliferation comes from additional mouse experiments.  
Octamer-4 (Oct4) is a mammalian Pit-Oct-Unc (POU) transcription factor expressed 
in the early stages of the developing embryo and expression is restricted to the inner 
cell mass.  Homozygous Oct4 mutant mice develop only until the blastocyst stage due 
to a lack of an inner cell mass resulting in decreased trophoblast proliferation.  
Importantly in these studies, treatment of Oct4 null mutants with exogenous Fgf4 
resulted in an increase in trophectoderm cell proliferation 31.  These studies provide 
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evidence of the key interactions between inner cell mass and the surrounding 
trophectoderm that support the early developmental decisions directing trophoblast 
cell fate determination and subsequent proliferation.      
 
4.2 Other Signaling Pathways 
 Studies have indicated the involvement of signaling pathways other than Fgf4 
in early trophoblast cell proliferation and differentiation.  Estrogen-related receptor 
(ERRβ) is one such pathway.  Mutating the gene encoding for ERRβ, results in a 
complete absence of the diploid trophoblast layers of the placenta, an abnormally thick 
layer of giant trophoblast cells, and embryonic lethality around embryonic day (E) 9 
32.  Investigating ERRβ mutant embryos earlier in gestation (~E6), the extra 
embryonic ectoderm forms normally.  However, the demise of these embryos appears 
to be a failure of chorion formation resulting from the inability of trophoblast cell 
differentiation 32. These findings indicate the potential role of ERRβ in early 
trophoblast differentiation and proliferation.  Whether the ERRβ pathway is 
independent of the Fgf4 signaling pathway requires further analysis. 
 Additional studies have highlighted the involvement of the mitogen-activated 
protein kinase (MAPK) pathways in mouse embryonic development and placentation.    
These pathways are evolutionarily conserved and involved in transducing extracellular 
signals from growth factors such as Fgfs into intracellular responses 33.  The 
prototypical MAPK pathway is the extracellular signal-regulated kinase (ERK)1/2 
pathway.  The two related MAPK isoforms are known as ERK1 and ERK2.  Several 
studies have implicated these enzymes in the control of cell proliferation and 
differentiation 34.  Both Erk1 and Erk2 are widely expressed throughout the early-stage 
embryos.  Disruption of the Erk2 locus leads to embryonic lethality after implantation 
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in mouse development.  Erk2 mutants fail to form the ectoplacental cone and extra-
embryonic ecotderm.  Additionally, Erk1 fails to compensate for Erk2 function 
suggesting a novel function of Erk2 in normal trophoblast development in the mouse, 
likely via regulating the proliferation potential of trophectoderm cells during 
placentation 35. 
 Although this list is not exhaustive, together, these findings indicate the 
dynamic relationship of multiple pathways governing normal placental development.  
Like a number of transcription factors, disruption of discrete signaling pathways or 
downstream signaling intermediates regulated by these pathways can lead to 
detrimental effects during placental development. 
 
5 Comparative Placental Development: humans and mice 
The discussion thus far has focused on the use of mouse models to describe 
basic genetic mechanisms associated with placental development and function.  This is 
entirely consistent with the use of important mouse models (such as the Dlx3 null 
mouse) in the research described in this dissertation.  However, my fundamental goal 
is to use these crucial animal models to help inform our understanding of basic 
mechanisms at play that lead to human pathophysiology during pregnancy.  Thus, a 
brief discussion of the comparison of form and function between the mouse and 
human placentas is warranted.   
The basic architecture of both mouse and human placentas is remarkably 
similar with only a few differences observed at the microscopic level of these two 
species.  The placentas of both species are characterized as chorioallantoic, 
hemochorial placentas; perhaps the most intimate placental vascular relationship in 
mammals. The fetal and maternal circulatory interface of both species contains three 
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trophoblast cell layers (trichorial); two syncytiotrophoblast layers surrounding fetal 
endothelial cells of the fetal vasculature and a single cytotrophoblast cell layer 
adjacent to the maternal blood spaces 5 8 36.  Further, comparison of placental anatomy 
and gene expression of the murine and human placentas suggest analogous cell types 
exist between the two species 36.   
Consistent with mice, the structure of the human placenta is established during 
the first half of gestation 37.  Additionally, both mouse and human placentas are 
classified as discoid, meaning the functional exchange portion of the placenta reflects 
one discrete unit with a single place of attachment within the uterus.  In both species, 
maternal blood enters the placenta through a remodeled blood vessel network of large 
diameter, low-resistance vessels, known as maternal spiral arteries.  The remodeling 
that occurs to create these low-resistant vessels involves migration of fetal 
trophoblasts into these vessels.  The remodeling carried out by these trophoblasts is 
largely characterized by a loss of smooth muscle surrounding these vessels.  The site 
of fetal-maternal exchange in humans is referred to as the villus tree, while in the 
mouse, the labyrinth, and reflects the interface between fetal and maternal blood 
supplies. Within the fetal-maternal interface, the fetal chorionic branches and maternal 
blood sinusoids of both species are similar in tortuosity and dimension 36 8.  
Additionally, the umbilical vessels of both species connect the fetal capillaries of the 
placental exchange region with the fetal circulation 36.   
The similarities between mouse and human placentas are more pronounced 
when investigating the actual cell types.  Human extravillous trophoblasts (EVT) 
develop from anchoring villi and attach to the uterine basement membrane.  EVT’s are 
analogous to the trophobast giant cells of the murine placenta.  Both have the ability to 
be polyploid due to multiple rounds of DNA replication in the absence of intervening 
cytokinesis.  Human EVT’s and mouse trophoblast giant cells are similar in function 
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as well; both mediate the maternal invasion of the uterus.  Trophoblast invasion in 
both species is a precursor to the remodeling of maternal endothelium resulting in 
large diameter, low resistance spiral artery vessels.  Maternal spiral arteries present in 
both species facilitate proper placental profusion 38 39.  The cytotrophoblast cells of the 
anchoring villi are similar in function to the murine spongiotrophoblasts cells, due to 
the ability of the spongiotrophoblast cells to differentiate into giant cells.  Thus, 
murine giant trophoblast cells and the cytotrophoblast cells of the human anchoring 
villi serve in the formation of the interface of fetal-maternal exchange.   
A comparative proteomic and transcriptome investigation of microdissected 
placental tissue from the mouse labyrinth and the human villous tree near the end of 
gestation reveals 70% co-expression of orthologous genes in both species; over 80% 
of genes known that regulate placental differentiation in the mouse are co-expressed in 
both species.  More importantly, 34 novel candidate proteins identified in both mouse 
and humans are likely important in placental structure and/or function 40.  For 
example, integrin (Itga) 5 was identified in this screen.  Integrins mediate cell 
adhesion to basement membranes and extracellular matrix in addition to cell signaling 
in both humans and mice.   Homozygous loss of Itga5 in mouse models results in 
defects in yolk sac mesodermal structures leading to midgestation embryonic lethality 
at E10 41.  Altogether, these findings highlight key similarities between mouse and 
human placental structures and indicate an important role of mouse models for 
studying placental pathophysiology characteristic of human disease. 
 
6 Abnormal Placentation 
Disruption in fetal-maternal communication(s) within the labyrinth layer 
(mouse) or the villous tree (human) could lead to a multitude of disease states 
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including intrauterine growth restriction (IUGR), placental insufficiency, 
preeclampsia, and possibly fetal death.  As suggested earlier, numerous mouse 
knockout models have aided in the study of abnormal placentation.  In general, three 
critical areas can be defined as necessary for placental development: chorioallantoic 
attachment, branching morphogenesis at the chorioallantoic interface, and 
morphogenesis of the labyrinth layer.  The following discussion will outline the role 
each plays in establishment of the normal placenta and how disruption of these 
processes can result in compromised pregnancies. 
6.1 Chorioallantoic Attachment  
As discussed above, the initial stage of the formation of the labyrinth layer in 
the mouse is chorioallantoic attachment and defects at this stage of placentation have 
been characterized by midgestation embryonic lethality.   One notable pathway 
believed to be associated with this phenotype is the bone morphogenetic protein 
(Bmp) signaling pathway.  Knockouts of Bmp 2, -4, -5, and -7 have led to mesodermal 
differentiation defects culminating in aberrant development of the allantois 42,43.  For 
example, Bmp5/Bmp7 double mouse mutants die at E10.5 due to abnormal placental 
development.  More specifically, these mutants have defects in promoting the 
necessary proliferation and maintenance of trophoblast cells governing chorioallintoic 
fusion 43. 
In addition to Bmp signaling, cell adhesion molecules such as vascular cell 
adhesion molecule (Vcam) 1 and the gene encoding for integrin α (Itga) 4, are also 
believed to be involved in the process associated with chorioallantoic fusion.  Vcam1 
is expressed on the tip of the expanding allantois and binds to alpha 4 integrin, which 
is expressed on the basal surface of the chorion. This key interaction results in the 
fusion of the chorioallantoic membranes.   Loss of function mutations in mice in both 
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Vcam1 44 and Itga4 45 genes result in abnormal chorioallantoic fusion and in some 
cases, defects in the establishment of the placental labyrinth.  The similar placental 
phenotype observed in these separate mouse mutants argues for a mechanism whereby 
the interaction between these two cell adhesion molecules is necessary for 
chorioallantoic attachment.  However, these two molecules alone may not be 
mediating the entire fusion between the allantois and the chorion.  Mammalian relative 
of DnaJ (MrJ) null mice exhibit defective chorioallantoic fusion and die at 
midgestation, around E8.5 despite having normal expression of both Vcam1 and alpha 
4 integrin.  However, MrJ null mice do express reduced levels of specific transcription 
factors such as glial cells missing-1 (Gcm-1), which is necessary for fetal branching 
morphogenesis in the labyrinth layer 46.  MrJ appears to play a role, in conjunction 
with other genes, in facilitating branching morphogenesis responsible for proper 
placental vascularization.   Thus, chorioallantoic fusion is mediated by multiple genes 
likely via discrete mechanisms.  Lesions at any step results in failure in the fusion of 
the chorion and allantois and disruption of a viable pregnancy.  
 
6.2 Branching Morphogenesis 
In addition to chorioallantoic attachment, branching morphogenesis is critical 
for placental vascularization and fetal growth.  A large surface area is created by 
extensive branching morphogenesis of trophoblast-derived epithelium to create a 
villous network.  These fetal villi are subsequently vascularized with an elaborate 
capillary network.  This branching allows for the complex vascular interface necessary 
for fetal and maternal exchange in the placenta. 
Branching morphogenesis in the placenta is facilitated by the transcription 
factor glial cells missing-1 (Gcm-1).  Areas in the chorionic plate where folding 
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occurs and enagination of the allantoic mesoderm is initiated are preceded by the 
expression of Gcm-1.  Gcm-1 is expressed at focal sites in the chorionic plate as early 
as E8.0.  Trophoblast cells expressing the Gcm-1 gene initiate branching and 
coordinate the differentiation of trophoblast cells to fuse and form syncytiotrophoblast 
layers.  Gcm-1 is expressed at the distal tip of the branching villi 47.  Gcm-1 is 
expressed as long as the labyrinth continues to enlarge by villus branching processes 8.  
Mice with a mutation in Gcm-1 lack chorioallantoic branching, the chorion layer 
remains flat, trophoblast cells fail to differentiate and the fetal vasculature does not 
interact with the maternal blood sinuses 47.  The hallmark of the Gcm-1 gene deletion 
is the absence of the labyrinth compartment of the mouse placenta.  Additionally, Fgf 
signaling is required for chorioallantoic branching as indicated by the labyrinth defects 
found in Fgf receptor 2 mutant mice 48.  Thus, similar to chorioallantoic fusion, 
placental branching morphogenesis is due to the interplay between numbers of genes. 
 
6.3 Morphogenesis of the Labyrinth 
 Trophoblast stem cells reside in the chorion and remain as a self-renewing 
population of stem cells or differentiate into spongiotrophoblasts, trophoblast giant 
cells or syncytiotrophoblast cells found within the labyrinth.  Several key transcription 
factors appear to regulate this important balance of stem cell self-renewal or 
differentiation of stem cells into cell lineages in the developing placenta.  For 
example, the mammalian Achaete-Scute homologues (Mash-2) is involved in 
trophoblast cell proliferation.  Targeted deletion of this basic helix-loop-helix (bHLH) 
transcription factor results in a decreased spongiotrophoblast layer due to a restriction 
of trophoblast proliferation with a concurrent sustained rate of trophoblast cell 
differentiation into giant cells 18.  The labyrinth of Mash-2 mutants is reduced and 
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presumable not functional 9.  Another bHLH protein, Hand1, involved in yolk sac 
formation, as described above, also indirectly plays a role in morphogenesis of the 
labyrinth layer.  Hand1 has been implicated in trophoblast stem cell differentiation.  
Overexpression of Hand1 in trophoblast stem cells promoted trophoblast giant cell 
differentiation indicating its function to restrict cells toward trophoblast giant cell fate 
in the formation of the labyrinth 49.  Recent mouse studies have identified the 
transcription factor extra-embryonic tissue-spermatogenesis-homeobox gene (Esx)1 as 
a regulator of trophoblast function and vascularization of the labyrinth layer.  Esx1 is 
exclusively expressed in the chorion and is later expressed in the trophoblast 
compartment of the labyrinth 50.  Homozygous null Esx1 mutant mice exhibit a larger 
labyrinth, but the overall vascularization of the labyrinth is reduced 51.  These findings 
help to define the ability of Esx1to regulate the vascularization of the placental 
labyrinth.   
Another mouse model associated with placental insufficiency and abnormal 
labyrinth morphology is the BPH/5 mouse model of preeclampsia.  The BPH/5 mouse 
has been developed by Robin Davisson’s lab here at Cornell University.  The 
phenotype for this mouse was originally discovered while searching for a suitable 
model of hypertension.  At E12.5 the BPH/5 mouse exhibits reduced and irregular 
fetal blood vessel branching within the labyrinth layer and an overall reduction in 
expansion of the labyrinth compared to C57 control mice 52.  It is unknown whether 
failure in the expansion of the labyrinth layer dictates the other classic preeclamptic 
phenotypes, including spontaneous late gestational hypertension and intrauterine 
growth restriction found in this mouse model.  To date, not a single gene or subset of 
genes has been deemed responsible for any phenotype including abnormal labyrinth 
morphogenesis observed in the BPH/5 mouse.  A more in depth discussion of the 
BPH/5 mouse will follow below. 
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These studies from mice indicate a complex organization of genes involved in 
the development of the fetal-derived labyrinth vasculature.  The dependence of this 
organization on genetic contributions, numerous signaling pathways and potentially, 
other external signals, is clearly closely regulated.  Aberrant expression of any one 
labyrinthine vascularization contributor may result in placental insufficiency and 
compromised fetal health. 
 
7 External Factors Affecting Placental Function 
 Disease states such as intrauterine fetal growth retardation (IUGR) and 
preeclampsia can arise due to a number of factors including abnormal placentation 
caused at least in part by aberrant gene expression, as described above, an imbalance 
of angiogenic potential and oxidative stress caused by an inappropriate accumulation 
of reactive oxygen species.    The following sections of Chapter 1 provide some 
important examples of mechanisms associated with placental dysfunction leading to 
fetal distress and failed pregnancies. 
Barker and colleagues carried out a key study, which provided the field of 
placental dysfunction novel insights into the potential link between maternal metabolic 
well-being, placental growth abnormalities and risk associated with adult onset of 
disease.   This longitudinal study examined weight and placental size at birth of 449 
fetuses and those measurements were correlated with adult blood pressure at ~50 years 
of age.  Examination of the data revealed adult mean systolic pressure rose by 15 mm 
Hg as placental weight increased from less than or equal to 1 lb to greater than 1.5 lb.  
Further, blood pressure fell by 11mm Hg as birth weight increased from less than or 
equal to 5.5 lb to greater than 7.5 lb.  In general, these correlations suggest that the 
highest blood pressure found in these adults was associated with a low birth weight 
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and relatively large placentas 53.  The findings from this study suggest altered 
placentation may lead to an abnormal fetal circulatory adaptation, and ultimately 
present as hypertension in the adult.  Further studies have analyzed this same theory of 
fetal programming within the uterus due to maternal well-being in the context of type 
2 diabetes 54.  These findings indicate the same trend of adult onset of disease that was 
found in the hypertension study.  This theory of intrauterine fetal programming based 
on maternal well-being became known as the “Barker hypothesis”, and provides the 
basis for our understanding of the critical role maternal health may have, not only on 
the fetus during development, but also the major repercussions that may occur well 
into adult life.  As such, any placental dysfunction has the unique ability to not only 
affect fetal well-being during gestation but increase the “risk” of that fetus to some 
adult diseases. 
 
8 Placental Dysfunction in Preeclampsia 
 Preeclampsia affects 5-10% of all pregnancies worldwide and is responsible 
for both maternal and neonatal morbidity and mortality.  This disease is characterized 
by a late gestational onset of maternal hypertension and proteinuria 55 56.  
Preeclampsia is also frequently related to maternal edema and hyperuricemia, which is 
a high level of uric acid in the blood.  Hemolytic anemia Elevated Liver enzymes and 
Low Platelet count or HELLP syndrome is also frequently associated with 
preeclampsia.  Although the symptoms of preeclampsia have been well characterized, 
the causes of this disease are unknown.  Several studies indicate that generalized 
endothelial dysfunction, along with placental and maternal accumulation of free 
radicals, may promote a cycle of events that account for a majority of the clinical 
aspects of preeclampsia.  The relevance of preeclampsia to this dissertation comes 
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from recent observations that in the Dlx3 null mouse model, misregulation of placental 
morphogenesis occurs concurrent with reduced expression of placental growth factor, 
a key marker of preeclampsia 57.  Moreover, studies reported in this dissertation reveal 
that in a mouse model of preeclampsia, Dlx3 and several key Dlx3 target genes are 
mis-expressed early in gestation in the BPH/5 mouse supporting the possibility that 
the Dlx3 gene network may be playing an important role in early genetic 
determination of this disease.  The following sections provide an overview of key 
features of placental dysfunction during preeclampsia.  
 
8.1 Endothelial Cell Dysfunction in Preeclampsia 
 Data reported from several laboratories indicates that preeclampsia is a 
maternal response to a generalized endothelial cell dysfunction.  Increased circulating 
fibronectin, factor VIII antigen, and thrombomodulin, which are all markers of 
endothelial cell injury, have been found in preeclamptic patients 55,58.  A decreased 
production of endothelial-derived vasodilators such as prostacyclins, increased 
production of endothelins and enhanced vascular reactivity to angiotensin II also 
suggests abnormal endothelial function during preeclampsia 56.  Additionally, 
misregulation of vascular endothelial growth factor (VEGF) in maternal circulation 
has also been linked to the pathogenesis of preeclampsia.  VEGF is an endothelial-
specific mitogen that promotes angiogenesis and its activities are mediated primarily 
by interaction with two high-affinity cell surface receptor tyrosine kinases:  kinase-
insert domain region (KDR) and fms-like tyrosine kinase-1 (Flt-1) 55,59.  Alternative 
splicing of Flt-1 leads to an endogenously secreted soluble protein, sFlt-1, which lacks 
the cytoplasmic and transmembrane domain of the full length receptor, but maintains 
the ligand-binding domain 60.  sFlt-1 can antagonize not only circulating VEGF, but 
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also placental growth factor (PGF) by binding to these molecules in circulation and 
preventing their interactions with endogenous receptors located in the placental 
vasculature.  PGF is another member of the VEGF family that is placentally derived 
and predominately acts to promote angiogenesis in the placenta.  Karumanchi and 
colleagues have recently reported that in a nested case-control study of preeclamptic 
and control patients, serum concentrations of sFlt-1 are increased, while levels of PGF 
are markedly reduced providing important biomarkers with predictive value in the 
subsequent development of preeclampsia 59,61.  Consistent with these observations, the 
BPH/5 mouse displays abnormal endothelial cell function and secretion of pro-
angiogenic factors such as VEGF and PGF.  Close examination of E10.5 decidual 
vessels in the BPH/5 placentas reveal narrowed lumens and indicate a thickened 
arterial wall, in contrast to the open lumens and thin arterial walls of C57 control 
mouse placentas 52.  These data suggest that maternal spiral artery remodeling may be 
disrupted in the BPH/5 model. 
Although preeclampsia is clearly a multi system disease, endothelial cell 
dysfunction appears to play a major role in the phenotype.  The differential patterns of 
angiogenic factor(s) expression found in human PE, in conjunction with the abnormal 
placental morphology in the BPH/5 mouse, strongly indicate the role of endothelial 
cell dysfunction in the pathophysiology responsible for preeclampsia. 
 
8.2  Contribution of Fetal and Maternal Free Radicals in Preeclampsia 
In some reports, the pathology associated with preeclampsia may be accounted 
for by an increase in placental and maternal free radicals during gestation.  A free 
radical is any molecule containing one or more unpaired electron 62.  Free radicals are 
part of a broader category of reactive oxygen species (ROS), which include oxygen-
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containing free radicals, like hydroxyl radical (HO•), superoxide anion radical (O2•-), 
and nitric oxide (NO•).  ROS also consist of reactive molecules that do not contain 
unpaired electrons, such as hydrogen peroxide (H2O2), hypochlorous acid (HOCl), and 
peroxynitrite anion (ONOO-).  ROS can function as signal transducers in normal 
physiological states 62, but overproduction of ROS can result in numerous health 
problems including atherosclerosis, ischemic heart disease, cancer, diabetes, 
preeclampsia, and neurodegenerative diseases such as Alzheimer’s disease, 
Parkinson’s disease, and Huntington’s disease 63. 
Preeclampsia has been characterized by distinct pathological lesions of the 
decidual arterioles, known as acute atherosis 64.  More specifically, the ROS associated 
with nitrotyrosine was detected by immunostaining around foam cells in human 
placenta atherosclerotic lesions 65.  This condition may be due to an increase in ROS 
caused by lipid peroxidation or nitrotyrosine formation, or a decrease in superoxide 
dismutase (SOD) expression and activity.  SOD’s are responsible for converting ROS 
into hydrogen peroxide, where cellular components such as catalase can convert it into 
oxygen and water.  Two different SOD isoforms have been identified in the placenta 
in response to antioxidant therapy, mitochondrial (Mn)SOD isoform and cytosolic 
Cu,Zn-SOD isoform.  The Mn SOD isoform is expressed in the syncytiotrophoblast 
cells and in villous vascular endothelium.  While the cytosolic Cu,Zn-SOD isoform is 
expressed primarily in the villous stroma 66.  The two different SOD isoforms found in 
different cell types in the placenta, as a result of antioxidant therapy, may indicate 
different SOD requirements of specific cell types or the SOD expression is a direct 
correlation to the degree of placental oxygenation 67. 
Several studies have investigated the contribution of natural antioxidants, such 
as vitamins C and E, in the maternal diet, on the occurrence of preeclampsia.  While 
potentially exciting, the overall effect(s) of antioxidant therapy on the incidence of 
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preeclampsia has been controversial and inconsistent 68.  This inconsistency in 
response to antioxidant therapy may be attributed to a particular critical time frame of 
antioxidant administration.  Antioxidants administered during preconception and early 
gestation may be key for counterbalancing abnormal oxidative stress associated with 
the onset of preeclampsia 69.  Any placental “insult” including abnormally high levels 
of ROS within the developing placenta during this timeframe may lead to abnormal 
placentation and potentially direct effects on fetal growth.   
Antioxidant therapy using the SOD mimetic, Tempol, in the BPH/5 mouse 
model of preeclampsia has demonstrated positive effects.  Chronic administration of 
Tempol to BPH/5 mice throughout gestation significantly improved fetal growth and 
survival.  Further, Tempol administration ameliorated pregnancy-induced maternal 
hypertension and proteniuria in this model.  Tempol therapy normalized levels of ROS 
in all placental zones in the BPH/5 mouse placenta 70.  Using the BPH/5 mouse as a 
model for preeclampsia indicates the potential benefits of antioxidant therapy on 
maternal and fetal health during preeclampsia.  A more in depth analysis of the 
possible benefits of antioxidant therapy on the Dlx3 mouse model will be discussed in 
Chapter 4.   
 
9 Distal-less (Dlx) 3 Mouse Model of Placental Insufficiency 
 The Roberson lab became interested in the transcription factor Distal-less 
(Dlx) 3 when examining transcriptional mechanisms associated with the control of the 
glycoprotein hormone α subunit gene in placental trophoblasts 71.  The α subunit is a 
key subunit for chorionic gonadotropin (CG) expressed in the primate placenta.  Dlx3 
was identified as a key transcriptional regulator of the α subunit by virtue of its 
binding to the junctional regulatory elements within the promoter region of this gene.  
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Loss of Dlx3 function in choriocarcinoma cells results in diminished expression of the 
α subunit 71.  Studies of human placental section obtained from pregnancies 
terminated at 8 weeks gestation suggest that in humans, Dlx3 is expressed in cyto- and 
syncytiotrophoblasts at the time of peak CG production 72.  These studies support 
speculation that Dlx3 may be playing a key role in the regulation of expression of CG 
subunits, thus aiding in maintenance in maternal recognition of pregnancy in women.   
Dlx3 null mouse dies mid-gestation ~ E 9.5 due to placental insufficiency 22.  More 
specifically, Dlx3 is expressed largely within trophoblasts of the labyrinth and Dlx3 
null placentas lack expansion in the labyrinth layer of the placenta 23.  The gene profile 
associated with the Dlx3 mouse model may give insight into the placental 
insufficiency exhibited in preeclampsia and other placental diseases.  The features of 
the Dlx3 gene network will be described in more detail below.  
 
9.1  Dlx Family Members 
 Dlx3 is one of a six-member (Dlx1-6) Distal-less family of homeodomain-
containing transcription factors 73.  Dlx proteins are homologs of Drosophila Distal-
less (Dll) genes; in flies, Dll appears to contribute to limb specification and 
development 74.  Loss of Dll function results in a homeotic change in the identity of 
ventral appendages (for example, legs and antennae) resulting in the loss of the 
appendage 74.  Both mouse and human Dlx genes are found in three convergently 
transcribed pairs linked to Hox clusters.  Hox genes are critical in embryonic 
development for the proper number and placement of embryonic segment structures 
(such as legs, antennae, and eyes) 75.  In both humans and mice, Dlx1 and Dlx2 are 
linked to the Hoxd cluster, Dlx3 and Dlx4 are linked to the Hoxb cluster and Dlx5 and 
Dlx6 are linked to Hoxa cluster 22,73.  The distinct clustering pattern of Dlx and Hox 
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genes suggest important relationships between the two classes of homeobox genes in 
the developmental processes they control. 
 
9.2  Dlx3 Expression Pattern 
Dlx genes are expressed primarily in the forebrain, branchial arches, and 
tissues derived from the epithelial/mesenchymal interactions during development 22,73.  
More specifically, Dlx3 is expressed in hair follicles, tooth germ, branchial arch 
mesenchyme, and in the interfollicular epidermis 76.  Dlx3 also functions in the normal 
differentiation of mammalian epidermis.  Ectopic expression of Dlx3 in the basal layer 
of mouse epidermis resulted in cessation of proliferation and the activation of 
profilaggin, a late differentiation marker of keratinocytes, resulting in the 
transformation of basal cells into more differentiated keratinocytes 77.  The profilaggin 
gene has a Dlx3 binding site located in the 5’ regulatory region and Dlx3 has been 
shown to be a positive transcriptional regulator of this structural protein 77.  
Interestingly, Dlx3 and Dlx4 expression is both spatially and temporally separate from 
other Dlx genes.  As outlined above, mammalian Dlx genes are arranged in distinct 
bigene clusters (Dlx1/Dlx2, Dlx5/Dlx6, Dlx3/Dlx4, formally known as Dlx7) and 
exhibit nested patterns of expression in developing visceral branchial arches.  Each 
bigene cluster is under different regulatory mechanisms.  Ruddle and colleagues have 
demonstrated that the 245 bp enhancer element located in the intercistronic region of 
the Dlx3-4 cluster, whose DNA sequence is highly conserved between mice and 
humans, and can regulate a visceral branchial arch specific expression pattern of the 
Dlx3 gene 78.  Despite the observation that both Dlx3 and 4 are expressed within the 
placental in mice and humans, the precise role of this intercistronic regulatory region 
within the Dlx3/4 cluster in the placenta is currently not known. 
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In humans, the aberrant expression of Dlx3 is of clinical significance leading to 
two known disease states: tricho-dento-osseous (TDO) syndrome 76,79 and 
Amelogenesis imperfecta (AI) 80.  TDO is inherited as an autosomal dominant trait 
leading to tooth defects, kinky hair at birth and craniofacial bone abnormalities; it is 
characterized by a four-nucleotide deletion downstream of the DNA-binding 
homeodomain, resulting in a premature truncation of the protein.  Similarly, AI shares 
characteristics associated with TDO and is the result of a two nucleotide deletion that 
causes a frameshift, altering the last two amino acids of the DNA-binding 
homeodomain, resulting in a premature truncation of the protein 80.  Interestingly, 
there have been no reports regarding the incidence of failed pregnancy outcomes in 
TDO or AI patients.  This may not be unexpected since these Dlx3 mutations are 
thought to result in a partial loss of function rather than complete cessation of Dlx3 
activity.  Moreover, TDO and AI are exceedingly rare disorders leaving open the 
question of the role of these Dlx3 mutations on placental function and pregnancy 
outcomes. 
 
9.3  Dlx3 Transcriptional Activity 
The DNA-binding homeodomain of Dlx3 is similar to many other transcription 
factors in that it displays high affinity for a core TAATT DNA-binding motif 
indicating that it can recognize specific sequences and function as a transcriptional 
activator or a repressor depending on cell type and physiological state.  The full 
consensus DNA-binding sequence of Dlx3, (A/C/G)TAATT(G/A)(C/G), has been 
shown by our lab as a cis-acting element necessary for the transactivation of the 
promoter for the human α subunit gene of chorionic gonadotropin hormone 71.  In 
most cases, Dlx3 functions as a cell-type-specific transcriptional activator in placental 
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trophoblast cells.  However, Dlx3 has also been shown to repress pan neural markers 
in the anterior neural plate in the developing Xenopus embryo 81.  Therefore, the 
functional outcome of the transcriptional activity of Dlx3 may depend on not only cell 
context and physiological state, but also the availability of heterodimeric binding 
partners, which may have positive or negative transcriptional activities.  One of the 
key questions examined in the research outlined in the dissertation focuses on Dlx3 
binding partners and how these putative interacting partners influence transaction 
potential in placental trophoblasts. 
 
9.4 Identification of the Dlx3 gene network 
In placental cells, the research from the Roberson lab suggests that Dlx3 is 
largely playing a transcription stimulating role in trophoblasts.  To more fully 
investigate the Dlx3 gene network, our lab set out to use microarray analyses to 
examine changes in transcript abundance within the placental disk, specifically 
comparing Dlx3+/+ and Dlx3-/- placentas at E9.5.  These genes were identified by gene 
profiling analysis using an Affymetrix microarray.  Results revealed 401 genes that 
were differentially expressed and the signal-log-ratio absolute value of 33 genes was 
higher or lower than 0.5 when compared to the wildtype mouse placenta 57.  The genes 
were subjected to gene network analysis revealing two interrelated gene networks that 
were strongly impacted by the loss of Dlx3; a cell-to-cell signaling and interaction 
gene network and a network composed of genes related to hematological disease.  
Several important molecules emerged from this analysis.  As indicated earlier, PGF 
transcript levels were markedly reduced with the loss of Dlx3 suggesting a potential 
transcriptional role in the regulation of the PGF gene.   A second important molecule 
discovered in the cell-to-cell signaling interaction network was matrix 
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metalloproteinase-9 (MMP-9), a proteinase involved in extracellular matrix (ECM) 
remodeling.  Both microarray analysis and subsequent validation by qRT-PCR 
demonstrated that the expression of MMP-9 mRNA was reduced in the Dlx3-/- mouse 
placenta 57.  Studies described in this dissertation take advantage of the data obtained 
from the array analyses and use MMP-9 gene expression as a model system for how 
Dlx3 can serve as a transcriptional activator in placental cells.  Moreover, our studies 
suggest that both Dlx3 and MMP-9 are misregulated in a mouse model of 
preeclampsia, leaving open the question of the role of Dlx3 and the Dlx3 gene network 
in regulation of disease progression during preeclampsia.  The following sections help 
to frame the background of how MMP-9 (as well as other MMPs) aid in regulating 
placental morphogenesis.   
 
10 The Role of MMPs in Placental Development 
 As indicated above, maternal vascular remodeling is essential for proper 
perfusion of the developing placental vascular bed.  This process is dependent on the 
invasion of cytrotrophoblasts through the ECM of the maternal decidua.  Ultimately 
this process results in the remodeling of the maternal spiral arteries and sustained 
blood flow into the intervillious space 82.  MMPs appear to play a key role in this 
process.  The placental abnormalities exhibited in the Dlx3 mouse model and a link 
between aberrant Dlx3 expression and MMP-9 transcript levels indicate the potential 
role of MMP-9 in the gene profile associated with the pathophysiology of placental 
insufficiency in the Dlx3 null mouse model. 
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10.1 Matrix Metalloproteinase-9 (MMP-9) Function 
MMP-9 is a member of the zinc-dependent proteinase family known for their 
ability to degrade ECM 83.  Early studies provide evidence that MMP-9 degrades 
denatured collagens and basement membrane components 84.  More recently, MMP-9 
is has been shown to cleave fibrin 85, serpin α1-proteinase inhibitor 
86, interleukin-1β  
(IL-1β) 87, and transforming growth factor-β (TGF-β) 88 revealing the involvement of 
MMP-9 in many processes including tissue remodeling, inflammatory responses, and 
metastasis in the progression of cancer.  Pro-inflammatory cytokines such as tumor 
necrosis factor-α  (TNF-α) and IL-1β selectively up-regulate the expression of MMP-
9 in macrophages 89.  However, TGF-β has been shown to have an inhibitory effect on 
several members of the MMP family, including MMP-1, MMP-3 and MMP-9 in 
fibroblasts 90.  Studies from Chen and colleagues indicate that a nuclear factor-κB 
(NF-κB) site is responsible for the suppressive activity of TGF-β in the regulation of 
MMP-9 gene transcription 91.  As indicated above, the Ets family of transcription 
factors also governs MMP-9 transcriptional activity.  For example, reporter 
transfection assays revealed epidermal growth factor (EGF) activation of MMP-9 gene 
promoter required Ets-1 and Ets-2 92.  Together these findings indicating there are 
numerous pathways responsible for the expression and activity of MMP-9.  
 
10.2 Matrix Metalloproteinase-9 (MMP-9) Contribution(s) to Preeclampsia 
 The exact role MMP-9 plays in the pathophysiology of preeclampsia remains 
unclear and somewhat controversial.  In normal placental development, MMP-9 
functions to degrade various components of the extracellular matrix (ECM) including 
type IV, V, VII and X collagens, fibronectin, and gelatin 93.  Degradation of these 
ECM components is necessary for proper remodeling of the maternal spiral arties from 
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high-resistance, low capacity arteries to low-resistance, high capacity venous-like 
structures 82,94 to facilitate proper placental profusion 95. 
Extravillous trophoblast invasion of maternal spiral arteries is a multistep 
process.  This process first requires proteolytic degradation of decidual/endothelial 
ECM followed by active cell migration through the degraded matrix 96.  Briefly, 
MMP-2 and MMP-9 are secreted as latent enzymes and are activated outside invading 
fetal trophoblast cells where their activity is further regulated by tissue inhibitors of 
metallopeptidases (TIMP) 1, 2, and 3 97.  Cell adhesion molecules, particularly 
integrins, play an important role in the transformation of extravillous trophoblasts 
from stationary to mobile 98.  During the invasion process, key receptors are 
upregulated or down regulated by the invading extravillous trophoblasts.  For 
example, invasion into the maternal decidua requires downregulation of  ITGA6B4 (a 
laminin receptor), but upregulation of ITGA5B1 (a fibronectin receptor) and 
ITGA1B1 (a laminin/collagen receptor) 99. 
As integral components to the extravillous trophoblast invasion process, MMP-
9 and family member MMP-2 are expressed in invasive extravillous trophoblasts.  
Increased secretion of MMP-9 and MMP-2 have also been detected in intrauterine 
tissue at parturition in several species including humans and rats 100.  Interestingly, 
several studies indicate decreased MMP-9 mRNA expression 101 and immuno-staining 
102 in human preeclamptic placentas.   
Despite these findings, other studies indicate no difference in MMP-2 and 
MMP-9 expression levels in normal pregnancies compared to pregnancies complicated 
by preeclampsia.  For example, specific immuno-capture assays examining placental 
bed biopsies revealed no change in MMP-2 and MMP-9 transcript levels across 
normal and complicated pregnancies 93.  Additionally, human plasma examined from 
normal and pregnancies complicated by preeclampsia again found no difference in 
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MMP-9 levels 103.  A more in depth discussion of MMP-9, its relationship to Dlx3 and 
its potential role in the pathophysiology of abnormal placentation related to the Dlx3 
mouse model and preeclampsia will follow in Chapter 3. 
 
11 Imaging of Placental Vasculature 
Central to the studies described in Chapter 4 in this dissertation is the ability to 
visualize placental vasculature in the healthy and diseased state.  As such, some 
preliminary discussion regarding vascular imaging is warranted here to set the 
framework for my later discussion of imaging in Chapter 4 and reflect efforts to 
develop novel and innovative methodologies for vascular imaging within the mouse 
placenta. 
 
11.1 Historical Imaging Tools 
Traditionally, placental vasculature has been imaged in a fixed state with the 
aid of latex/plastic casts and analyses of structure using an electron microscopy.  In 
what is now considered one of the most important papers on placental vasculature in 
mice, Adamson and colleagues 5 prepared vascular casts of mouse placenta from 
E10.5 to term and found remarkable changes in placental vascular morphology 
throughout gestation.  For example, maternal arteries carrying maternal blood into the 
uterus branched into 5-10 dilated maternal spiral arteries.  The endothelial-lined spiral 
arteries converge into a small set of vascular channels at the trophoblast giant cell 
layer and carry maternal blood directly to the base of the placenta.  Maternal blood 
was then found to flow through the intervillous spaces of the labyrinth layer towards 
the maternal side of the placenta, countercurrent to the direction of the fetal capillary 
blood flow.   
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Trophoblast cells from the early embryo were found to invade the uterus in two 
distinct patterns.  Trophoblast giant cells expressing the proliferin gene invaded 
following implantation in a pattern associated with remodeling the maternal spiral 
arteries.  Dilation of the spiral arteries was obvious between E10.5 and E14.5.  
Meanwhile, the second pathway detected trophoblast cell invasion after E12.5, 
invading the interstitial spaces within the labyrinth layer 5.  Most importantly, 
Adamson and colleagues found that the transition from endothelial-lined maternal 
artery to trophoblast-lined blood spaces is associated with the invasion of trophoblast 
giant cells 5.  Although this imaging technique has led to a novel view of the placental 
vascular beds, the static nature of these images does not allow for complete spatial and 
temporal resolution of placental vasculature. 
 
11.2 Advancements in Imaging Techniques 
11.2.1 2-Photon Excited Fluorescence Microscopy 
Advancements in imaging capabilities have allowed for greater resolution of 
vasculature.  One such innovative technique is 2-photon excited fluorescence 
microscopy (2PE). Briefly, a femtosecond laser is tightly focused inside a specimen 
that has been labeled with a fluorescent molecule (ie GFP); at the focus of the laser 
beam, the intensity can become high enough to induce two-photon excitation of the 
fluorescent molecule.  Due to the non-linear excitation, the resulting fluorescence is 
only produced in the focal volume where the laser intensity is the highest.  2PE 
excitation is spatially localized due to the dependence of two photons arriving at the 
same time for excitation to occur.  Moreover, the fluorescence depends on the square 
of the intensity, rather than it being linearly proportional, as in the case of one-photon 
excitation.  After exciting fluorescent molecules at one location, the laser beam raster 
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scans the entire surface of the specimen resulting in a three-dimensional map 
representing the distribution of the fluorescently labeled tissue.  Additionally, because 
2PE occurs only at the focus of the laser, sample artifacts due to photobleaching and 
photo-damage of the tissues are negligible compared to linear imaging tools 104. 
2PE also allows for imaging depths up to 500µm as shown in brain, skin, and 
kidney without the loss of image resolution 105.  More recent studies have shown the 
capability of reaching an imaging depth of 1mm in in vivo imaging of adult mouse 
brains at 1280 nm with approximately 1-nJ pulse energy at the sample surface 106.  
Further, 2PE allows for quantification of the velocity of red blood cells (RBC) in vivo 
107.  This method has recently been used to quantify blood flow changes in rat cortex 
following optically induced microstrokes 108.   2PE also has the capability to capture 
live cells as demonstrated in the imaging of Drosophila embryonic neural stem cells 
by Rebollo and colleagues 109.  Additionally, 2PE live cell imaging has advanced the 
understanding of sensory axon regeneration in live transgenic zebrafish embryos 
expressing green fluorescence protein (GFP) driven by a sensory neuron specific 
promoter 110.  2PE has the potential to surpass previous vascular casting techniques, 
allowing for microscopic definition of placental vasculature and the ability to image in 
real time. 
 
11.2.2 Micro-computed Tomography (micro-CT) 
Another breakthrough in vascular imaging capabilities has come by way of 
utilizing micro-computed tomography (micro-CT).  Higher spatial and temporal 
resolutions are key technical advancements to obtain quantitative three-dimension 
(3D) vascular reconstructions such as with mouse placental vasculature.  This 
technique is used and discussed in studies outlined in Chapter 4 of this dissertation.  
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Essentially micro-CT, much like tomography (CT), utilizes X-rays to create cross-
sections of a 3D object that will later be analyzed by computer software to render a 
virtual image in the x, y and z planes.  The term “micro” indicates the micrometer 
range of the pixels representing the cross-sections.  Generally, there are two different 
principle constructions of micro-CT scanners.    The first is consistent with clinical CT 
scanners.  For this construction, the X-ray detector is rotated around the stationary 
specimen 111.  The second construction principle is utilized mainly in ex vivo 
experiments.  The object in this design is rotated around a stationary X-ray source.  
This set up allows the object to be rotated vertically 112 or horizontally 113 orthogonal 
to the X-ray source allowing for optimization of geometric magnification.   
The first advances in micro-CT were mainly driven by a need for evaluating 
bone anatomy and density 114.  This technology has allowed for complex quantization 
of bone density 115, osteogenesis 116, osteoporosis 117, bone resorption 118, bone 
remodeling 119, bone regeneration 120 and many more.   With the use of contrast 
agents, evaluation of vascular structures in small animals was made possible with 
micro-CT.  To date numerous studies have investigated the vasculature of organ 
systems in healthy and diseased conditions, namely renal vasculature 107,121, hepatic 
vasculature 122, cerebral vasculature 123, and coronary arteries 124.   
Recent work from Rennie and colleagues, has taken advantage of the ability to 
evaluate vascular structures using micro-CT imaging technology.  By injecting a 
micro-CT specific compound into the placental vasculature of mice preceding micro-
CT imaging, Rennie et. al. obtained surface renderings of arterial and venous placental 
mouse vasculature at embryonic days (E) 13.5, 15.5 and 18.5.  Surface area and 
volume measurements were determined for vessels greater than the micro-CT 
machine’s minimum resolvable diameter of 0.03 mm.  More importantly, this imaging 
analysis allowed for a greater understanding of placental vasculature through 
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gestation.  Specifically, these findings determined arterial surface area and volume 
were unchanged from E13.5-15.5, but increased significantly at E18.5 (to 170 ± 
13mm2 and 7.2 ± 0.8mm2, respectively).  The trend of increased diameter of venous 
surface areas and volumes were similar to arterial measurements, but smaller in scale 
125.   
Together these findings demonstrate the superb imaging potential of mouse 
vasculature using micro-CT analysis.  Employing micro-CT imaging tools, we sought 
to explore the placental insufficiency associated with the Dlx3 mouse model.  Chapter 
4 will reveal an in depth analysis of the Dlx3 mouse placental vasculature.  
  
12 Study Aims 
 Recent findings indicate that the homeodomain transcription factor, Dlx3, 
exhibits placental insufficiency resulting in early embryonic death 22,23.  The research 
presented in this dissertation examines the central hypothesis that Dlx3 and the gene 
targets of Dlx3 help to direct normal placental labyrinth morphogenesis in the mouse 
placenta.  Further, misregulation of key features of this gene network appears to be 
correlated with changes in gene expression associated with the pathophysiology of 
preeclampsia in women.  To further understand fundamental aspects of the molecular 
genetic control of placental morphogenesis by the Dlx3 gene network, a number of in 
vitro and in vivo studies were carried out to examine my central hypothesis.  In 
Chapter 2, studies focus on the function of Dlx3, its interacting partners, and the effect 
this physical interaction has on Dlx3 function.  Chapter 3 explores the link between 
Dlx3 and its’ target gene, MMP-9.  Finally, Chapter 4 reveals the effects of 
incremental loss of Dlx3 on fetal fitness by investigations into fetal growth patterns 
during gestation.  This collection of studies provide a number of new insights into the 
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role of Dlx3 as a placental-specific transcriptional regulator and how the Dlx3 gene 
network may underlie important gene expression decisions that lead to preeclampsia. 
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CHAPTER TWO 
 
SMAD6 REPRESSES DLX3 TRANSCRIPTIONAL ACTIVITY THROUGH 
INHIBITION OF DNA BINDING 
 
 
 
 
 
 
 
 
 
This research was originally published in Journal of Biological Chemistry. Kathie A. 
Berghorn*, Patricia A. Clark*, Li Han*, Michael McGrattan, Robert S. Weiss and 
Mark S. Roberson. Smad6 represses Dlx3 transcriptional activity through inhibition of 
DNA binding. Journal of Biological Chemistry. 2006; 281:20357-20367. Copyright 
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reprinted with permission. * These authors contributed equally to this work.  
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Abstract 
Dlx3 is a homeobox-containing transcription factor required for normal placental 
development in mice. Here we demonstrate that DLX3 interacts with SMAD6, a 
member of a larger family of transcriptional regulators generally thought to regulate 
transforming growth factor β/bone morphogenetic protein signaling. 
Immunocytochemical and immunoprecipitation studies demonstrate overlapping 
nuclear localization and physical interaction between DLX3 and SMAD6 in human 
choriocarcinoma cells and in differentiated trophoblasts from human placenta. In vitro 
protein interaction studies mapped the SMAD6 interaction domain within DLX3 to 
residues 80-163, a region of DLX3 that includes a portion of the homeodomain. DLX3 
and DLX4 share homology within this region, and DLX4 was also found to bind 
SMAD6. Using the Esx1 gene promoter as a model for a Dlx3-responsive gene, 
studies demonstrate two near consensus Dlx3 binding sites within the proximal 2.3 kb 
of the transcription start site. Interestingly, binding of DLX3 to one of these two sites 
was inhibited by interaction with SMAD6. Consistent with this result, expression of an 
Esx1 promoter luciferase reporter was increased by overexpression of DLX3; this 
effect was reversed with co-expression of SMAD6. Further, small interfering RNA 
mediated knockdown of endogenous SMAD6 increased DLX3-dependent expression 
of the Esx1 gene promoter. Thus, SMAD6 appears to functionally interact with DLX3, 
altering the ability of DLX3 to bind target gene promoters. SMAD6 appears to play a 
modulatory role in the regulation of DLX3-dependent gene transcription within 
placental trophoblasts. 
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Introduction 
The Dlx family of transcriptional regulators includes six members in mammals, 
arrayed in pairs and aligned with the Hox gene clusters along different  
chromosomes 1,2. DLX3 is tandemly arrayed with DLX4 on human chromosome 17 
and is involved in developmental determination of multiple tissues, including the first 
and second branchial arches, teeth, bone, and multiple epithelia, including the skin, 
mammary gland primordia, and the placenta 3. The relationship between convergently 
transcribed pairs of Dlx family members and specific Hox gene clusters has suggested 
that, although independent of Hox gene expression patterns, these homeodomain-
containing transcription factors are clearly involved in important aspects of 
developmental morphogenesis (reviewed in Ref. 2). The importance of Dlx3 during 
development and in the adult arises from several different observations of disease 
states. Mutations in DLX3 are believed to be causally related to TDO, a genetic 
disorder manifested by taurodontism, hair abnormalities, and increased bone density in 
the cranium 4-6. The defect in DLX3 leading to TDO appears to be associated with a 
four-nucleotide deletion just downstream of the homeodomain, resulting in a 
premature truncation of the protein. AI with taurodontism has similar characteristics as 
TDO and has also been associated with mutations with DLX3 in some families 
investigated, albeit distinct from the four nucleotide deletion/mutation described  
above 7. AI is an autosomal dominant trait leading to dental enamel defects and 
enlarged pulp chambers and has been associated with a two-nucleotide deletion within 
the homeodomain of DLX3. This deletion again results in a frameshift and premature 
truncation of DLX3 in the carboxyl terminus, primarily downstream of the homeobox. 
In addition to TDO and AI, Dlx3/Dlx4 have been identified in the gene interval 
thought to be involved in some forms of craniofacial abnormalities, including cleft 
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palate 8. The putative involvement of Dlx3 in the occurrence of cleft palate is also 
supported by the murine model deficient in endothelin-A receptor, which results in 
cleft palate and hypoplasia of the mandible 9-11. In this model, Dlx3 expression is 
thought to be dependent upon endothelin-1 through a Gαq/Gα11-dependent 
mechanism. In the Gαq/Gα11-deficient mouse, Dlx3, among other factors, is 
specifically down-regulated, supporting the speculation of the importance of Dlx3 in 
cranio-facial morphogenesis 12. Thus, the role and importance of Dlx3 in morphogenic 
aspects of development and in epithelial differentiated function is rather far reaching. 
The Dlx3 null mouse dies in utero by E10 due to putative placental failure 13. This 
was associated with a failure in the development/morphogenesis of the placental 
labyrinth compartment of the murine placenta. Further, genetic loss of Dlx3 was 
correlated with reduced expression of an additional homeobox factor, Esx1, 
suggesting that Dlx3 may be an important transcriptional regulator of Esx1 promoter 
activity. Studies from our laboratory identified DLX3 as a cell type-specific 
transcriptional activator in placental trophoblasts. DLX3 binds to and transactivates 
the promoter for the glycoprotein hormone α subunit gene via a cis-acting element 
required for full basal activity of this gene 14. The glycoprotein hormone α subunit is a 
subunit of the heterodimeric glycoprotein hormone, CG. Trophoblast-derived CG has 
been identified in primates and equine and appears to play a critical role in the 
maintenance of early pregnancy in women, providing early gonadotropic support to 
the CL and maintenance of progesterone production 15-17. Both for the case of the α 
subunit promoter and regulation of Esx1 in the Dlx3 null mouse, Dlx3 appears to 
function as a putative transcriptional activator. However, it has also been proposed 
that Dlx3 can serve as a negative regulator of gene transcription in amphibian models 
2. This apparent activation/repression capability may be due to variable heterodimeric 
partners of Dlx3 (as proposed in Ref. 2), dependent upon cell context and 
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physiological state. This observation was the impetus for us to examine potential 
binding partners of DLX3 in the context of the human placenta. The present studies 
identify SMAD6 as a binding partner for DLX3 using a yeast two-hybrid screen of a 
human term placental cDNA library. DLX3 and SMAD6 are co-localized in the 
nucleus of cells of trophoblast origin including cytotrophoblasts and syncytial 
trophoblasts from fully differentiated human term placenta. Interaction between DLX3 
and SMAD6 alters the DNA binding properties of DLX3 such that SMAD6 serves as 
a negative regulator of DLX3-dependent gene transcription of the Esx1 promoter. 
 
Materials and Methods 
Plasmids and cDNAs 
    All plasmids used in these studies were prepared by two cycles through cesium 
chloride using standard protocols. Expression vector for human DLX3 was generously 
provided by Dr. Maria Morasso (National Institutes of Health, Bethesda MD). A series 
of deletion mutants of the DLX3 cDNA were constructed by PCR. To facilitate 
cloning into the pKH3 vector (generously provided by Dr. Jun-Lin Guan, Cornell 
University, Ithaca, NY), EcoR I and Cla I restriction sites were added to the forward 
and reverse primers, respectively. The forward primers used in these reactions were as 
follows: forward 1, 5’-TCAGGAAT TCAAATGAGCGGCTCCTTCGATCGC-3’, 
forward 40, 5’-TCAGGAATTCAACTGGGC TATTACAGCGCTCCTCAG-3’, 
forward 80, 5’-TCAGGAATTCAATACTCGCCCAAGT CGGAATATACC-3’, 
forward 121, 5’-TCAGGAATTCAAATGGTGAACGGCAAGCCCAAAAAG-3’, and 
forward 195, 5’-TCA GGAATTCAACTGGAACACAGCCCCAACAACAGT-3’. 
The reverse primers used in these reactions were as follows: reverse 128, 5’-
GTACATCGATCACGGCTTTCGGACC TTCTTGGGCTTCCC-3’, reverse 163, 5’-
GTACATCGATCAAGCTAGCTCGGCGCGCTCAGGCAA-3’, reverse 202, 5’-
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GTACATCGATCAACTGTATTGGGACTGTGCTCCAG-3’, and reverse 287, 5’-
GTACATCGATTCAGTACACAGCCCCAGGGTT-3’. PCR products were cloned 
initially into the pGEM T-Easy vector (Promega Corp., Madison, WI). Once verified 
by nucleotide sequence analysis, fragments were subcloned into the pKH3 vector for 
use in studies. SMAD6 expression plasmid was a gift from Dr. Ali Hemmati-
Brivanlou (The Rockefeller University, New York, NY). SMAD4 expression vector 
was a gift from Dr. Colin Clay (Colorado State University, Fort Collins, CO). The 
human DLX4 cDNA was obtained by PCR from RNA isolated from JEG3 cells using 
the following primers: 5’-TCAGGAATTCAAATGACCTC TTTACCCTGTCCC-3’ 
and 5-GTACATCGA TCACATCATCTGAGGCAG TGC-3’. The resulting DLX4 
cDNA was cloned into pKH3 and verified by nucleotide sequence analysis. Esx1-
2.3kb promoter was obtained by PCR using mouse genomic DNA and the following 
primers: 5’ primer (5’-GGTACCAGCACCGAGCTATCACAACCATCA-3’) and 3’ 
primer (5’-GCTAGCTACCAGCTGCTTCTCCCGTA-3’). To facilitate cloning, Kpn I 
and Nhe I restriction enzyme sites were engineered at the end of the 5' primer and 3’ 
primer respectively. The PCR products were cloned into pGEM T-Easy vector. After 
Kpn I and Nhe I digestion, the promoter fragment was subcloned into a luciferase 
reporter vector. The fidelity of the construct was confirmed by nucleotide sequence 
analysis. PCR-based site-directed mutagenesis was used to disrupt the distal DLX3 
binding site within the Esx1 luciferase reporter. This mutation substituted a Not I 
restriction site for the near consensus DLX3 binding site. The mutation was confirmed 
using nucleotide sequence analysis. The human α subunit gene promoter luciferase 
reporter has been reported previously 14. 
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Yeast two-hybrid screen 
To investigate novel protein-protein interactions, full-length DLX3 served as the 
bait protein with a human term placental cDNA library serving as the target. The bait, 
human DLX3 cDNA was cloned into the vector pGBKT7 and transformed in the yeast 
strain AH109. A pretransformed human term placental Matchmaker cDNA library was 
in yeast strain Y187 (BD Biosciences/Clontech, Palo Alto, CA). The bait and library 
plasmids were expressed as GAL4 fusion proteins. 3-amino-1,2,4-triazole was titrated 
(5-35 mM) using the bait strain to control background yeast growth. A concentration 
of 12 mM 3- amino-1,2,4-triazole was used in the library screen. The bait and library 
strains were mated with an efficiency of approximately 4%. The bait strain required 
Leu- Synthetic Dropout (SD) minimal medium, and the library strain required Trp- SD 
minimal medium. Mating was carried out in YPDA media containing 0.003% adenine 
hemisulfate. Following mating of the bait strain with the human placental library, 
yeast was initially plated on medium stringency SD media (His-/Leu-/Trp-) plates. 
When colonies were of sufficient size, colonies were replicate plated on high 
stringency SD medium (Ade-/His-/Leu-/Trp-/X-α-Gal) plates to verify that they 
maintained the correct phenotype. A colony filter lift assay was performed to access 
β-galactosidase activity to identify and rank the strength of potential interactions. 
Once identified, yeast plasmids were isolated using disruption with glass beads and 
plasmids rescued/purified using the Qiagen Miniprep reagents and spin column 
(Qiagen Inc., Valencia, CA). Identity of the rescued plasmids was verified by 
nucleotide sequence analysis. The interaction between DLX3 and target genes was 
examined using a reconstitution assay where both plasmids were co-transformed into 
the AH109 yeast strain and plated on high stringency SD medium.   
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Preparation of JEG3 cell nuclear extracts 
Subconfluent JEG3 cells were used for the preparation of nuclear extracts. Cells 
were washed twice with ice-cold Dulbecco’s Phosphate Buffered Saline (PBS; 
Invitrogen Corp., Carlsbad, CA). Cells were collected by scraping in ice-cold PBS 
supplemented with 1:1000 dilution of protease inhibitor cocktail (referred to as 
protease inhibitor cocktail; Sigma-Aldrich Corp., St. Louis, MO), 5 mM benzamidine, 
and 0.2 mM phenylmethylsulfonyl fluoride (PMSF). Cells were pelleted by 
centrifugation and resuspended in a hypotonic buffer consisting of 120 mM potassium 
chloride, 30 mM sodium chloride, 30 mM Hepes (pH 8.0), 0.3 M sucrose, protease 
inhibitor cocktail, 5 mM benzamidine, and 0.2 mM PMSF and allowed to swell for 15 
min on ice. Cells were lysed by douncing and nuclei were isolated by layering the 
broken cell lysate over a sucrose cushion (0.9 M sucrose) followed by centrifugation 
at 2000×g for 30 min at 4˚C. The nuclear pellet was resuspended in a buffer 
containing 10 mM Tris (pH 7.5), 50 mM NaCl, 5% glycerol, 1 mM ethylenediamine 
tetraacetic acid (EDTA), protease inhibitor cocktail, 5 mM benzamidine, and 0.2 mM 
PMSF. Additional sodium chloride was added to a final concentration of 450 mM and 
nuclear proteins were extracted with constant rocking at 4˚C for 30 min. Nuclear 
extracts were clarified by centrifugation (85,000×g for 60 min) and the nuclear extract 
was stored in aliquots at –80˚C until later use. Protein concentrations of the nuclear 
extracts were determined by Bradford assay. 
 
Immunoprecipitation (IP) from JEG3 nuclear extracts and Western blotting 
analysis 
JEG3 cell nuclear extracts (200µg) were suspended in 1ml of 0.1% Triton X buffer 
(50 mM Tris (pH 7.6), 50 mM sodium chloride, 0.1% Triton X, protease inhibitor 
cocktail, 5 mM benzamidine, and 0.2 mM PMSF). To pre-clear the nuclear extracts, 
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protein A/G-agarose (Santa Cruz Biotechnology Inc., Santa Cruz, CA) was added to 
each suspension and allowed to mix for 1 h at 4˚C with gentle rocking. Following 
centrifugation (1200×g for 1 min) to remove protein A/G-agarose, antibodies were 
added at the following dilutions: normal rabbit serum at 1:1000; Dlx3 antibody at 
1:1000; SMAD6 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 1:100. 
Following 2 h at 4˚C of gentle rocking, protein A/G-agarose (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) was added and allowed to mix for an additional 2 
h. Complexes were then washed four times with 0.1% Triton X buffer. Samples were 
then suspended in an equal volume of 2×SDS loading buffer (100mM Tris (pH 6.8), 
4% SDS, 20% glycerol and 200 mM dithiothreitol). Protein samples were boiled for 3 
min and chilled for 5 min on ice. Proteins were resolved by SDS-polyacrylamide gel 
electrophoresis and transferred to polyvinylidine difluoride membranes by 
electroblotting. Membranes were blocked with nonfat dried milk (5%) in Tris-buffered 
saline [10 mM Tris (pH 7.6), 150mM sodium chloride] containing 0.1% Tween 20 
(TBST). For western blots, the DLX3 antibody was used at 1:5000 in TBST, 5% 
nonfat dried milk. The reciprocal western blot from IPs using the SMAD6 antibody 
was not possible since the IP heavy chain IgG blocked visualization of SMAD6 on 
western blot due to similar molecular size. In other western blot studies, the SMAD6 
antibody was used at 1:500 and the actin antibody (Santa Cruz Biotechnology Inc., 
Santa Cruz CA) was used at 1:1000 dilution. Proteins bands were visualized by 
chemiluminescence reagents (PerkinElmer Life Sciences, Wellesley, MA).  
 
Immunocytochemistry 
JEG3 cells were cultured on glass slides or coverslips for 24 h, rinsed one time 
with potassium phosphate buffered saline (KPBS), then fixed for 20 min with 4% 
paraformaldehyde. Slides or coverslips were then stored in 70% ethanol until used. 
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Prior to use, slides were rinsed in KPBS seven times over 1 hour. JEG3 cells were 
incubated with primary antibody (SMAD6 at 1:100; DLX3 at 1:500) overnight at 4˚C. 
Slides were again rinsed with KPBS followed by incubation with a fluorescent-
conjugated secondary antibody (Alexa 594, Molecular Probes, Eugene OR; and Cy2, 
Jackson Immunoresearch Labs, Westgrove, PA) in KPBS-Triton X at 37˚C for 2 h. 
Cells were rinsed in KPBS, dehydrated through a graded series of ethanol, cleared 
with xylene and coverslips attached with Krystalon (EM Science, Gibbstown NJ). 
Samples of human term placenta (derived from elective caesarian section) were 
obtained from Cayuga Medical Center, Ithaca, NY under the guidelines and approval 
of the Cornell University and the Cayuga Medical Center Committees on the Use of 
Human Subjects in Research. Samples were collected, fixed with 4% 
paraformaldehyde for 48 h and transferred to 70% ethanol until processing. Tissues 
were paraffin embedded and 5 µm sections were obtained. Immunocytochemistry was 
performed as previously described 14, except that fluorescent-conjugated secondary 
antibodies were used as described above. 
 
Recombinant proteins and immuno-precipitation analysis 
Recombinant SMAD6, SMAD4, DLX4, DLX3 and deletions of DLX3 were 
prepared using a coupled transcription and translation Wheat Germ Extract System 
(Promega Corp., Madison, WI) following the prescribed protocol. Proteins were 
radioactively labeled using 35S methionine (1,000Ci/mmol at 10mCi/ml; Amersham, 
Piscataway, NJ). A portion (10%) of each recombinant protein was saved for input 
analysis. Protein combinations were added at a 1:1 (by volume) mixture to a 0.1% 
Triton X buffer along with appropriate antibody at specified concentrations (DLX3 at 
1:1000; SMAD6, Santa Cruz Biotechnology Inc., Santa Cruz, CA at 1:100; and 
SMAD4, Santa Cruz Biotechnology Inc., Santa Cruz, CA at 1:500). Following 2 h of 
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gentle rocking at 4˚C, protein A/G-agarose (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA) was added and allowed to mix for an additional 2 h. Complexes were then 
washed four times with 0.1%Triton X buffer. Proteins were resolved by SDS-
polyacrylamide gel electrophoresis, the gel was fixed in 25% methanol, and 15 % 
glacial acetic acid for 1 h with gentle rocking at room temperature. The gel was then 
washed three times in 40% isopropanol solution, dried and bands visualized by 
autoradiography. 
 
Electrophoretic mobility shift assay 
Electrophoretic mobility shift assays (EMSA) were carried out as described 
previously 14,18 using the indicated antibodies. Reactions (without probe) were 
maintained at room temperature for 30 min followed by addition of 32P-labeled 
oligonucleotide DLX3 binding site probes (the junctional regulatory element or JRE 
from the glycoprotein hormone α subunit promoter 14 and two putative DLX3 binding 
sites identified within the Esx1 promoter). The binding reactions were maintained an 
additional 30 min then resolved on native polyacrylamide gels. To determine if 
SMAD6 could displace prebound DLX3 in EMSA, binding reactions containing 
DLX3 alone were allowed to incubate with probe for 30 min to reach equilibrium. 
SMAD6 protein was then added and the reactions were incubated for an additional 30 
min. These reactions were compared to binding reactions where both DLX3 and 
SMAD6 were added together and incubated for the full 60 min. Following 
electrophoresis, the gels were dried and DNA-protein complexes were visualized by 
autoradiography. All DNA binding studies were conducted at least three times with 
similar results. The nucleotide sequences for probes were as follows (only one strand 
indicated): JRE: 5’-ACGTCATGGTAATTACACCAAG-3’ Distal binding site: 5’-
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ACA AGGAGCTAATTTACTTCCT-3’ Proximal binding site: 5’-
TTAGGGCTCTAATTCAGACTCT-3’. 
 
Cell culture and transient transfection studies 
JEG3 cells were cultured in monolayer using Dulbeco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS). Before transfection 
studies, cells were split to 35 mm dishes and sub-confluent cultures were used. JEG3 
cells were transiently co-transfected with an Esx1 promoter luciferase reporter 
construct, DLX3 expression vector at a constant dose (2.0 µg) and increasing doses of 
SMAD6 expression vector using lipofection (FuGENE 6 transfection reagent; Roche 
Diagnostics Inc., Indianapolis, IN). All transfections were carried out with a constant 
amount of DNA by supplementing reactions with the parent vector pKH3. Luciferase 
activity was determined after 24 h of transfection using reagents from the Luciferase 
Reporter Assay System (Promega Corp., Madison, WI), and luciferase activity was 
standardized by total cell protein amount (luciferase/1.0 µg) as determined by 
Bradford assay. All transfection studies were conducted in triplicate on at least three 
separate occasions with similar results. Data are shown as means (n=3) ± standard 
errors of the mean of a representative experiment. 
 
Preparation of stable cell lines expressing small interference RNA (siRNA) 
The mammalian expression vector, pSUPER-retro-neo (pSR; OligoEngine, Seattle, 
WA) was used for preparation of retrovirus containing specific siRNAs and expression 
of siRNAs in JEG3 cells following viral infection. Each gene-specific insert targeted a 
19-nucleotide sequence within the human SMAD6 mRNA. The siRNA sequences were 
as follows: SMAD6-#1: 5’CACATTGTCTTACACTGAA SMAD6-#2: 
5’TCAAGGTGTTCGACTTCGA SMAD6-#3: 5’GCCACTGGATCTGTCCGAT The 
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plasmids were referred to as SMAD6 siRNA #1, #2 and #3. A control siRNA vector 
(also prepared in pSR) was constructed using a 19-nucleotide sequence 
(5’TTCTCCGAAC GTGTCACGT) putatively without significant similarity to any 
mammalian gene sequence and therefore served as an appropriate negative control 
(OligoEngine, Seattle, WA). The forward and reverse strands of oligonucleotides 
containing the siRNAs and nonsense sequence also contained Bgl II and Hind III sites 
at the 5’end of the forward and reverse oligonucleotides, respectively. The 
oligonucleotides were annealed and inserted into the pSR vector after digestion of the 
vector with Bgl II and Hind III. These siRNAs were a self-contained hairpin loop for 
the double stranded siRNA. All siRNA sequences were confirmed by nucleotide 
sequencing.  
 
Cell culture, transfection and retroviral infection of siRNAs 
HEK293 Phoenix Ampho packaging cells (American Type Culture Collection; 
Manassa, VA) were cultured in DMEM containing 10% FBS and were transfected 
with the pSUPER-retro-neo siRNA plasmids using FuGENE 6 transfection reagent 
(Roche Diagnostics Inc., Indianapolis IN). Forty-eight hours following transfection, 
the culture media containing the retrovirus for individual siRNAs and control siRNA 
were filtered through a 0.45-µm filter, and the viral supernatant was used for infection 
of JEG3 cells in the presence of 8 µg/ml polybrene. JEG3 cells were exposed to the 
retrovirus overnight, cell were then washed with fresh medium and allowed to recover 
for 24 h. Following infection, stable cell lines were selected using neomycin at 500 
µg/ml for 7 days (time until untransfected cells all died) then cultures were maintained 
in medium containing 500 µg/ml neomycin. Transient transfections of the siRNA cell 
lines were carried out as described above. 
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Statistical analysis 
Luciferase data were subjected to analysis of variance and differences between 
treatments were determined using Tukey’s Studentized Range Test. Probability of less 
than 0.05 (p<0.05) was considered statistically significant. 
 
Results 
DLX3 and SMAD6 functionally interact in a yeast two-hybrid screen 
Full-length human DLX3 was used as a bait protein in a yeast two-hybrid screen of 
a human term placental library. The screen included coverage of approximately 
3.4×106 independent clones. Once colonies were identified from the original screen 
and library plasmids were rescued, plasmids were retransformed in a reconstitution 
assay with the bait vector into the AH109 yeast strain. The library plasmid resulting in 
the most robust interaction (as measured by β-galactosidase activity) with DLX3 was a 
cDNA containing the entire coding region of SMAD6. Transformation of the SMAD6 
library vector alone did not support yeast growth on high stringency SD medium (Ade-
/His-/Leu-/Trp-/X-α-Gal) plates in the presence of 12 mM 3-amino-1,2,4-triazole. 
Transformation of Dlx3 bait vector minimally supported yeast growth under the same 
conditions. Co-transformation of DLX3 bait and SMAD6 library plasmid resulted in 
rescue of yeast growth (Figure 2.1A).  
 
DLX3 and SMAD6 are co-localized in the nucleus in choriocarcinoma cells and in 
human placental trophoblasts 
Initially, studies focused on examining localization of DLX3 and SMAD6 proteins 
in cells of trophoblast origin. DLX3 and SMAD6 were expressed and localized 
primarily in the nuclear compartment in JEG3 cells (Figure 2.1B), a choriocarcinoma 
cell line of trophoblast origin. Consistent with this observation, DLX3 and SMAD6 
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were nuclear localized to both cytotrophoblast and syncytial trophoblast within 
microvilli of fully differentiated term human placenta. Localization of DLX3 in term 
placenta provided additional insight into the expression pattern of DLX3 during 
gestation in primates. We have previously shown DLX3 in placental trophoblasts in 
human placenta obtained at 8 weeks gestation during peak production 
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Figure 2.1. DLX3 and SMAD6 interact in yeast two hybrid and co-localize in 
placental trophoblasts. A. Yeast two-hybrid screen of a human term placental library 
was carried out using full length DLX3 as bait. Following plasmid rescue, Gal4 DNA 
binding domain-DLX3 bait was co-transformed along with Gal4 activation domain-
SMAD6 into the AH109 yeast strain and plated on (-His, -Leu,  
-Trp) media as described in Methods. B. JEG3 cells were plated on glass slides and 
fixed as described in Materials and Methods. Double labeled immunocytochemistry 
was used to determine localization of DLX3 (green) or SMAD6 (red). The merged 
images demonstrate overlapping expression patterns. Human term placenta was 
obtained, fixed and sectioned as described in Materials and Methods. Similar double 
labeled immunocytochemistry was used to localize DLX3 and SMAD6. The white 
arrow head identifies nuclei in syncytial trophoblasts while the black arrow head 
identifies nuclei in cytotrophoblasts. Bar = 20 µm. 
This figure is kindly provided by Dr. Kathie A. Berghorn. 
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of hCG 14. The current studies support the conclusion that DLX3 expression may be 
maintained within trophoblast cell populations until term in the human placenta. 
Since both DLX3 and SMAD6 were expressed endogenously in the JEG3 
horiocarcinoma cell model, we sought to use this model for subsequent analyses. We 
have used JEG3 cells previously for molecular analysis of gene regulatory processes 
related to glycoprotein hormone and DLX3 gene promoter expression 14,18,19. IP studies 
using nuclear extracts from JEG3 cells and SMAD6 antibody revealed that DLX3 and 
SMAD6 interact in mammalian cells (Figure 2.2A). The reciprocal study using DLX3 
antibody to IP SMAD6 was not possible due to the molecular size of SMAD6 and 
interference with the IgG heavy chain used in the IP studies. However, this constraint 
was overcome with preparation of DLX3 and SMAD6 as recombinant proteins labeled 
with [35S] methionine. IP of recombinant DLX3 and SMAD6 with the DLX3 antibody 
revealed specific association with SMAD6 but not Smad4 (Figure 2.2B). Thus, the 
original interaction defined in the yeast system was supported by IP studies in 
choriocarcinoma cells that endogenously express these two proteins and in vitro using 
recombinant DLX3 and SMAD6 proteins. 
 
Structure/function analysis of the DLX3/SMAD6 interaction interface 
To further understand the mechanism of the DLX3/SMAD6 interaction, we 
constructed a series of deletion mutants of DLX3 (Figure 2.3A). The rationale for 
these mutations was predicated on existing understanding of important domains within 
DLX3 defined by others 20,21, centering upon the homeodomain (residues 130-189; 
Figure 2.3A), the centrally located DNA binding domain. DLX3 deletion mutants 
were prepared in vitro along with full-length DLX3 and SMAD6. SMAD6 IP was then 
used to determine the domains sufficient to support interaction with DLX3. Initially, 
we identified the importance of DLX3-(1-202), which bound SMAD6 at levels similar  
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Figure 2.2. DLX3 and SMAD6 interact in the JEG3 choriocarcinoma cell model.  
A. JEG3 cell nuclear extracts were used in immunoprecipitation (IP) studies. IPs 
included the use of normal rabbit serum (NRS) or antisera (ab) directed against DLX3 
or SMAD6. Recombinant DLX3 (rDLX3; without HA epitope tag) and IPs were 
resolved by SDS-PAGE and Western blots for DLX3 were carried out (IB DLX3).  
Molecular size standards (MW) are depicted to the left of the panel. B. Recombinant 
DLX3, SMAD6 and SMAD4 were produced using wheat-germ lysates in a coupled 
transcription/translation reaction containing 35S methionine (Input).  DLX3 and either 
SMAD6 or SMAD4 were combined followed by IP with the DLX3 antibody (DLX3 
IP). The input and IPs were resolved by SDS-PAGE, the gels fixed and dried and 
autoradiography was used to visualize bands. 
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Figure 2.3. Deletion mutants of DLX3 reveal interaction interface with SMAD6.   
A. A series of DLX3 deletions (characterized in schematic form) were prepared using 
PCR. The numbers represent amino acid designations for the termini of wild type 
DLX3 and each mutant. B. Wild type DLX3, SMAD6 and the DLX3 deletion series 
were prepared as recombinant proteins as described in Figure 2B (Input) and subjected 
to IP studies using the SMAD6 antibody (SMAD6 IP) and recombinant SMAD6 and 
the combination of deletions mutants indicated. The input and IPs were resolved by 
SDS-PAGE, gels were fixed and bands visualized by autoradiography. Asterisks (*) 
designate bands consistent with protein-protein interactions. 
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to DLX3-(1-287) (Figure 2.3B). DLX3-(121-287) bound SMAD6 as well, suggesting 
that SMAD6 interaction domain required at least a portion of the homeodomain 
(Figure 2.3B). Based upon these results, we predicted that DLX3-(121-202) mutant 
would also bind SMAD6. This was not readily interpretable in our studies since 
putative degradation fragments/products of these recombinant deletion mutants were 
of similar molecular size as the DLX3-(121-287) mutant. Subsequent DLX3 deletion 
mutants defined a region of DLX3-(80-163) that was sufficient to bind SMAD6 in 
vitro (Figure 2.3B). These studies again supported the conclusion that at least the 
amino-terminal portion of the homeodomain was sufficient for interaction with 
SMAD6 in vitro. Alignment of DLX3 with DLX4 (another member of the DLX 
family expressed in placenta 22) revealed approximately 37% amino acid conservation 
within this region (residues 80-163; Figure 2.4A), with higher levels of homology 
particularly clustered within the homeodomain, supporting the prediction that DLX4 
may also bind SMAD6. Based upon in vitro studies, recombinant full-length DLX4 
bound SMAD6 similar to DLX3-(1-287) (Figure 2.4B). DLX3-(195-287), previously 
shown not to bind SMAD6 (Figure 2.3B), was used in these studies as a negative 
control.  
 
DLX3 binds to the 5’-flanking sequence of the Esx1 promoter 
To begin to examine the functional significance of the DLX3/SMAD6 interaction 
on gene transcription, we cloned 2.3 kilobases of the 5’-flanking sequence of the Esx1 
promoter. The report of the Dlx3 null mouse provided evidence that the loss of Dlx3 in 
vivo was correlated with a loss of Esx1 mRNA in mouse placenta 13. Taking advantage 
of this observation, we identified two near consensus Dlx3 binding sites within the 
2.3-kb promoter fragment. The distal site was located at -2135 and the more proximal 
site at -585 relative to the transcription start site of the Esx1 promoter, as previously  
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Figure 2.4. DLX4 binds SMAD6. A. Alignment of DLX3 and DLX4 between 
residue 80 and 198 reveals regions of conserved sequence within the SMAD6 
interaction domain (residue 80-163). The consensus amino acid sequence is listed in 
bold below the alignment. B. Wild type DLX31-287, DLX3195-287, SMAD6 and DLX4 
were prepared as recombinant proteins as described in Figure 2 (Input) and subjected 
to IP studies using the SMAD6 antibody (Smad6 IP) and recombinant SMAD6 and 
combinations of DLX3 or DLX4 as indicated. The input and IPs were resolved by 
SDS-PAGE, gels were fixed and bands visualized by autoradiography. Asterisks (*) 
designate bands consistent with protein-protein interactions. 
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Figure 2.5. Two putative Dlx3 binding sites are present within the Esx1 
promoter.  A. The junctional regulatory element (JRE), a consensus Dlx3 binding site 
from the glycoprotein hormone α subunit promoter was compared to the distal 
(position -2135) and proximal (position -585) binding sites from the Esx1 promoter. 
The central core of the binding site is underlined. B. Electrophoretic mobility shift 
assays (EMSA) were used to compare binding complexes formed on the JRE, the 
distal and proximal Dlx3 binding sites within the Esx1 promoter using JEG3 cell 
nuclear extract and recombinant DLX3. Equal amounts of nuclear extracts or 
recombinant DLX3 were added to each binding reaction. Recombinant DLX3 in these 
studies was epitope tagged with three copies of the HA epitope (3xHA-DLX3). 
Binding reactions were resolved on native polyacrylamide gels. The gels were dried 
and bands visualized by autoradiography. Free probe is designated by an arrow at the 
bottom of the gel.  This figure is kindly provided by Ms. Li Han. 
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defined 23. At both of these two sites, the central core of the binding site (TAATT) was 
conserved; however, the two nucleotides present on the 3’ termini of this central core 
were not conserved (Figure 2.5A). These nucleotides varied from the consensus Dlx3 
binding site 24 we defined in the human glycoprotein hormone α subunit promoter 14. 
Using EMSAs, we compared the DNA binding complexes formed when using the 
distal (-2135) and proximal (-585) putative Dlx3 binding sites from the Esx1 promoter 
and nuclear extracts from JEG3 cells (Figure 2.5B). As a positive control, the JRE 
from the α subunit promoter was used. Figure 2.5B depicts direct comparison of 
complexes formed with all three of these binding sites. The distal site was more 
similar to the JRE binding complex electrophoretic mobility when compared to the 
proximal site. When using recombinant DLX3 in EMSA (Figure 2.5B), all three sites 
were sufficient to bind DLX3; however, clear differences in the relative binding of 
DLX3 for these binding sites were revealed. The recombinant DLX3 was slightly 
larger in molecular size due to the presence of the three hemagglutinin (HA) epitopes 
engineered into the recombinant protein. The rank order of relative binding for 
recombinant DLX3 was the JRE (highest) > the distal site > the proximal site (lowest). 
We focused our attention on the distal DLX3 binding site within the Esx1 gene 
promoter. EMSA studies using nuclear extracts and antiserum against DLX3 provided 
direct evidence that endogenous DLX3 can bind to this site (Figure 2.6A). The 
addition of the DLX3 antibody to EMSA binding reaction resulted in supershifted 
complexes that were not evident using preimmune normal rabbit serum (NRS). The 
addition of the SMAD6 or the C/EBP antiserum to these binding reactions did not 
appreciably alter complex formation in EMSA, suggesting that SMAD6 may not 
directly participate in DNA binding with DLX3 and that DLX3 antibody interactions 
were specific. To determine the importance of this site to DLX3-induced Esx1 gene 
transcription, the distal site was mutagenized to a Not I restriction site and examined   
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Figure 2.6. The distal binding site of the Esx1 promoter binds DLX3 and is 
necessary for full DLX3-induced gene transcription. A. Using only the distal 
binding site for DLX3 and JEG3 cell nuclear extract (JEG3 NE), studies examined if a 
DLX3 antibody would disrupt binding of endogenous proteins including DLX3 to this 
site. Binding reactions were resolved on native polyacrylamide gels, the gels were 
dried and bands visualized by autoradiography. Addition of a DLX3 antibody (DLX3 
ab) to binding reactions resulted in the formation of a super shifted complex as 
indicated (supershift). Normal rabbit serum was used as a control for the DLX3 
antibody. In some binding reactions, the JEG3 NE was boiled and then added to 
reactions containing the DLX3 ab as a negative control. Free probe is designated by an 
arrow at the bottom of the gel. B. Transient transfection studies were used to 
determine the relative importance of the distal DLX3 binding site on expression of the 
Esx1 promoter luciferase reporter gene. JEG3 cells were transiently transfected with 
either wild type Esx1 luciferase reporter or an Esx1 luciferase reporter containing a 
mutation within the distal DLX3 binding site. Cells were cotransfected with control 
plasmid or a DLX3 expression vector (2 µg; designated – or +). Data are reported as 
relative luciferase activity standardized for protein for a representative study 
(n=3/treatment). The designations a, b and c indicate significant differences (p<0.05).   
This figure is kindly provided by Ms. Li Han. 
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using a luciferase reporter gene approach in transient transfection studies (Figure 
2.6B). The wild type Esx1 promoter was strongly induced by DLX3. The mutation in 
the distal putative DLX3 binding site reduced DLX3-induced Esx1 expression by 
>50% (p<0.05), suggesting that this site was important for promoter activity induced 
by DLX3. 
We then sought to determine the impact of SMAD6 on DLX3 DNA binding. 
Reconstitution EMSAs using recombinant DLX3 and SMAD6 demonstrated that the 
DLX3/SMAD6 interaction effectively reduced/ blocked association of DLX3 with the 
distal DLX3 binding site within the Esx1 promoter (Figure 2.7A). In this experiment, 
SMAD6 alone did not form a complex with the distal DLX3 binding site. When 
SMAD6 was titrated into the binding reactions containing DLX3, the DLX3 binding 
complex was diminished in a dose-dependent manner. Using the JRE as probe, a 
similar titration of SMAD6 protein reduced DLX3 binding, albeit to a lesser extent 
compared to the distal site of the Esx1 promoter. Studies then focused on determining 
if prebound DLX3 could be displaced by SMAD6 in EMSA binding reactions (Figure 
2.7B). Binding reactions compared addition of DLX3 concurrent with SMAD6 and 
reactions where DLX3 binding was allowed to reach equilibrium then SMAD6 was 
added. These studies revealed that for the distal probe, SMAD6 competed for DLX3 
binding regardless of order of protein addition. Similar levels of competition were not 
observed using the JRE (stronger relative binding), suggesting that SMAD6 can 
compete for DLX3 binding particularly on gene targets that have relatively weaker 
DLX3 binding sites, like those characterized within the Esx1 gene promoter. 
To assess the functional consequences of the DLX3/SMAD6 interaction on the 
Esx1 promoter, we again used the Esx1 promoter-luciferase reporter construct (Figure 
2.8). Based upon the binding studies described above, our prediction was that SMAD6 
overexpression would probably repress expression of the Esx1 promoter induced by  
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Figure 2.7. SMAD6 attenuates DLX3 DNA binding. A. To examine the effects of 
SMAD6 on DLX3 binding, recombinant DLX3 and SMAD6 were prepared in vitro 
and used in electrophoretic mobility shift assays (EMSA) with the distal DLX3 
binding site within the Esx1 promoter and the JRE. As observed earlier, DLX3 bound 
this site while increasing doses of SMAD6 (as represented by the grey triangle) did 
not bind.  Binding reactions containing a constant dose of DLX3 and increasing doses 
of SMAD6 resulted in a dose dependent reduction in DLX3 binding for the distal site 
and to a lesser extent for the JRE. B. EMSA studies were carried out to determine if 
order of protein addition had an impact on the ability of SMAD6 to interfere with 
DLX3 binding. Using the distal and JRE probes, binding reactions were assembled 
where DLX3 was added and allowed to reach equilibrium (DLX3) then SMAD6 was 
added (DLX3 > SMAD6). This was compared to binding reactions where DLX3 and 
SMAD6 were added concurrently (DLX3 + SMAD6). For both A. and B., free probe 
and DLX3 complexes are designated by arrows. 
This figure is kindly provided by Ms. Li Han. 
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DLX3. Using transient transfection in JEG3 cells, overexpression of DLX3 and 
SMAD6 resulted in increased levels of ectopically expressed DLX3 and SMAD6 
(Figure 2.8A). Further, DLX3 overexpression increased Esx1 luciferase activity 
(p<0.05; Figure 2.8B). Titration of SMAD6 into this system resulted in reduced basal 
activity of the Esx1 reporter gene (p<0.05). Consistent with our prediction, o-
transfection with increasing doses of SMAD6 expression vector along with DLX3 
resulted in a marked inhibition (p<0.05) of DLX3-induced Esx1 promoter activity. 
DLX3-induced activation of the α subunit gene promoter was also reduced by 
overexpression of SMAD6 (data not shown). In an effort to determine the specificity 
of SMAD6 action on gene transcription in general, we examined the effects of 
SMAD6 on the trophoblast Kunitz domain protein (TKDP) 1 (Figure 2.8C) and Rous 
sarcoma virus promoters (data not shown). TKDP1 promoter expression 25,26 is 
trophoblast-specific but not dependent upon DLX3 expression (Figure 2.8C). The 
Rous sarcoma virus promoter is constitutively active in trophoblast cells. In contrast to 
the effects of SMAD6 on DLX3-induced expression of the Esx1 and α subunit 
promoter, SMAD6 had no appreciable effect on the TKDP promoter and actually 
increased expression of the Rous sarcoma virus promoter in a dose-dependent manner. 
These studies support the conclusion that SMAD6 does not confer global non-specific 
transcriptional repression and probably the effects of SMAD6 on Esx1 and α subunit 
promoter activity are specific. 
 
siRNA-mediated knockdown of SMAD6 resulted in increased expression of the Esx1 
gene promoter.  
Whereas overexpression studies can be informative, interpretation of such studies 
must be cautious. To examine the effects of SMAD6 on DLX3-dependent gene 
expression, we developed stable cell lines expressing specific SMAD6 siRNA hairpin  
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Figure 2.8. SMAD6 attenuates DLX3-dependent promoter activation in JEG3 
cells. A. To determine the levels of ectopic expression of DLX3 and SMAD6 in 
overexpression studies, JEG3 cells were transiently transfected with expression 
vectors for DLX3 (+DLX3; 2 µg) or SMAD6 (+SMAD6; 2 µg). Whole cell lysates 
were prepared and western blot analyses were carried out using the DLX3 and 
SMAD6 antibodies. B. Transient transfection studies in JEG3 cells were used to 
investigate the functional relevance of SMAD6 on DLX3-dependent gene expression. 
Co-transfection of the Esx1 gene promoter-luciferase reporter with DLX3 (constant 
dose, 2 µg) and increasing doses of SMAD6 expression vector (0, 0.5, 1.0 and 2.0 µg; 
represented by the grey triangle) resulted in a dose dependent decrease in expression 
of the Esx1 luciferase reporter. C. Similar studies were carried out using the TKDP-1 
gene promoter luciferase reporter. As a control for DLX3 action, the Esx1 promoter 
was also used. TKDP-1-Luc activity was unaffected by DLX3 or increasing doses of 
SMAD6 expression vector. Data for all panels are reported as relative luciferase 
activity standardized for protein from representative studies (n=3/treatment). For B. 
and C. The designations a, b and c indicate significant differences (p<0.05) within 
experiment; ns = not significantly different.  This figure is kindly provided by Ms. Li 
Han. 
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Figure 2.9. siRNA-mediated knockdown of SMAD6 results in enhanced DLX3-
dependent expression of the Esx1 Luc reporter. A. Stable cell lines were selected 
using neomycin resistance following infection with retrovirus expression empty vector 
(Vector Control), three separate, independent siRNAs specific for SMAD6 (SMAD6 
siRNA #1-3) or a control siRNA (Control siRNA). Following selection, cell lysates 
were prepared and western blot analysis was used to determine SMAD6 protein levels. 
The cell lines were also assayed for DLX3 and ACTIN using specific antibodies. 
SMAD6 protein levels were reduced approximately 57% with siRNAs #1 and 3.  B. 
The Control siRNA and SMAD6 siRNA#1-3 cell lines were used in transient 
transfection studies using the Esx1 Luc reporter in the absence or presence of DLX3 
expression vector (2 µg). Data are reported as relative luciferase activity standardized 
for protein from representative studies (n=3/treatment). The designations a, b, c and d 
indicate significant differences (p<0.05).  This figure is kindly provided by Ms. Li 
Han. 
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loops (Figure 2.9A). Two of the three siRNA cell lines examined were found to have 
specific reductions in SMAD6 protein expression (SMAD6 siRNAs #1 and #3; 57% 
reduction compared to control siRNA) but not expression of DLX3 nor ACTIN 
(internal controls; Figure 2.9A). Transfection studies in the control siRNA and the 
SMAD6 siRNA cell lines using the Esx1 luciferase reporter demonstrated that basal 
activity of this promoter was elevated (p<0.05) in the siRNA#1 and siRNA#3 cell 
lines but not in the control and siRNA#2 cell lines. In response to DLX3, Esx1 
luciferase promoter activity was enhanced (p<0.05) in SMAD6 siRNA#1 and 
siRNA#3 cell lines but not in control or siRNA#2 cell lines [control siRNA (5.0-fold) 
versus siRNA#1 (7.3-fold) and siRNA#3 (8-fold)] in a manner highly correlated with 
the percentage loss of SMAD6 in these cell lines (Figure 2.9B). Thus, consistent with 
the overexpression studies, loss of endogenous SMAD6 was highly correlated with 
enhanced DLX3-dependent transcription of the Esx1 gene promoter. 
 
Discussion 
The present studies provide novel evidence for the functional association between 
DLX3, a distal-less class homeobox factor required for normal placental development 
in the mouse, and an inhibitory Smad, SMAD6. The role of DLX3 as a transcriptional 
activator is clear based upon studies in mammalian systems, such as the glycoprotein 
hormone α subunit gene promoter 14, the expression of the homeobox factor Esx1 in 
the Dlx3 null mouse 13, and the role of Dlx3 in the regulation of the osteocalcin gene 
27. Moreover, Dlx3 has been linked to transcriptional activation as well as 
transcriptional repression in Xenopus (reviewed in Ref.2). The ability of Dlx3 to serve 
in several different ways as a transcriptional modulator may be best explained by the 
presence of variable tissue- and cell type-specific binding partners. The present study 
provides important evidence that DLX3 and SMAD6 form a complex in a yeast 
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system, in mammalian cells in culture and in vitro using recombinant proteins. DLX3 
and SMAD6 also display overlapping expression in the nucleus of differentiated 
human term placental trophoblasts, suggesting that a functional interaction between 
these two proteins may be important in vivo. The finding that one DLX3 interacting 
partner is an inhibitory Smad may also reflect important cross-talk between the 
transforming growth factor (TGF) β/bone morphogenetic factor (BMP) signaling 
system and important developmental determinants that require DLX3. 
    Smad proteins are transcriptional regulators that can be subdivided into essentially 
three classes (reviewed in Refs. 28-30). Regulated or R-Smads (Smad 1, 2, 3, 5 and 8) 
are substrates of the serine/threonine kinase catalytic activity of TGFβ/BMP type I 
receptors. Phosphorylation of R-Smads promotes the association with a common or C-
Smad (Smad4) and subsequent nuclear translocation of the R- and C-Smad complex to 
affect TGFβ/BMP/Smad-specific target genes. Others have demonstrated an 
interaction between Smad4 and Dlx1 in the context of cytokine regulation of 
hematopoietic cells 31. A third unique subclass of this family is the inhibitory or I-
Smads (Smad 6 and 7). In the context of TGFβ/BMP signaling, I-Smads essentially 
oppose the activity of the stimulatory R- and C-Smads at several levels. I-Smads have 
been shown to compete for R-Smad binding to the type I TGFβ/BMP receptor, 
providing an inhibitory mechanism for R-Smad activity 32. In addition, Smad6 has 
been shown to interfere with the ability of Smad1 to form a complex with Smad4, 
independent of Smad1 phosphorylation state 33. I-Smads also form complexes with 
Smurfs, E3 ubiquitin ligases that appear to be involved in I-Smad nuclear export and 
marking target proteins (for example the TGFβ/BMP receptors and I-Smads 
themselves) for degradation by the proteosome, again contributing to an inhibitory 
action 28-30. 
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In the nuclear compartment, Smad6 appears to recruit the transcriptional co-
repressor C-terminal binding protein to target genes related to BMP action 34. Based 
upon the present studies, DLX3 and SMAD6 were localized to the nucleus of 
placental trophoblasts independent of apparent TGFβ/BMP signaling. Smad6 has been 
shown to serve as a transcriptional co-repressor following interaction with another 
homeodomain transcription factor, Hox c-8 35,36. In these studies, Smad6 complexed 
with Hox c-8 appeared to be sufficient to recruit histone deacetylase activities to Hox 
c-8-dependent genes thus repressing transcription via altered organization of 
chromatin structure. Our studies suggest that the interaction between DLX3 and 
SMAD6 may utilize an entirely different mechanism for transcriptional repression in 
human placental cells. SMAD6 interaction clearly resulted in a reduction of DLX3 
DNA binding activity, probably via steric interference. Our results demonstrate that 
the SMAD6 interaction interface includes the first two α helices of the homeodomain. 
SMAD6 interaction would then potentially interfere with DLX3 DNA binding, since 
these two α helices are central to DNA binding as well. This mechanism potentially 
alleviates a need for recruitment of transcriptional co-repressor activities, since a 
DLX3-SMAD6 complex association may preclude association of DLX3 with specific 
target gene promoter elements. Increased SMAD6 protein levels using overexpression 
inhibited DLX3-dependent gene expression. Conversely, reductions in the expression 
of endogenous SMAD6 using siRNA knockdown provides important evidence that 
DLX3-dependent gene expression may be particularly sensitive to relatively modest 
changes in SMAD6 protein levels in placental cells. These complementary approaches 
underscore the potential importance and sensitivity of DLX3-dependent genes to 
SMAD6 regulation. This may be largely true of Dlx3 target genes with binding sites 
that have low relative binding affinity, like Esx1.   
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The Dlx3 homeodomain is centrally located and serves as a DNA binding domain, 
one of the defining characteristics of all homeobox transcription factors 37,38. The 
domain structure of Dlx3 has been examined in studies defining a bipartite nuclear 
localization signal (residues 124-150) in a region adjacent to and including a portion 
of the homeodomain; transcriptional activation domains have been ascribed to 
residues 1-43 and 189-220; and Ser138 within the homeodomain is an apparent 
substrate for protein kinase C isozymes 20,21,24. The deletion mutagenesis carried out in 
the present studies defined residues 80-163 within DLX3 as the SMAD6 interaction 
domain in vitro. This region of DLX3 contains the first full α helix and approximately 
two-thirds of helix 2 within the homeodomain. In addition, this interaction interface 
contains Ser138, a substrate for PKC activity. Several possibilities exist for how DLX3-
SMAD6 association may alter DNA binding. Perhaps the most obvious is a steric 
interference model, since the interaction interface includes a portion of the 
homeodomain. In addition, the presence of Ser138 in this interaction domain lends 
itself to potentially interesting speculation. The equivalent of this serine residue is 
conserved in all six Dlx family members 1, consistent with the observation that, like 
DLX3, DLX4 is also a SMAD6 interacting protein. Using recombinant Dlx3, Morasso 
and co-workers demonstrated that phosphorylation at Ser138 by PKC (most strongly by 
PKCα) resulted in partial inhibition of Dlx3 DNA binding 21, consistent with the 
potential effects of SMAD6 on DNA binding. This supports speculation that 
phosphorylation of Dlx3 at Ser138 may alter or increase Smad6 binding leading to 
reduced DNA binding at Dlx3 target genes. Studies are currently underway to address 
this possibility.   
R- and C-Smads appear to be constitutively expressed in most cell types whereas I-
Smads are subject to regulation by a number of growth factors, such as EGF, TGFβ 
and BMPs. In many cases the effects of these growth factors are mediated through R- 
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and C-Smad-dependent transcriptional mechanisms. This has led to a hypothesis 
implicating an intracellular negative feedback loop, whereby positive TGFβ/BMP 
signals are modulated over time by accumulation of induced I-Smads (reviewed in 
Ref. 39). Interestingly, Dlx3 expression patterns during Xenopus development depend 
in part upon BMP signaling gradients 40,41. Inhibition of these gradients using the BMP 
receptor antagonist chordin resulted in a dose-sensitive inhibition of Dlx3, Dlx5 and 
Dlx6 mRNA expression. Dlx3 expression in mouse keratinocytes was also reported to 
be subject to regulation by BMPs 42 in a manner potentially coordinate with I-Smad 
expression. This supports speculation that not only might BMP-regulated Smad6 
expression serve as a negative feedback mechanism controlling the duration of Smad 
signaling but increased BMP-dependent Smad6 expression may lead to important 
modulation of Dlx3-dependent gene expression. BMPs have been shown to regulate 
early embryogenesis during the perimplantation period, such that these types of 
ligands are probably present and important during placental morphogenesis 43. 
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CHAPTER THREE 
 
MATRIX METALLOPROTEINASE 9 IS A DLX3 TARGET-GENE IN 
PLACENTAL CELLS 
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Abstract 
Matrix metalloproteinases (MMPs) are a large group of proteolytic enzymes 
that regulate extracellular matrix composition during normal biological processes such 
as during placental morphogenesis.  Previous microarray studies in mouse placenta 
suggested that at E9.5, MMP-9 transcript abundance was dependent upon Distal-less 3 
(Dlx3), a homeodomain-containing placental-specific transcriptional regulator.  Here 
we investigate putative mechanism(s) for Dlx3-dependent MMP-9 gene transcription 
and activity in placental trophoblasts and examine the hypothesis that Dlx3 and MMP-
9 may be involved in genetic mechanism(s) underlying preeclampsia (PE) using the 
murine model of PE, the BPH/5 mouse. Initial studies confirmed array data, 
demonstrating that MMP-9 secretion and catalytic activity were reduced in placental 
explants from Dlx3-/- mice compared to controls.  To investigate mechanisms of gene 
transcription, 1.9 kb of the murine MMP-9 5’ flanking sequence was cloned for use in 
luciferase-based reporter gene assays.  Bioinformatic analysis of this promoter 
fragment identified two near-consensus Dlx3 binding sites and MMP-9 promoter-
luciferase reporter activity was increased 3-5 fold by overexpression of Dlx3 in a 
human trophoblast cell line (JEG3).  Recombinant Dlx3 was able to bind to both 
putative Dlx3 binding sites in vitro.  Using JEG3 cell nuclear extracts, DNA affinity 
chromatography revealed a Dlx3-containing complex formed specifically at both Dlx3 
binding sites. Mutations in both elements resulted in a reduction of basal expression of 
the MMP-9 gene promoter and abolished regulation by overexpression of Dlx3.  
Chromatin immunoprecipitation studies in JEG3 cells also demonstrated that Dlx3 
binds to the human MMP-9 promoter in cells and siRNA-mediated knockdown of 
human Dlx3 resulted in marked reduction in endogenous human MMP-9 transcript 
levels and secreted MMP-9 protease activity.  Since MMP-9 has been shown to be 
mis-regulated in term human placentas during PE, we sought to determine if Dlx3 and 
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MMP-9 transcript levels were altered during early and late gestation in the BPH/5 
model of PE.  Quantitative PCR revealed that MMP-9 mRNA level was reduced in 
early gestation (E9.5) and increased during late gestation (E18.5) in placentas of 
BPH/5 mice.  Further, MMP-9 transcript mis-regulation was correlated with changes 
in Dlx3 mRNA levels in this study.  These studies provide novel evidence that Dlx3 
may be involved in the transcriptional regulation of mouse and human MMP-9 gene 
expression in placental trophoblasts.  Further, MMP-9 and Dlx3 are coordinately mis-
regulated in the BPH/5 mouse model suggesting these two genes may be involved in 
the gene network underlying placental pathologies in PE. 
 
Introduction 
During pregnancy, the placenta forms the critical fetal-maternal interface to 
support fetal nutrient supply and exchange of gases and waste products that underlie 
the coordinated growth and development of the mammalian fetus in utero.  In the 
mouse, the primary site of exchange occurs within the placental labyrinth.  The 
labyrinth layer is formed by distinct inter-digitations between fetal blood vessels and 
maternal blood spaces that are paramount for nutrient exchange to meet the metabolic 
demands of the growing fetus 1.  Accurate morphogenesis and function of the 
labyrinth compartment depends upon a number of dynamic cellular processes such as 
controlled proliferation, differentiation, cell migration, and (re)organization of the 
extracellular matrix (ECM) environment.  Any genetic or environmental insult(s) that 
interferes with these dynamic processes can potentially disrupt the morphogenesis of 
the labyrinth and result in placental insufficiency, intrauterine growth restriction 
(IUGR) of the fetus and ultimately embryonic lethality.   
Placental cell migration is critical for normal placental morphogenesis.  For 
example, cytotrophoblasts migrate through the extracellular matrix (ECM) of the 
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maternal decidua and engage in remodeling of the maternal spiral arteries 2,3.  This 
vascular remodeling leads to enlargement of vessel diameter, decreased vascular 
resistance and sustained blood flow into the intervillious space and ultimately 
appropriate perfusion of the placental vascular bed 4.  Inadequate maternal spiral artery 
remodeling has been detected in the placentas of women with fetal IUGR and/or 
symptoms consistent with preeclampsia (PE) 5,6.  These observations suggest that the 
dynamic process of cytotrophoblast invasion and maternal spiral artery remodeling is 
required for successful placental perfusion and a productive pregnancy 7.  Matrix 
metalloproteinases or MMPs appear to play a key role in ECM breakdown and 
remodeling at several levels.  For example, MMP-1 and 9 have been found in normal 
human decidual samples collected as biopsies from term pregnancies and MMP-1 
specifically was demonstrated to be reduced in deciduas collected from patients with 
PE 4.  In these same studies, MMP-9 expression was clearly inducible in decidual cells 
following activation of protein kinase C; however, PE did not appear to alter this 
response in the maternal tissues examined.  Additionally, Campbell and colleagues 
used a bilayer co-culture model to examine the effect of decidual endothelial cells on 
MMP secretion and cytotrophoblast migration from PE pregnancies 8.  These studies 
provide evidence that cytotrophoblasts from PE pregnancies secreted significantly less 
MMP-2 and MMP-9 compared to control. These observations were supported by other 
studies demonstrating decreased MMP-9 mRNA expression 9,10 and histological 
staining 11,12 in human PE placentas.   Collectively, these results suggest that abnormal 
trophoblast invasion of the maternal vasculature in PE may be due in part to mis-
regulation of specific MMPs, including MMP-9; however, these observations remain 
controversial since others have been unable to identify a specific role for MMPs 
during trophoblast invasion.  One such study examined chorionic villous biopsies 
taken from pregnancies complicated by PE, HELLP syndrome, or IUGR compared to 
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matched control patients.  A specific immuno-capture assay revealed the presence of 
both MMP-2 and 9 (but not MMPs-1, 3 8 or 13) activity in these tissues; however, 
total MMP-2 and MMP-9 activity was not different in complicated and uncomplicated 
pregnancies. The authors concluded that misregulation of MMP-2 and -9 early in 
pregnancy were not correlated with maternal pregnancy complications 13.  
Additionally, human pregnancies complicated by gestational hypertension found 
circulating levels of pro-MMP-9 and its inhibitor, tissue inhibitor of 
metalloproteinase-1 (TIMP-1), to be higher in hypertensive patients compared to 
control women; however, pregnancies complicated by PE did not reveal such 
differences indicating differences in the pathophysiological gene profiles characteristic 
of PE and gestational hypertension 14.  Yet, another study indicated significantly 
higher immunohistochemical MMP-9 levels in decidual cells and adjacent interstitial 
trophoblasts in preeclamptic placental sections verses gestational age-match control 
women 15.  While difficult to reconcile, these studies may collectively support the 
conclusion that the MMP-9 gene profile may be misregulated in at least a subset of PE 
patients potentially reflecting an abnormal trophoblast invasive phenotype. 
  Dlx3 is one of six Distal-less family members characterized as homeobox-
containing transcription factors necessary for the development of numerous tissues 
including the mouse placenta 16,17.  Targeted deletion of Dlx3 results in midgestation 
embryonic lethality (~E9.5-10) due to placental labyrinth defects suggesting the Dlx3 
and Dlx3-dependent gene targets play a critical role in labyrinth development 1,17.  
Microarray analysis of Dlx3 null placentas collected at embryonic day (E) 9.5 linked 
Dlx3 to aberrant expression of a number of genes critical to placental function, 
including reduced expression of placental growth factor, a key marker of PE and 
MMP-9 18.  The present studies examined the hypothesis that Dlx3 may regulate 
MMP-9 directly at the transcriptional level in placental cells.  Data presented here 
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demonstrates that Dlx3 is a key regulator of MMP-9 transcript levels and secreted 
MMP-9 catalytic activity in mouse placental explants and human choriocarcinoma 
cells.  Dlx3-dependent regulation of the MMP-9 gene promoter occurred through near 
consensus cis regulatory elements within the mouse and human MMP-9 gene 
promoters suggesting the effects of Dlx3 on the MMP-9 gene promoter were direct.  In 
an attempt to reconcile the role of MMP-9 during PE, we examined expression levels 
of Dlx3 and MMP-9 early and late in gestation in a new model of PE, the BPH/5 
mouse.  These studies provide novel evidence of mis-regulation MMP-9 transcript 
levels in BPH/5 mouse placentas early in gestation, correlated with Dlx3 transcript 
expression.  These studies support the conclusion that Dlx3 is a critical transcriptional 
regulator of mouse and human MMP-9 gene expression.  Further, mis-expression of 
Dlx3 and MMP-9 in the BPH/5 mouse model during gestation suggests that these 
genes may be important markers of early disease progression during PE in this model. 
 
 
Materials and Methods  
Animals- Dlx3-/- mice were a generous gift from the laboratory of Dr. Maria Morasso 
at the National Institutes of Health.  BPH/5 mice have been developed in the 
laboratory of Dr. Robin Davisson here at Cornell University and described in some 
detail elsewhere 19.  All mice used in these studies were maintained and used in full 
compliance with protocols approved by the Cornell University Institutional Animal 
Care and Use Committee.  All animals had free access to food and water; qualified 
Cornell University lab animal veterinarians were responsible for all animal care.  
 
Culture of Placental Explants, JEG3 cells and Gel Zymography- Mouse placental 
explants were harvested at E9.5 from Dlx3+/- females that were mated with Dlx3+/- 
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males.  At the time of dissection, embryos were dissected free of uterine and placental 
tissues and used for genotyping as described 18,20.  Placental explants (essentially the 
placental disk with minimal maternal deciduas; n = 4-6 explants/genotype) were 
washed 3 times in Dulbecco’s Phosphate Buffered Saline (DPBS) and then cultured in 
Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with fetal bovine 
serum (10%) at 37˚C in 5% CO2 as previously described 
18,20. Following a two hour 
equilibration period, media was removed and replaced with fresh media.  Media was 
collected four hours later (6 hours following the start of culture) and all media samples 
were snap frozen and stored at -80˚C until zymography studies could be completed. In 
some studies using siRNA-mediate Dlx3 knockdown (described below), stably 
transfected JEG3 cells were split to new culture dishes and cultured to 50-80% 
confluence.  Cells were washed with DPBS and placed in fresh media.  Media was 
collected from these cultures in a manner identical to the placental explants and media 
samples were again stored at -80˚C until subsequent assays.  
Zymography studies were carried out as previously described 21.  Briefly for 
zymography studies, equal volumes of conditioned culture media from the placenta 
explant study and the siRNA knockdown cell lines were resolved in 10% gelatin 
Zymogram gels (Bio-Rad Laboratories, Hercules, CA).  Following electrophoresis, 
proteins within these gels were allowed to renature in 2.5% Triton X-100 for 30 
minutes at room temperature and incubated in Developing Buffer (Millipore, Billerica, 
MA), containing 50mM Tris-HCl, 0.2M NaCl, 5mM CaCl2 and 0.02% Brij35, for 30 
minutes at room temperature and then placed in fresh Developing Buffer overnight at 
37˚C.  The gels were then stained with 0.5% Coomassie Brilliant Blue (Sigma, St. 
Louis, MO) in methanol/acetic acid/water (40:10:50 v/v) for 30 minutes at room 
temperature followed by destaining with methanol/acetic acid/water (50:10:40) for 4 
hours at room temperature.  The presence of clear bands in the gels at 92kDa and 
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105kDa reflected the gelatinase activity of human MMP-9 and mouse MMP-9, 
respectively.  Bands were visualized using BioRad Gel Imaging system and gelatinase 
activity was quantified using densitometry analysis.   
 
Western Blotting Analysis- Conditioned media from placental explants was suspended 
in SDS-PAGE loading buffer (100mM Tris (pH6.8), 4% SDS, 20% glycerol, and 
200mM DTT), boiled for 3 minutes and incubated on ice for 5 minutes.  Complexes 
were resolved by SDS-PAGE and transferred to polyvinylidine difluoride membranes 
by electroblotting.  Membranes were blocked in 2x casein (Vector laboratories, 
Burlingame, CA) in Tris-buffered saline (10mM Tris (pH 7.6), 150mM sodium 
chloride) containing 0.1% Tween 20 (TBST) for 1 hour at room temperature.  The 
following antibodies were used at a 1:1000 dilution in western blotting: MMP-9 
(Abcam, Cambridge, UK), thrombospondin 2 (BD Transduction Labs, San Jose, CA) 
and the Dlx3 20 antibody.  Actin antibody (Santa Cruz, Santa Cruz, CA) was used at 
1:500 dilution.  All protein bands were visualized by chemiluminesence reagents.  All 
Western blotting studies were carried out on at least 3 separate occasions with similar 
results. 
 
Plasmids and cDNA- All plasmids used in these studies were purified using two cycles 
through cesium chloride.  1.9kb portion of the mouse MMP-9 promoter was obtained 
by PCR using mouse genomic DNA and subsequently cloned into a luciferase reporter 
vector using the following primers: MMP-9 forward primer, 5’-
ggtaccgtcagagcattcattgtagaag-3’; MMP-9 reverse primer, 5’-
ggatccgagattttaaagaggcagtaaa-3’.  Cloning of this promoter fragment was facilitated 
by adding restriction sites Kpn1 and Bam H1 to the forward and reverse primers, 
respectively.  The fidelity of MMP-9 luciferase reporter was verified by nucleotide 
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sequence analysis.  PCR-based site-directed mutagenesis was used to disrupt the two 
Dlx3 binding sites located at -1498 and -825 within the mouse MMP-9 promoter 
luciferase reporter.  These mutations substituted a Not-1 restriction site for the near 
consensus Dlx3 binding sites.  These mutations were confirmed using nucleotide 
sequence analysis.  The pKH3-Dlx3 expression construct has been previously reported 
20 and encodes mouse Dlx3 with the addition of three HA epitopes at the amino 
terminal end of the protein.  Additionally, both the human glycoprotein hormone α 
subunit gene promoter luciferase construct and the PGF gene promoter luciferase 
construct have been previously reported 18,22. 
 
Cell Culture and Transient Transfection Studies- JEG3 cells were cultured in 
monolayer using DMEM supplemented with fetal bovine serum (10%).  Before 
transfection studies, cells were split into 6-well tissue culture dishes and grown to 50-
80% confluence.  To compare relative gene promoter activity, JEG3 cells were 
transiently transfected with a luciferase reporter vector that did not contain a promoter 
fragment (empty), the MMP-9 promoter-luciferase construct, the human -204 α 
subunit gene promoter-luciferase construct or the placental growth factor (PGF) 
promoter-luciferase construct, the latter two known to be expressed in human 
trophoblasts.  Additionally in some studies, the MMP-9 promoter-luciferase construct 
was transiently co-transfected with increasing doses of pKH3-Dlx3 expression vector, 
a constant dose of Smad6 (2µg) or a combined constant dose of pKH3-Dlx3 
expression vector (2µg) in combination with Smad6 (2µg).  All transfections were 
carried out utilizing Genejuice transfection reagent (EMD4Biosciences, Gibbstown, 
NJ) and a constant amount of total DNA by supplementing reactions with the empty 
expression vector, pKH3.  Luciferase activity was determined after 24 h of 
transfection using reagents from a luciferase reporter assay system (Promega 
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Corporation, Madison, WI).  Luciferase activity levels were standardized using total 
cellular protein as determined by a Bradford assay.  All transfections were conducted 
in triplicate on at least 3 separate occasions.  Data are shown as means (n=3) ± 
standard error of the mean for a representative experiment.   
 
Recombinant protein synthesis and electrophorectic mobility shift assay- Recombinant 
Dlx3 protein was prepared using a coupled transcription and translation Wheat Germ 
Extract system (Promega Corporation, Madison, WI) following the prescribed 
protocol.  Electrophoretic mobility shift assays (EMSAs) were carried out as described 
previously 20,22.  Briefly, binding reactions (without radiolabeled probe) containing 
non-specific DNA were maintained at room temperature for 20 minutes followed by 
the addition of 32P-labeled oligonucleotide Dlx3 binding site probes from the two 
putative Dlx3 binding sites indentified within the mouse MMP-9 promoter.  The 
binding reactions were incubated another 20 minutes at room temperature and 
resolved on native polyacrylamide gels.  Following electrophoresis, the gels were 
dried, and DNA-protein complexes were visualized by autoradiography.  All DNA 
binding studies were conducted at least 3 times with similar results.  The nucleotide 
sequences for the probes were as follows (only the top strand is represented): MMP-9 
-1498 binding site, 5’-ctaaaacaaattaacaaacaa-3’ and; MMP-9 -825 binding site, 5’-
cagtctcctaatttccaatca-3’. 
 
Preparation of JEG3 Cell Nuclear Extracts- Near confluent JEG3 cells were washed 
twice with ice-cold DPBS and collected by scraping in ice-cold DPBS supplemented 
with a 1:1000 dilution of protease inhibitor mixture (Sigma-Aldrich, St. Louis, MO), 
5mM benzamidine, and 0.2mM phenylmethylsulfonyl fluoride.  Cells were pelleted by 
centrifugation and resuspended in a hypotonic buffer consisting of 120mM potassium 
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chloride, 30mM sodium chloride, 30mM Hepes (pH8.0), 0.3M sucrose, protease 
inhibitor mix supplemented with 5mM benzamidine, and 0.2 mM 
phenylmethylsulfonyl fluoride and allowed to swell for 15 minutes on ice.  Cells were 
lysed by dounce homogenization and nuclei were isolated by layering the broken cell 
lysates over a sucrose cushion (0.9M sucrose), then centrifuging at 2000 x g for 30 
minutes at 4˚C.  The nuclear pellet was resuspended in buffer containing 10mM Tris 
(pH 7.5), 50 mM NaCl, 5% glycerol, 1mM ethylenediaminetetraacetic acid (EDTA), 
protease inhibitor mixture, 5mM benzamidine, and 0.2 mM phenylmethylsulfonyl 
fluoride.  Additional sodium chloride was added to a final concentration of 450mM 
and nuclear proteins were extracted at 4˚C for 30 minutes with constant agitation.  
Nuclear extracts were clarified by centrifugation (85,000x g for 60 minutes), and the 
nuclear extracts were stored in aliquots at -80˚C until later use.  The protein 
concentration of each nuclear extract was determined by Bradford assay.   
 
DNA affinity chromatography- M-280 streptavidin Dynabeads® (Invitrogen, Carlsbad, 
CA) were washed 3 times in wash buffer, 10mM Tris pH7.5, 1mM EDTA, 2M NaCl.  
The nucleotide sequences for the two putative Dlx3 binding sites on the MMP-9 
promoter (-1498 and -825) were biotinylated on the 5’ end.  The biotinylated DNA 
binding sites were incubated with washed Dynabeads for 15 minutes at room 
temperature with constant shaking.  Dynabeads-DNA mixture was washed in wash 
buffer twice followed by one wash in 50mM Tris pH 7.5, 1mM EDTA, 100mM KCl, 
5% glycerol, 0.1% Trition X-100, and 1mM dithiothreitol (incubation buffer) to 
equilibrate the affinity matrix to incubation conditions.  JEG3 cell nuclear extracts 
(60ug) were added to the Dynabeads-DNA mixture plus 100ul incubation buffer and 
incubated at room temperature 30 minutes with gentle shaking every 2 minutes. In 
some cases, these binding reactions also included 50 or 100 fold molar excess of 
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unbiotinylated competitor oligonucleotides. Following this incubation, the Dynabeads-
DNA-protein mixture was washed 3 times in incubation buffer.  Complexes were 
suspended in 2XSDS loading buffer (100mM Tris (pH6.8), 4% SDS, 20% glycerol, 
and 200mM DTT).  Samples were boiled for 3 minutes and chilled on ice for 5 
minutes, resolved by SDS-PAGE and immunoblotted using the Dlx3 antibody as 
described above.  
 
Chromatin Immunoprecipitation Assay-  Protein A/G beads (Invitrogen, Carlsbad, 
CA) were blocked overnight with 1mg/ml sonicated salmon sperm DNA and 1mg/ml 
bovine serum albumin (BSA) at 4˚C with gentle agitation then washed in TE buffer 
several times.  JEG3 cells were transiently transfected with either the pKH3-Dlx3 
expression vector or a mock transfection containing only the pKH3 expression vector, 
using Genejuice (EMD4Biosciences, Gibbstown, NJ) as described above.  Twenty-
four hours following transfection, cells were fixed in 1% formaldehyde in PBS for 10 
minutes at 37˚C.  Glycine (125mM) was added to quench the crosslinking and cells 
were incubated on ice for 5 minutes.  Cells were rinsed with DPBS and collected in 
1ml DPBS containing 1 Complete Mini Protease Inhibitor tablet (Roche, Indianapolis, 
IN).  Cells were centrifuged at 4000 RPM for 5 minutes and resuspended in 1% SDS, 
10mM EDTA, 50mM Tris (pH7.9), 1mM DTT containing 1 Complete Mini Protease 
Inhibitor tablet (Roche, Indianapolis, IN).  Cells were incubated on ice for 10 minutes 
and sonicated using a Diagenode Bioruptor UCD-200 sonicator at 27% amplitude 20 
times, 10 seconds per round with 1 minute between sonications.  Lysed cells were 
centrifuged for 10 minutes at 13,000 RPM at 4˚C and the supernatant was collected.  
Chromatin was pre-cleared with blocked agarose beads for 3 hours at 4˚C with gentle 
agitation.  After centrifugation, 10% of each sample was removed for analysis of input 
controls and 100µl of each sample was mixed with 900µl of a buffer containing 0.5% 
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Trition X-100, 2mM EDTA, and 10mM Tris pH 7.5, 150mM NaCl, 1mM DTT and 1 
Complete Mini Protease Inhibitor tablet (Roche, Indianapolis, IN).  Complexes were 
incubated with the anti-HA (1:500; Sigma-Aldrich, St. Louis, MO) or Acetyl-Histone 
H3 (1:1000; Abcam, Cambridge, UK) antibodies overnight at 4˚C with gentle 
agitation.  Blocked agarose beads were added to each reaction and incubated at 4˚C for 
an additional 2 hours.  Complexes were washed four times in a buffer containing 
0.25% Tergitol-type NP-40, 0.5% SDS, 2mM EDTA, 20mM Tris (pH8.0), 250mM 
NaCl, 0.2µl/ml leupeptin, and 0.2µl/ml aprotinin.  Complexes were then resuspended 
in 100mM NaHCO3, 1% SDS and incubated at 65˚C overnight followed by a phenol-
cholorform extraction.  Real time PCR was performed using appropriate primers 
MMP-9 forward primer 5’-gattacaggaatgagccacca-3’, MMP-9 reverse primer 5’-
ctgtaggttgtaagtccgcaac-3’, human glycoprotein hormone α subunit gene (h α JRE) 
forward 5’-tgacctaagggttgaaacaagataag-3’, h α JRE reverse 5’-ggaaattccatccaatgattga-
3’, distal h α JRE forward 5’-agtttctttgtggatgaagagatagacg-3’ and distal hα JRE 
reverse 5’-tttccgaacttcaaaggccctg-3’.  The distal site on the human glycoprotein 
hormone α subunit gene served as a negative control.  A standard curve was generated 
with the appropriate sample inputs, representing a 1:2, 1:20, and a 1:200 dilution.  
 
Preparation of Stable Cell Lines Expressing Small Interference RNA’s (siRNAs)- The 
mammalian expression vector, pSUPER-retro-neo (OligoEngine, Seattle, WA) was 
used for preparation and expression of specific siRNAs.  Each gene-specific insert 
targeted a 19-nucleotide sequence within the human Dlx3 mRNA.  The Dlx3 siRNA 
sequence was as follows: 5’-gtagaagactgtagctata-3’.  A control siRNA vector was also 
prepared in pSUPER-retro-neo vector using a non-specific 19-nuclotide mammalian 
gene sequence (5’-ttctccgaacgtgtcacgt-3’), which served as a negative control for all 
studies (Applied Biosystems, Foster City, CA).  To create stable cell populations of 
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siRNA expressing cells, JEG3 cells were cultured and transfected as outlined above.  
Twenty four hours following transfection, stable cell lines were selected for using 500 
µg/ml neomycin in the culture media.   
 
Immunocytochemistry- Control and stably transfected JEG3 cells were cultured on 
glass bottom culture dishes (MatTek Corporation, Ashland, MA) for 24 hours, rinsed 
with DPBS and fixed with 4% paraformaldehyde for 20 minutes on ice.  Cells were 
then washed twice with cold DPBS and permeabilized in 0.3% Triton X-100 for 20 
minutes at room temperature.  Cells were then washed twice in DPBS and blocked in 
3% bovine serum albumin (BSA) for 1 hour at room temperature.  Primary Dlx3 
antibody (1:500) was then delivered to the cells in 3% BSA overnight at 4˚C.  Cells 
were washed twice in 0.3%Triton X-100 followed by incubation with a fluorescence-
conjugated secondary antibody (Alexa 488, Molecular Probes Inc., Eugene, OR) for 1 
hour at room temperature.  Finally, cells were washed twice in DPBS and stained with 
DAPI glue (Vector labs, Burlingame, CA). 
 
Quantitative (q)PCR- siRNA knockout cell lines were grown to ~80% confluence and 
RNA was harvested using TRIzol® (Invitrogen, Carlsbad, CA).  Additionally, 
placental RNA was harvested and prepared using TRIzol® (Invitrogen, Carlsbad, CA) 
from the BPH/5 and C57 mice at E9.5 and E18.5.  RNA was subjected to q-PCR using 
TaqMan® probes (Applied BioSystems, Foster City, CA) for MMP-9 and Dlx3, 
respectively.  Analysis of the qPCR data has been previously described 18.   
 
Statistical Analysis-Data were subjected to analysis of variance and differences 
between treatment groups using a Student’s T-Test.  Probability of less than 0.05 
(p<0.05) was considered statistically significant. 
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Results 
Dlx3-/- mouse placentas have reduced levels of MMP-9 protein and gelatinase 
activity- The Dlx3 knockout mouse dies at midgestation (~E9.5-10.5) due to placental 
dysfunction 17,18,20.  Further, placental microarray studies revealed that MMP-9 
transcript levels were markedly reduced in the placentas of Dlx3-/- mice at E9.5 
suggesting that MMP-9 may be an important target of Dlx3-dependent gene regulation 
18.  Given the critical role MMPs and in particular, MMP-9 plays in the remodeling of 
placental ECM during trophoblast cell invasion and maternal spiral artery remodeling, 
we sought to investigate the activity levels of MMP-9 in the Dlx3-/- mouse model.  
Using Dlx3+/+, +/-, -/- mouse placental explants; we initially examined relative levels of 
secreted MMP-9 assayed in culture media (Figure 3.1A).  Western analysis revealed 
that loss of both Dlx3 alleles resulted in a marked reduction in secreted MMP-9 in 
these cultures.  This was corroborated by zymography studies of gelatinase activity 
using the same media collected 4 hours after culture (Figure 3.1B).  Gelatinase activity 
associated with MMP-9 was again markedly reduced (p<0.05) in the Dlx3-/- placentas 
in culture. Similar observations were made examining media samples collected at the 
6 hour time point (data not shown).  The reduction in secreted MMP-9 activity was not 
attributable to an overall reduction in secretion from these explants since secretion of 
the anti-angiogenic glycoprotein, thrombospondin 2 23,24 was increased markedly in a 
gene dosage-dependent manner where the highest thrombospondin 2 secretion 
occurred in the Dlx3 null placentas.  These observations were consistent with changes 
in thrombospondin 2 transcript levels in the Dlx3-/- placenta in our previous array 
studies 18.   Interestingly in the Dlx3+/- placentas, MMP-9 protein levels and gelatinase 
activity was increased compared to the wildtype controls (p<0.05; Figure 3.1A and B).  
On potential interpretation of this observation is that haploinsufficiency at the Dlx3 
loci induces an apparent compensatory mechanism associated with elevated MMP-9 
 
 
116 
protein and gelatinase activity; however, a more complete understanding of this 
mechanism(s) awaits further investigation.    
 
MMP-9 gene promoter is active in placental cells and responsive to Dlx3 
overexpression- To further investigate the mechanisms associated with Dlx3 
regulation of the mouse MMP-9 gene, we cloned a 1.9kb portion of the 5’-flanking 
region of the mouse MMP-9 promoter and incorporated this promoter fragment into a 
luciferase reporter gene.    Initially, we compared the expression level of the MMP-9 
promoter fragment to other promoters known to be expressed in JEG3 
choriocarcinoma cells as a model for placental trophoblasts.  In transient transfection 
studies, MMP-9 promoter activity was observed to be ~175 fold greater (p<0.05) than 
the empty luciferase reporter (Figure 3.2A).  Using equal amounts of reporter plasmid  
for transfection, MMP-9 promoter activity was similar to another placental-specific 
gene promoter, 5.2kb portion of the 5’-flanking region of mouse placental growth 
factor (PGF) gene promoter (Figure 3.2A)18; however, both MMP-9 and PGF 
promoter activity was markedly less (p<0.05) than the transcriptional activity 
associated with the human glycoprotein hormone α subunit gene promoter 25.    
Transient co-tranfection studies with the MMP-9 gene promoter and increasing 
doses of pKH3-Dlx3 expression vector revealed the MMP-9 gene promoter was 
responsive to Dlx3 overexpression in a dose dependent manner (Figure 3.2B). 
Overexpression of Dlx3 was confirmed using Western blot analysis making use of the 
HA epitope on the overexpressed Dlx3 in cell lysates used to analyze luciferase 
activity.  These studies provide important evidence that Dlx3 was overexpressed in a 
dose-dependent manner; further, additional western analysis examining Dlx3 (rather 
than the HA epitope) revealed that overexpression was evident at 2-3 fold over  
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Figure 3.1. MMP-9 protein and gelatinase activity is reduced in the Dlx3-/- mouse 
placenta. A. Wildtype (Dlx3+/+), Dlx3 heterozygous (Dlx3+/-), and Dx3 null (Dlx3-/-) 
placental explants (n=4-6/genotype) were cultured for four hours and media was 
collected.  Western blot analysis was used to determine secreted MMP-9 and 
thrombospondin 2 protein abundance in the Dlx3-/- compared with Dlx3+/+.  B. 
Zymography studies were performed to determine the amount of secreted MMP-9 
gelatinase activity from the explant study. Gels were scanned and densiotometry 
measurements were obtained to determine the level of gelatinase activity 
corresponding to a band consistent with the molecular weight of MMP-9.  All studies 
were replicated on at least three separate occasions with equivalent results. 
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endogenous levels of Dlx3 (data not shown) suggesting that these overexpression 
studies did not reflect supra-physiological conditions.   
Upon examination of 1.9kb portion of the mouse MMP-9 gene promoter, two 
Dlx3 near-consensus binding sites were identified; one near the proximal end of the 
MMP-9 gene promoter at -825 and one near the distal portion of the promoter at -1498 
relative to the transcription start site 26.  Although both sites contain the core TAATT 
motif, the flanking nucleotides from each site varied from the Dlx3 consensus site 
(A/C/G) TAATT (G/A)(C/G) (Figure 3.3A).   Electrophoretic mobility shift assays 
(EMSA) compared relative DNA binding of both the distal (-1498) and proximal (-
825) sites using recombinant Dlx3 (rDlx3).  Addition of rDlx3 resulted in dose-
dependent DNA binding (Figure 3.3B).   These studies were corroborated with studies 
using DNA affinity chromatography (Figure 3.3C).  Using JEG3 nuclear extracts as a 
source of Dlx3, the distal (-1498) Dlx3 binding site was able to bind Dlx3 in this assay 
and Dlx3 binding was competed for using 50 and 100 fold molar excess of 
unbiotinylated oligonucleotides for the -1498 and -825 binding sites. These studies 
support the conclusion that recombinant and endogenous Dlx3 can bind these sites in 
vitro. 
 
Dlx3 binding sites within the mouse MMP-9 gene promoter are required for 
basal and Dlx3-induced transactivation- In order to evaluate the importance of these 
near consensus Dlx3 binding sites within the mouse MMP-9 gene promoter, both the 
distal (MMP-9 ∆-1498) and proximal (MMP-9 ∆-825) sites were mutated alone and in 
combination in the context of the luciferase reporter. Each construct was transiently 
co-transfected into JEG3 cells with control vector or pKH3-Dlx3 to facilitate Dlx3 
overexpression.  Both of the individual mutants resulted in marked reduction (p<0.05) 
in basal expression of the MMP-9 luciferase reporter (p<0.05); however, neither  
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Figure 3.2. An MMP-9 promoter fragment coupled to a luciferase reporter is 
active in placental cells and responsive to Dlx3 overexpression.  A.  Transient 
transfection studies in JEG3 choriocarcinoma cells were used to compare the relative 
promoter activity of the 1.9kb portion of the MMP-9 gene promoter-luciferase reporter 
(MMP-9) to the luciferase reporter construct without a functional promoter (Empty), a 
0.2kb portion of the glycoprotein hormone α-subunit (Ha-204), and 5.2kb placental 
growth factor (PGF) gene promoter luciferase reporter.  B.  Dlx3 overexpression was 
used to test the inducible activity of the MMP-9 luciferase reporter in JEG3 cells. 
Cotransfection of the MMP-9 luciferase reporter with a control vector (2.0µg) or 
increasing doses of an expression vector encoding hemaglutinin (HA) epitope-tagged 
Dlx3 (0.5, 1.0, and 2.0µg) were carried out.  Data are reported as relative luciferase 
activity standardized by total cellular protein content from representative studies 
(n=3/treatment).  Western analysis was used to confirm HA-tagged Dlx3 
overexpression (inset).  Lane 1 is control; Lanes 2 through 4 are HA-Dlx3 expression 
vector doses of 0.5, 1.0 and 2.0 mg, respectively.  Actin was used as a lane loading 
control. All studies were replicated on at least three separate occasions with equivalent 
results. 
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Figure 3.3.  Dlx3 binds to two cis elements within the MMP-9 promoter fragment.  
A.  Bioinformatic investigation of the MMP-9 gene promoter identified two near-
consensus Dlx3 binding sites based upon homology to a consensus Dlx3 site.  The 
positions of these sites (designated as probes) were at -1498 and -825 relative to the 
start site of transcription.  B. Using electrophoretic mobility shift assay (EMSA), both 
binding sites were found to bind recombinant (r) Dlx3 with differing relative affinity. 
Dlx3 complexes as well as free probe are identified by arrows to the left of the panel.   
C. Using JEG3 nuclear extracts as a source of Dlx3 binding activity, DNA affinity 
chromatography followed by Western Blot studies revealed Dlx3 bound the -1498 site 
consistent with EMSA.   Competition studies using the -1498 and -825 binding sites at 
50 and 100 fold molar excess of unbiotinylated oligonucleotides were used to 
demonstrate specificity of binding.  The same experiment was performed on the -825 
site with similar results (data not shown). All studies were replicated on at least three 
separate occasions with equivalent results. 
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mutation blunted the response to Dlx3 overexpression (Figure 3.4).  Only the 
combined mutations (MMP-9 ∆-1498+825) abolished (p<0.05) responsiveness of this 
promoter to Dlx3 overexpression (Figure 3.4).  These findings indicate the interaction 
between Dlx3 and the cis-elements within the MMP-9 gene promoter are necessary for 
full transcriptional activation in placental trophoblasts.   
 
Smad6 blocks the effects of Dlx3 on the MMP-9 gene promoter-  As previously 
reported, Smad6 (an inhibitory or iSmad) has the ability to physically interact with and 
repress Dlx3 transcriptional activity on the human glycoprotein hormone α subunit 
and Esx-1 gene promoters in JEG3 cells 20.  This repression is thought to be due to 
Dlx3-Smad6 interactions leading to allosteric interference of Dlx3 DNA binding to 
target genes.  We sought to investigate the transcriptional regulation of Smad6 on 
MMP-9 gene promoter activity in JEG3 cells.  Co-transfection of pKH3-Dlx3 
expression vector with the MMP-9 luciferase reporter resulted in a predictable ~four 
fold increase (p<0.05) in luciferase expression.  Smad6 overexpression alone did not 
have an impact on the MMP-9 promoter luciferase reporter; however, when co-
transfected together, Smad6 expression effectively blocked Dlx3-dependent induction 
of the MMP-9 reporter (Figure 3.5).  These results are entirely consistent with 
previous studies of other dlx3 target genes and provide additional evidence that Dlx3 
engagement on the MMP-9 gene promoter is necessary for full transcriptional 
regulation of this gene.   
 
Dlx3 binds to the human MMP-9 gene promoter and is required for full MMP-9 
expression in JEG3 cells-   Studies thus far focused on the regulation of the mouse 
MMP-9 gene promoter consistent with our previous microarray studies of the Dlx3-/- 
mouse placenta 18.  We next sought to examine the putative binding of Dlx3 on the  
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Figure 3.4.  Mutations within the two Dlx3 binding sites reduce basal MMP-9 
promoter activity and abolish response to overexpression of Dlx3.  Dlx3 binding 
sites within the MMP-9 gene promoter were mutated using a PCR-based site-directed 
mutagenesis.  The 1.9kb portion of the MMP-9 gene promoter (wildtype), the 
mutation at the distal -1498 site (MMP-9 ∆-1498), proximal -825 site (MMP-9 ∆-825) 
and the combined mutations (MMP-9 ∆-1498+825) were cloned into a luciferase 
reporter.  Transient transfection studies were performed in JEG3 cells with MMP-9 
gene promoter-luciferase reporter constructs cotransfected with a control pKH3 vector 
(2.0µg) or 2.0µg of pKH3-Dlx3 expression vector.  Data are reported as relative 
luciferase activity standardized by total cellular protein content from representative 
studies (n=3/treatment).  All studies were replicated on at least three separate 
occasions with equivalent results. 
04000
8000
12000
Dlx3
Control
MMP-9 MMP-9
D -1498
+ 
D -825
MMP-9 
D -1498
MMP-9
D -825
Li
gh
t 
u
n
it
s/
m
g 
p
ro
te
in
126
 
 
127 
 
 
 
 
 
 
Figure 3.5.  Smad6 blocks Dlx3-induced MMP-9 promoter activity.  Transient co-
transfection studies were carried out in JEG3 cells with the MMP-9 luciferase reporter, 
and Dlx3 and Smad6 expression constructs.  Control cells were transfected with the 
reporter and control expression plasmids.  Some cells were cotransfected pKH3-Dlx3 
(2 mg), or CMV-Smad6 (500 ng) or the combination Dlx3 and Smad6.   Data are 
reported as relative luciferase activity standardized by total cellular protein content 
from representative studies (n=3/treatment). All studies were replicated on two 
separate occasions with equivalent results.
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human MMP-9 gene promoter using chromatin immunoprecipitation assay (ChIP).  
Boinformatic analysis of the human MMP-9 gene promoter revealed three near 
consensus Dlx3 binding sites containing the core TAATT motif within 2kb portion of 
the 5’ flanking region specifically located at -1812, -1268 and -889 relative to the 
transcriptional start site of this gene (Figure 3.6A). Preliminary ChIP studies using our 
Dlx3 polyclonal antibody clearly demonstrated that this antibody was not of ChIP 
qualified and could not be used reliably for ChIP studies.  As an alternative, pKH3-
Dlx3 expression vector was transiently transfected in JEG3 cells and subsequent ChIP 
studies made use of the three HA epitopes engineered into this overexpressed protein.  
The HA ChIP studies revealed specific Dlx3 binding on the MMP-9 gene promoter at 
or near the -889 element (p<0.05; Figure 3.6B).  Negative and positive controls for 
this ChIP study included examining a no antibody IP control, ChIP of the human 
glycoprotein hormone α subunit gene promoter at the junctional regulatory element 
(JRE) and a ChIP target ~2 kb upstream from the JRE on the same segment of DNA.  
Dlx3 engaged the JRE robustly in this assay (p<0.05) while the distal portion of the α 
subunit gene promoter served as a negative control.  Lastly, all three targets were 
identified by ChIP using an acetylated-histone H3 (Ac-H3 IP) immunoprecipitation 
(Figure 3.6C).  These ChIP studies provide strong evidence that the human MMP-9 
gene promoter binds Dlx3 in placental trophoblasts. 
 
siRNA mediated knockdown of human Dlx3 resulted in decreased endogenous 
MMP-9 transcript levels and gelatinase activity- To examine a requirement for 
Dlx3 on the human MMP-9 gene promoter, we sought to investigate endogenous 
MMP-9 transcript and protein abundance in an environment where Dlx3 was reduced 
in JEG3 cells.  To create such an environment, we developed JEG3 cell lines stably 
expressing a specific Dlx3 siRNA hairpin.  The siRNA Dlx3 cell line was  
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Figure 3.6. Human Dlx3 occupies the MMP-9 gene promoter endogenously.  A. 
Analyses of the human MMP-9 gene promoter revealed three near consensus Dlx3 
binding sites containing the core TAATT motif within a 2kb portion of the 5’ flanking 
region specifically located at -1812, -1268 and -889 relative to the transcriptional start 
site of this gene. B.  Chromatin immunoprecipitation (ChIP) studies were carried out 
in cells overexpressing HA-tagged Dlx3.  Three separate targets were assayed by PCR 
following ChIP.  As a positive control, the junctional regulatory element from the 
human a subunit gene promoter (h a JRE) was used; a target approximately 2 kb 
downstream of the JRE within the a subunit gene was used as a negative control; the 
putative Dlx3 binding at position -889 was arbitrarily selected within the human 
MMP-9 gene promoter.  Mock transfections include transfection with en empty pKH3 
plasmid.  For each condition, a ChIP reaction was carried out without the primary 
antibody as a control.  Acetylated-histone H3 (Ac-H3 IP) ChIP was used on all three 
targets as an additional positive control for the ChIP assay.  This ChIP study was 
carried out on two separate occasions, each in triplicate, with similar results. 
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characterized by reduction of ~60-70% of MMP-9 transcript abundance relative to the 
control siRNA cell line (Figure 3.7A).  Consistent with the transcript data, Dlx3 
protein levels were markedly reduced and this correlated well with reduced MMP-9 
protein levels as measured by Western blot analysis (Figure 3.7B) and 
immunocytochemistry (Figure 3.7C).   To evaluate a relationship between reduced 
Dlx3 protein levels and MMP-9 gelatinase activity, media from siRNA knockout cell 
lines was collected and subjected to zymography to investigate gelatinase activity 
associated with MMP-9.  Results indicated ~50% reduction (p<0.05) in MMP-9 
activity in the siRNA Dlx3 cell line compared to the siRNA control cell line (Figure 
3.8).  Combined these data support our working hypothesis that in human 
trophoblasts, Dlx3 engages the MMP-9 gene promoter and is necessary for MMP-9 
expression and gelatinase activity. 
 
Dlx3 and MMP-9 transcript levels during gestation in the BPH/5 mouse- As 
indicated earlier, misregulation of MMP-9 transcript and activity levels in the placenta 
has been associated with at least a subset of human patients experiencing PE 8,11,27; 
however, these finding have not been consistently observed across PE studies in the 
literature 13,14.  In an attempt to reconcile these disparities, we examined Dlx3 and 
MMP-9 transcript levels at two time points during gestation in a novel mouse model 
of PE, the BPH/5 mouse. The advantage of this animal model of PE is that these mice 
develop maternal disease (hypertension and proteinuria) in a manner consistent with 
human disease.  These mice are characterized by altered placental morphogenesis, 
failed maternal spiral artery remodeling and intrauterine growth retardation again 
consistent with PE in women 28.  Moreover, this mouse model provides the unique 
opportunity to examine specific gestational ages that are simply not possible in human 
patients.  In this study, we isolated placental RNA from both BPH/5 and C57control  
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Figure 3.7. Knockdown of human Dlx3 using siRNA results in reduced 
expression of MMP-9 in JEGS cells.  A. Knockdown of Dlx3 was accomplished in 
stably transfected JEG3 cells using specific siRNAs (siRNA control or Dlx3). In the 
siRNA Dlx3 cell lines, mRNA levels of endogenous MMP-9 were decreased ~60% 
compared to control cells or the control siRNA cell line as measured by qPCR.  B.  
Dlx3 protein levels were reduced by ~70% in the siRNA Dlx3 cell line as detected by 
immunoblot.  This result was correlated with reductions in MMP-9 protein levels in 
the same cell line. Actin was used as a lane loading control. C.  Immunocytochemistry 
was also used to demonstrate reduced levels of Dlx3 in the siRNA Dlx3 cell line 
compared to the control.  All studies were replicated on at least three separate 
occasions with equivalent results. 
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Figure 3.8.  Secreted MMP-9 gelatinase activity is reduced in the siRNA Dlx3 cell 
line.  Media collected from control siRNA and siRNA Dlx3 cell lines following four 
hours of culture was used in zymography assays to determine secreted gelatinase 
activity.  Gels were scanned and densiotometry measurements were obtained to 
determine the level of gelatinase activity corresponding to a band consistent with the 
molecular weight of MMP-9.   All studies were replicated on three separate occasions 
with equivalent results.
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mice at 2 different gestational time points, E9.5 and 18.5.  Figure 3.9 depicts steady-
state Dlx3 and MMP-9 mRNA levels as determined by q-PCR.  For each transcript 
within gestational age, the C57 transcript abundance was standardized to 1.0 and 
BPH/5 transcript levels are reported relative to the C57 value.  At the early gestational 
time point (E9.5) transcript levels of both Dlx3 and MMP-9 were markedly reduced 
(p<0.05).  At near term (E18.5), both transcripts were found to be upregulated 
compared to the C57 control.  These data provide the first report of altered Dlx3 
mRNA expression during early stages of PE in this model, well prior to onset of 
maternal disease in these mice.  Further, the correlation between altered Dlx3 and 
MMP-9 transcript levels was completely consistent with a role for Dlx3 in the 
regulation of MMP-9 gene expression in this model.  
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Figure 3.9.  Dlx3 and MMP-9 transcripts are misregulated in a mouse model of 
preeclampsia.  Placental RNA was collected from both BPH/5 and control C57 mice 
(n=3/genotype) at 2 different gestational time points, E9.5 and 18.5.  Quantitative PCR 
(q-PCR) was used to determine abundance of Dlx3 and MMP-9 transcripts using b 
actin as an internal standard.  For each transcript within gestational age, the C57 
control levels were set to 1.0 and Dlx3 and MMP-9 transcript levels are reported 
relative to this standardization. 
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Discussion 
Loss of Dlx3 has been linked to placental insufficiency and midgestation 
lethality in the Dlx3-/- mouse model 17. These findings suggest a dynamic role for Dlx3 
and putatively the Dlx3 gene network in facilitating proper placentation necessary for 
adequate fetal fitness and successful pregnancy in the mouse.  The current studies 
demonstrate the ability of this homeodomain-containing placental specific 
transcriptional regulator to bind to and regulate the mouse and likely human MMP-9 
gene promoters in trophoblasts.  Our working model suggests that within populations 
of placental trophoblasts, Dlx3-dependent regulation of MMP-9 expression and 
activity may underlie aspect of altered ECM remodeling potential leading to 
alterations in trophoblast invasive properties and placental morphogenesis in the 
mouse.  More broadly, the mechanistic relationship between Dlx3 and its gene target, 
MMP-9 may also contribute to early determinants related to the onset of maternal 
disease in the BPH/5 mouse model of preeclampsia. 
 MMPs are a complex family of proteolytic enzymes linked to various 
developmental processes including cell invasion, migration and ECM/tissue 
remodeling. This complexity is underscored by multiple levels of regulation of MMPs 
including changes in gene transcription and transcript abundance, requirements for 
zinc for MMP endopeptidase activity, post-translational cleavage of some of these 
enzymes for activity, subcellular localization (membrane associated versus secreted) 
and control of MMP activity by tissue inhibitors of MMP or TIMPs29.  The current 
studies provide important evidence for the role of Dlx3 in the regulation of MMP-9 
gene transcription and activity in placental trophoblasts.  MMP-9 proteolytic activity 
has been shown to degrade denatured collagens and basement membrane components 
30, cleave fibrin 31, serpin α1-proteinase inhibitor 
32, interleukin-1β  (IL-1β) 33, and 
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transforming growth factor-β (TGF-β) 34 revealing the involvement of MMP-9 in 
many processes including tissue remodeling, inflammatory responses, and metastasis 
in the progression of cancer.  As there are currently 20 recognized MMP family 
members in humans, it is difficult at present to ascribe specific functions to discrete 
members of this family without careful consideration of potential redundancies in 
activity.  In the placenta, it would appear that MMP-2 and MMP-9 may be playing 
central roles based on several published studies 8,9,11. One of the primary steps for 
proper placentation includes invasion of extravillous trophoblasts into maternal 
deciduas where extensive ECM remodeling appears to take place.  In the normal 
placenta, this includes extensive maternal spiral artery remodeling by trophoblasts to 
facilitate appropriate perfusion of the placental vascular bed 2.  When this fails to 
occur in a spatially and temporally restricted manner, placental dysfunction can occur, 
potentially leading to health complications.  For example in placental tissues examined 
from patients experiencing preeclampsia, shallow trophoblast invasion impairs spiral 
artery and arteriole remodeling causing reduced uteroplacental blood flow and 
compromised fetal fitness 6,35.  Similar observations of inadequate maternal spiral 
artery remodeling have also been made using the BPH/5 mouse model 36.  Currently 
the role of MMP-2 and MMP-9 during placental morphogenesis is controversial since 
only a subset of studies provide strong evidence of a role for these MMPs during 
placental development and possible complications such as those seen with 
preeclampsia 8,11,14,15.  The present studies extend our understanding of the specific 
role of Dlx3 and MMP-9 on placental morphogenesis in mouse and human trophoblast 
models. 
Our studies suggest that the Dlx3-/- mouse placenta is largely deficient in its 
ability to secrete MMP-9 and as such displays diminished MMP-9 gelatinase activity 
in vitro (Figure 3.1).  Since Dlx3 is expressed earlier in the etoplacental cone and 
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chorionic plate and later predominantly within trophoblast populations in the labyrinth 
17, it is reasonable to assume MMP-9 activity is playing a fundamental role in the 
ECM remodeling that occurs within these compartments to establish implantation and 
fetal/maternal vascular relationships.  Surprisingly, MMP-9 secretion and activity in 
the Dlx3+/- placenta was seen to be increased, appreciably higher than anticipated; this 
is perhaps suggestive of some compensatory mechanism.  Additional studies of this 
phenomenon will be necessary to fully understand the importance of this observation.  
Equally interesting was the observation that, unlike diminished secretion of MMP-9, 
thrombospondin 2 secretion was markedly elevated in the Dlx3-/- placenta.  These 
observations were consistent with predictions made from the microarray data 
comparing Dlx3+/+ and -/- placentas 18.   In those studies, thrombospondin 2 transcript 
levels were upregulated ~2-3 fold in Dlx3-/- placentas and this array data was validated 
using qPCR.  Thrombospondin 2 is a secreted glycoprotein known to inhibit 
angiogenesis, particularly in cancer models 23. It is presently unclear if Dlx3 may be 
playing a direct role in transcriptional repression of the thrombospondin 2 gene 
promoter or if the apparent elevation of thrombospondin 2 transcript levels and 
secretion observed in the current studies reflects a more complex and potentially 
indirect mechanism(s).  The reciprocal relationship between loss of MMP-9 secretion 
concurrent with elevated thrombospondin 2 secretion from the E9.5 mouse placenta 
raised the intriguing possibility that Dlx3 may regulate both the invasive properties of 
placental trophoblasts to establish fetal/maternal vascular relationships through 
regulation of MMP-9 (and potentially other ECM remodeling factors) and modulate 
angiogenic tone within the developing placenta through control of thrombospondin 2.  
While entirely speculative, alterations in the combined actions of these two secreted 
protein likely contributes to placental failure of the Dlx3-/- mouse at multiple levels. 
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 Perhaps the most exciting finding of the current studies is the characterization 
of mis-expression of Dlx3 and Dlx3 target genes such as MMP-9 in the BPH/5 mouse 
model of preeclampsia. The BPH/5 mouse exhibits a number of important 
characteristics of preeclampsia such as maternal hypertension and proteinuria late in 
gestation; BPH/5 mice display abnormal maternal spiral artery remodeling and   
placental insufficiency characterized by a decrease in branching morphogenesis and 
overall decreased labyrinth layer by E12.5; intrauterine growth retardation is also 
evident in this animal model 28,36.  These defects during pregnancy were shown 
recently to be largely ameliorated by feeding a superoxide dismutase mimetic 
suggesting that oxidative stress is playing an important role in progression of 
preeclampsia 28. Collectively, these observations provide exciting support that this 
mouse model may reflect an important resource in our understanding of the basic 
determinants that underlie this complex disease.    
The current studies examining transcript profiling of Dlx3 and MMP-9 during 
early and late gestation in the BPH/5 mouse support the conclusion that at both 
gestational ages transcript misexpression occurs, likely for different reasons.  One of 
the important early observations that lead to the identification of this model was that 
BPH/5 mice had reduced litter sizes 19.  This simple observation actually reflected 
important phenotypic variability during gestation associated with this model.  
Specifically, BPH/5 fetuses decline in number as gestation progresses suggesting that 
subsets of BPH/5 fetuses experience differing levels of intrauterine stresses.  Our 
current studies suggest that early in gestation, Dlx3 and MMP-9 transcript abundance 
is markedly reduced compared to the C57 control mice.  Although speculative, there is 
a strong likelihood that at this gestational age, the complete spectrum of fetal/placental 
phenotypic variation exists within the BPH/5 uterus and changes at this time likely 
reflect important changes associated with determinants of preeclampsia prior to the 
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onset of maternal disease.  Interestingly, loss of MMP-9 in the MMP-9 knockout 
mouse resulted in a compensatory mechanism in the cyclooxygenase (COX) 1 
pathway leading to enhanced production of prostaglandin E2 involved in increased 
vascular permeability in neutrophils 37.  While these studies did not consider the 
placenta, similar mechanisms may contribute to placental vascular (dys)function 
beyond an invasive phenotype.  Conversely, at late gestational age (E18.5), the 
positive correlation between Dlx3 and MMP-9 remains; however, both transcripts are 
essentially overexpressed.  This result reflects the subset of fetuses that remain viable 
at term in the BPH/5 mice and are clearly a phenotypically different population than 
those present at E9.5.  Nonetheless, these observations late in gestation may reflect 
important contributions to disease progression.  Equally plausible is the possibility that 
that at E18.5, changes in Dlx3 and MMP-9 transcript abundance in the BPH/5 mouse 
are a result (rather than a cause) of disease progression.  Future studies will focus on 
these possibilities. 
 In conclusion, the present studies highlight the important interplay between 
Dlx3 and MMP-9 in the placenta suggesting a role for both of these genes in proper 
placentation.   The MMP-9 gene promoter appears to be a target of Dlx3 
transcriptional regulation in both mouse and human trophoblasts.  The finding that 
thrombospondin 2 expression is also coordinately regulated within this gene network 
provides compelling evidence that Dlx3 may be controlling placental labyrinth 
development at multiple levels; controlling an invasive phenotype and modulating the 
angiogenic environment.  Finally, Dlx3 and MMP-9 may reflect important early 
genetic determinants in the BPH/5 mouse model of preeclampsia and represent 
important biomarkers for future studies focusing the pathophysiology of this disease. 
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Abstract 
Distal-less 3 (Dlx3), a homeodomain-containing placental-specific 
transcription factor, is required for normal placentation and fetal development in the 
mouse.  Dlx3-/- mice die at embryonic day (E) 9.5 putatively due to placental 
insufficiency.   Initially, to test the hypothesis that loss of Dlx3 within the placenta 
caused embryonic lethality in the Dlx3-/- mouse, Dlx3 conditional knockout mice were 
generated using an epiblast-specific Meox2CreSor.  A subpopulation of the Dlx3-/flox  x 
Meox2CreSor animals survived to weaning and beyond indicating loss of Dlx3 in the 
placenta likely is a primary cause of embryonic lethality associated with the Dlx3-/- 
mouse model.  Intrauterine growth retardation (IUGR), along with improper 
placentation, are hallmarks of preeclampsia in the BPH/5 mouse model and in women.  
Although the underlying genetic mechanism(s) for the BPH/5 phenotype has not been 
elucidated, studies reported in Chapter 3 of this dissertation reveal a reduction of Dlx3 
transcript levels in the placentas of BPH/5 mice at E9.5. These studies support for the 
hypothesis that early genetic determinants of preeclampsia in this model may include 
mis-regulation of the Dlx3 gene program.  The aim of the current studies was to 
determine if loss of a single Dlx3 allele would affect fetal growth in mice.  Dlx3+/- 
mice were characterized by a marked reduction in fetal weight and crown rump length 
compared to control fetuses beginning at E12.5 (p<0.05), which was compensated for 
by E18.5. This delay in fetal growth was correlated to increased oxidative stress and 
elevated apoptosis within Dlx3+/- placentas.  Consistent with these findings, 
supplementation Dlx3+/- mice with the superoxide dismutase mimetic, Tempol, 
throughout gestation effectively rescued the IUGR phenotype. Perhaps more 
interesting, supplementation of Tempol rescued a small proportion of Dlx3-/- animals 
to E12.5, fully 3 days beyond the timeframe of normal fetal demise. Dlx3+/- mice were 
also characterized by reduced VEGF in maternal serum at E12.5.  This putative loss in 
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angiogenic potential was correlated with reduced maternal spiral artery cross-sectional 
area (p<0.05). Administration of Tempol restored maternal spiral artery area in the 
Dlx3+/- mice consistent with the observed rescue of fetal growth.  Collectively, these 
data support the conclusion that haploinsufficiency at the Dlx3 locus results in reduced 
fetal fitness in midgestation corresponding with elevated oxidative stress and reduced 
maternal spiral artery cross-sectional area within the mouse placenta. Administration 
of antioxidant therapy throughout gestation effectively reduced oxidative stress and 
ameliorated this fetal/placental phenotype. 
Introduction  
Dlx3 is a homeodomain-containing transcription factor that has been known to 
play a role in many developing tissues.  Dlx3 is expressed in hair follicles, tooth germ 
cells, branchial arch mesenchme, interfollicular epidermis, and the developing 
placenta 1-3. In general, Dlx3 appears to play a key role in the differentiation of 
epithelial compartments including epidermis.  Ectopic expression of Dlx3 in the basal 
layer of mouse epidermis resulted in cessation of proliferation of the basal cells and 
the activation of profilaggin, a late differentiation marker of keratinocytes 4.  Deletion 
of Dlx3 in mice results in mid-gestational lethality due putatively to placental 
insufficiency; however Dlx3+/- mice are viable and fertile 2. In the primate placenta, 
Dlx3 was identified as a key transcriptional regulator of the α subunit of chorionic 
gonadotropin (CG), through its binding to the junctional regulatory elements within 
the promoter of this gene.  Consistent with these findings, loss of Dlx3 function in 
JEG3 choriocarcinoma cells results in diminished expression of the α subunit gene 5.  
Studies of human placental sections obtained from pregnancies terminated at 8 weeks 
gestation suggest that in humans, Dlx3 is expressed in trophoblasts cell populations at 
a time when CG production is highest5,6.  These studies support the conclusion that 
Dlx3 may be playing an important role in the regulation of expression of CG subunits, 
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thus aiding in maintenance of luteal function early in pregnancy in women.  Despite 
these important findings related to Dlx3 function in mice and humans, a number of 
questions remain regarding the significance of this homeodomain-containing 
transcription factor in the developing placenta.   
The placenta is the main site of exchange of gases, nutrients and hormones 
between mother and fetus throughout mammalian gestation.  Proper placentation is 
necessary to achieve the metabolic needs of the fetus for normal growth.  There are 
many examples in the literature linking improper placentation to intrauterine growth 
retardation (IUGR), placental insufficiency, embryonic death and preeclampsia 7 8.  
The cause of placental insufficiency stems from numerous factors including abberant 
gene expression, endothelial cell dysfunction, abnormalities in growth factor 
production, improper placental vascularization, all of which can lead to reduced 
placental perfusion and thus, nutrient delivery to the fetus.    Dlx3-/- animals die at 
~E9.5 2 likely due to abnormal placentation 6.  Interestingly, the Dlx3 mouse model 
shares placental phenotypic qualities observed in the preeclamptic mouse model, 
BPH/5 9.  Both the Dlx3 and BPH/5 mouse models display a lack in vascularization of 
the labyrinth layer, which in mice is the main site of fetal-maternal exchange 1,9.  In 
Chapter 3 of this dissertation, our studies demonstrate that both Dlx3 and the matrix 
metalloproteinase MMP-9 are misregulated early in gestation in the BPH/5 mouse 
model.  The shared placental phenotype and gene expression patterns of these mouse 
models suggest aberrant Dlx3 gene expression may be associated with a molecular 
gene program leading to placental insufficiency.   
The studies presented in Chapter 4 examine the role of Dlx3 in the developing 
placenta in greater detail.  Results from these studies provide indirect evidence that 
loss of Dlx3 specifically in the placenta (rather than the placenta and fetus) is the 
likely cause of fetal lethality in the Dlx3-/- mouse model since animals engineered to 
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have an epiblast-restricted gene deletion of Dlx3 survive to weaning and beyond.  
Further, we demonstrate loss of a single Dlx3 allele has marked effects on fetal growth 
patterns correlated with oxidative stress and vascular dysfunction in the placentas of 
these animals.   These defects are largely reversed with chronic administration of 
antioxidants prior to conception and throughout gestation.   
 
 
Materials and Methods 
Animals-  Generation of the Dlx3-/flox x Meox2 Cre+ animals.  B6 Dlx3+/- females were 
mated with Meox2CreSor males (Jackson Laboratories, Bar Harbor, ME) to generate 
Dlx3+/- Meox2 Cre+ males.  Dlx3+/- Meox2 Cre+ males were then mated with 
Dlx3flox/flox females 10 to generate the Dlx3-/flox x Meox2 Cre+ animals on a B6 
background.  Meox2CreSor expression is detected at embryonic day (E) 6 and is 
expressed in a mosaic pattern.   
Genotype for the Dlx3-/flox Meox2 Cre+ animals was determined by PCR.   In 
order to determine heterozygosity of Dlx3 gene we used a line that had been 
previously characterized including PCR methods were used that were previously 
described 2.  To assess for presence of the Dlx3 Flox allele we again used a line and 
PCR methods were used that were previously described 10.  The Cre mediated deletion 
of Dlx3 was determined by PCR using the following 3 primers.  Primer oIMR1542 (5’ 
GGGACCACCTCCTTTTGG CTTC 3’),  Primer oIMR 1871 
(5’AAGATGTGGAGAGTTCGGGGTAG 3’), and Primer oIMR 3671 (5’ 
CCAGATCCTCCTCAGAAATCAGC 3’).  Generation of 410bp band resulted in a 
Cre+/+ mouse, a 300bp band was equivalent to a Cre-/- mouse and a combination of a 
400bp band and a 300bp band was a Cre+/- animal.  The PCR cycling times were 94˚C 
 
 
155 
for 3 minutes followed by 35 cycles of 94˚C for 30 seconds, 69˚C for 1 minute, 72˚C 
for 1 minute and 72˚C for 2 minutes. 
All mice used in these studies were maintained and used in full compliance 
with protocols approved by the Cornell University Institutional Animal Care and Use 
Committee.  All animals had free access to food and water; qualified Cornell 
University lab animal veterinarians were responsible for all animal care.  
 
Analysis of Dlx3-/f Meox2 Cre+ animals-  Male and female Dlx3-/flox x Meox2 Cre+ 
animals along with gender matched, littermate controls were sacrificed at 
approximately 6 weeks of age and subjected to a complete small animal pathology 
diagnostic workup at Cornell University, College of Veterinary Science Pathology 
Department.  Tissue sections of liver, kidney, heart, lungs, skeletal muscle, ovary and 
testis, skin and teeth were fixed in 10% formalin and paraffin embedded.  Histological 
sections (10µm) were cut and stained with Hematoxylin and Eosin (H&E).  Sections 
were photographed on a Nikon Eclipse E400 microscope, using a 20x objective and 
SPOT Imaging Software (Diagnostic Instruments, Sterling Heights, MI).  
 
Embryos Weights and Crown Rump Measurements-  Embryo weights for the Dlx3+/- 
matings were assessed at five different gestational time points: E9.5, E10.5, E12.5, 
E15.5 and E18.5.  The yolk sac from each animal was used for genotyping.  Average 
embryo weights were assigned based on genotyping.  Embryos were weighed and 
photographed using a Nikon dissecting microscope, model SMZ-U, at a magnification 
of 1.4x.  Crown rump measurements of each animal were obtained using the Image J 
Analysis Software (NIH) line tool and measuring each animal from the top of the 
crown to the edge of the rump.   
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Tempol Administration and Vascular Endothelial Growth Factor (VEGF) assessment- 
Tempol (C9H18NO2-4-hydroxy tetramethylpiperidinyloxyl, Sigma, St. Louis MO) was 
administered in the drinking water of the Dlx3+/- female mice in light sensitive 
containers.  Tempol was given at a concentration of 2mM, 5 days prior to mating with 
Dlx3+/- male mice and continued throughout gestation until the animals were 
sacrificed at E12.5. Sterile water was used as the control for Tempol.  The 
experimental design was a 2x2 factorial comparing Dlx3+/+ receiving water, Dlx3+/+ 
receiving Tempol, Dlx3+/- receiving water and Dlx3+/- receiving Tempol. This study 
was carried out on two occasions with n=4-6 animals per cell in the factorial study.  At 
the time of sacrifice, maternal whole blood was collected from Dlx3+/- females from 
all treatment groups at E12.5 using cardiac puncture.  Maternal serum was collected 
by centrifugation at 2,000rpm for 10minutes at 4˚C.  Maternal vascular endothelial 
growth factor (VEGF) concentrations were assessed by ELISA (Invitrogen, Carlsbad, 
CA) as per manufacturer’s instructions.  
 
Oxidative Stress Analysis and Western Blot analysis-  Placental samples from Dlx3+/+ 
and Dlx3+/-  animals were collected at E10.5, E12.5, and E15.5.  All samples were 
subjected to the protein Oxidation Detection Kit, OxybotTM (Millipore, Billerica, MA).  
Complexes were resolved on SDS-polyacrylamide gel electrophoresis and transferred 
to polyvinylidine difluoride membranes by electroblotting.  Membranes were blocked 
in 2x casein (Vector laboratories, Burlingame, CA) in Tris-buffered saline (10mM Tris 
(pH 7.6), 150mM sodium chloride) containing 0.1% Tween 20 (TBST) for 1 hour at 
room temperature.  For OxyblotTM, primary and secondary antibodies were provided 
in the protein Oxidation Detection Kit.  An additional Western blot used an Actin 
antibody at 1:500 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in TBST-1X 
casein.  Protein bands were visualized by chemiluminesence reagents. 
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Assessment of placental reactive oxidative species-  Placental tissues were collected 
from both genotypes in the Tempol and water treated groups.  These dissections were 
characterized as full thickness section from the uterine wall through the chorionic 
plate.  Yolk sac from the corresponding embryo was collected and used for 
genotyping.  Placental tissues were frozen on dry ice in Optical Cutting Temperature 
Compound (OCT) (Fisher Scientific, Pittsburg, PA) and sectioned on a microtome at 
16µm.  Sections were washed twice in Dulbecco’s phosphate-buffered saline (DPBS; 
Invitrogen, Carlsbad, CA) and stained with dihydroethidium (DHE; Sigma, St. Louis, 
MO) for 10 minutes at room temperature in the dark.  Following the staining, samples 
were washed twice in DPBS.  Sections were assessed for DHE stain using a spinning 
disc confocal imaging system (CSU-10) mounted on a Nikon Eclipse TE2000-U 
inverted microscope at 60x.  Background was subtracted for each section to calculate 
the DHE.     
 
Assessment of Placental Apoptosis-  Placental tissues were collected from both 
genotypes in the Tempol and water treated groups.  As described above, yolk sac from 
the corresponding embryos was collected and used for genotyping.  For these studies, 
placental tissues were fixed in 10% formalin and paraffin embedded.  Sections were 
cut at 10µm and subjected to apoptosis analysis using a terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) Apoptosis Detection kit (Millipore, 
Billerica, MA).  Stained sections were analyzed using a Nikon Eclipse E400 
microscope, 10X objective and SPOT Imaging Software (Diagnostic Instruments, 
Sterling Heights, MI).  Positively stained cells were visualized and counted in a 10x 
relative field of view for each sample.   
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Micro-Computed Tomography (micro-CT) Analysis-  Dlx3+/- female mice mated with 
Dlx3+/- male mice were assigned to either the Tempol or water treated group.  
Treatments of groups were carried out as described above and animals were sacrificed 
at E12.5.  Pregnant Dlx3+/- females were prepped for imaging with a cardiac injection 
of micro-CT compound, Microfil (Flow Tech, Carver, MA), to fill placental 
vasculature and imaged as described previously 11.  The scans were performed using 
the GE CT120 micro-CT scanner (GE Heathcare, London, Ontario, Canada). For each 
dataset, 1200 projections were obtained at 0.3° intervals over 360° using 80keV, 
32ma, 100ms exposure time and 25µm x-y-z resolution. Prior to each scan, 10 bright-
field images were acquired with no objects in the field of view, providing a correction 
for detector non-uniformity. Proper placement of the subject will be done with the 
assistance of X-ray fluoroscopy to ensure that the entire specimen was included within 
the scanning field of view.  Each image dataset collected was transferred from the 
CT120 system to an image-processing workstation (HP xw8400 with 8 CPU cores and 
16GB RAM). The projection views were used to reconstruct a CT image using a 
convolution back-projection approach implemented in 3D, giving a 80×80×50 
mm3 volume of image data with .25µm isotropic voxels in analog-to-digital units.  
Analysis was carried out utilizing Microview software (GE Healthcare, Piscataway, 
NJ) measuring volumes of maternal blood spaces associated with the maternal 
contribution to the implantation site, maternal spiral artery, and overall branching 
number of maternal spiral arteries.  Volume measurements for maternal contribution 
to the implantation site and maternal spiral artery were calculated as previously 
described 11; maternal spiral artery branching numbers were observed and counted in 
3D rendered images in Microview software (GE Healthcare, Piscataway, NJ).  A 
branch point was defined as any deviation from the initial maternal artery vessel 
flowing from the uterine artery into the placental vasculature. 
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Assessment of Placental labyrinth, artery and vein area-  Dlx3+/- female mice mated 
with Dlx3+/- male mice were assigned to either the Tempol or water treated group.  
Treatments of groups were carried out as described above and animals were sacrificed 
at E12.5.  For these studies, placental tissues were fixed in 10% formalin and paraffin 
embedded.  Placental sections were cut at 10µm and stained with Masson’s Trichrome 
followed by staining with H&E.  Stained placental sections were imaged on Aperio 
Scanscope and images stored for later analysis.  Sections representing the widest 
portion of the placental disk were evaluated further.  The labyrinth compartment was 
easily discernable with H&E staining and the presence of nucleated fetal red blood 
cells.  Full placental area and the area of the labyrinth defined manually and 
quantitated using Aperio software.  Maternal arteries (n=12 or 13/treatment group) 
were identified as cross-sectional areas containing non-nucleated maternal red blood 
cells surrounded by a layer of smooth muscle.  Maternal veins (n=12 or 13/treatment 
group) were identified as vessels containing maternal red blood cells without 
associated smooth muscle.  The areas of these vessels were defined manually and 
quantitated using Aperio software.  Data are presented as relative measures of areas of 
the labyrinth, maternal arteries or maternal veins as a ratio of the total placental area. 
Statistical Analysis-  All data are expressed as means ± SE.  Comparisons were made 
by Student’s t-test or by Mann-Whitney U test, where appropriate.  A P value of <0.05 
was considered statistically significant; a P value of <0.1 was considered a trend.   
Results 
Mice with conditional epiblast-restricted deletion of the Dlx3 gene survive to  
weaning-  Our initial studies sought to examine the effects conditional deletion of 
Dlx3 within the epiblast to determine if embryonic loss of Dlx3 resulted in embryonic 
lethality consistent with the Dlx3-/- mouse model.   Surprisingly, Dlx3-/flox  x 
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Meox2CreSor animals survived to weaning and beyond albeit with substantial defects at 
several levels.  Dlx3-/flox  x Meox2CreSor mice were smaller at birth than gender matched 
littermate controls and clearly displayed abnormal hair growth (Figure 4.1A). The 
Dlx3-/flox  x Meox2CreSor females were observed as much smaller in stature than the 
male littermates. 
 Histological examination of numerous tissues revealed marked and predictable 
differences between the Dlx3-/flox  x Meox2CreSor animals and their littermate controls.  
Figure 4.1B depicts immature gonads of both the male and female Dlx3-/flox  x 
Meox2CreSor compared to the littermate controls.  Dlx3-/flox  x Meox2CreSor testis have 
fewer mature spermatozoa in the seminiferous tubules as well as a lower number of 
interstitial cells.  Dlx3-/flox  x Meox2CreSor ovaries contained primary and secondary 
follicles, but no preovulatory follicles or corpora lutea, as seen in the littermate 
control.  In the skin of the Dlx3-/flox  x Meox2CreSor mice, the epidermis was 
characterized by acanthosis (Figure 4.1B); scattered hair follicles are observed which 
contained normal hairs, but most hair follicles are mildly distended by the presence of 
amorphous keratin.  The structure and distribution of the hair follicles, as well as the 
percentage of follicles in each stage of the hair cycle, are comparable between the 
Dlx3-/flox  x Meox2CreSor mice and littermate controls.  In the Dlx3-/flox  x Meox2CreSor 
mice, both the enamel and dentin layers of the teeth were found to be irregular in 
thickness compared to littermate controls.  The pulp cavity in the Dlx3-/flox  x 
Meox2CreSor teeth is often narrowed and there are infiltrates of neutrophils and 
macrophages, along with areas of hemorrhage in the surrounding periodontal tissue 
and gingiva.  The ameloblasts are similar in both groups of mice, but the odontoblast 
layer is thinner and more disorganized in the Dlx3-/flox  x Meox2CreSor mice.  Altogether 
these results indicate the impact of loss of Dlx3 in the developing embryo was 
substantial in many tissue types that have been shown to express Dlx3 as part of a 
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developmental program.  Importantly, when Dlx3 deficient embryos develop in the 
presence of a Dlx3+/- placenta, the potential survival rate of that embryo increases 
dramatically.  This provides indirect evidence that the placental lesions within the 
Dlx3-/- embryo likely are the primary cause of embryonic lethality in this knockout 
model. 
 
Loss of one Dlx3 allele results in altered growth kinetics in the embryo-  Complete 
Dlx3 deletion in mice leads to midgestational embryonic lethality due to abnormal 
placentation 1,2.  This outcome hinders assessment of the role of Dlx3 later in 
pregnancy.  We sought to examine the impact of haploinsufficiency at the Dlx3 loci on 
fetal growth and placental viability during gestation.  Embryos from Dlx3+/- matings 
were genotyped and weighed at five different gestational time points, embryonic days 
(E) 9.5, 10.5, 12.5, 15.5, and 18.5 Figure 4.2 illustrates growth kinetics in the Dlx3+/- 
mouse embryo compared to the wildtype littermate controls.  Similar embryonic 
weights were observed at the E9.5 and E10.5 time points for the Dlx3+/- embryos and 
wildtype littermate controls.  However, at E12.5, Dlx3+/- fetal weight was reduced 
(p<0.05) compared to the controls.  By E15.5 the difference in weight between 
genotypes appeared to be less; and at E18.5, the fetal weights were indistinguishable 
between genotypes (data not shown).  These results indicate that haploinsufficiency at 
the Dlx3 loci may be involved in creating an intrauterine environment that is 
detrimental to normal patterns of fetal growth.  Interestingly, Dlx3+/- embryos appear  
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Figure 4.1. Dlx3 epiblast-conditional knockout survives to parturition with 
growth abnormalities. A. Dlx3-/flox  x Meox2CreSor female animals are considerable 
smaller in stature at 6 weeks of age and display visible abnormal hair growth patterns 
in contrast to wildtype gender matched control littermates.  Male Dlx3-/flox  x 
Meox2CreSor mice display a similar growth and hair pattern phenotype compared to 
littermate controls (Data not shown).  B. Hemotoxylin and Eosin (H&E) stained 
sections of gonads, bone and teeth from Dlx3-/flox  x Meox2CreSor animals indicate 
structural and developmental irregularities compared to wildtype littermate controls. 
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to compensate for this IUGR phenotype later in gestation via mechanisms that are 
currently unknown. 
 
Loss of one Dlx3 allele results in placental oxidative stress-  Placental tissues were 
collected from Dlx3+/- and wildtype animals at 3 different gestational time points 
E10.5, E12.5 and E15.5, around the time of altered fetal growth kinetics observed 
above.  Tissues were subjected to an OxyblotTM (Millipore, Billerica, MA) and 
investigated for increased carbonyl side chains in protein.  Protein carbonyl groups are 
a direct result of oxidative reactions with ozone or oxides of nitrogen or by metal 
catalyzed oxidation thereby serving as a marker of oxidative stress.  Figure 4.3 reveals 
an increased overall abundance of protein carbonyl modifications in the Dlx3+/- mouse 
placentas compared to wildtype controls.  Additionally, the degree of oxidative stress 
increased to a higher degree throughout gestation in the Dlx3+/- placentas.  Increased 
accumulation of protein carbonyl groups observed at E12.5 in the Dlx3+/- placentas 
correlates with the IUGR phenotype at the same gestational time point (Figure 4.2).   
 
Antioxidant therapy prior to and during gestation rescues the IUGR Dlx3+/- 
phenotype-  Studies described above suggest increase oxidative stress in the Dlx3+/- 
placenta correlated with the IUGR phenotype.  Based on this correlation, we sought to 
examine the effects of antioxidant therapy on fetal and placental well-being in the 
Dlx3+/- mouse.  The superoxide disumutase mimetic, C9H18NO2-4-hydroxy 
tetramethylpiperidinyloxyl (Tempol) has been used as an antioxidant in many 
experimental settings including the prevention of symptoms of neurodegenerative 
disease in IRP2 knockout mice 12, reducing renal dysfunction and injury associated 
with ischemia in the kidney 13, and most significant to our studies, oral administration 
of Tempol normalized embryo birth weights and placental development in the BPH/5  
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Figure 4.2. Dlx3+/- matings reveal a potential intrauterine growth (IUGR) 
phenotype. Dlx3 heterozygous (Dlx3+/-) animals were mated and sacrificed at four 
different gestations ages, E9.5, E10.5, E12.5, E15.5 (n≥4/timepoint).  Dlx3+/- and +/+ 
embryos display similar growth patterns at E9.5 and E10.5.  By E12.5 Dlx3+/- embryos 
weights (mg) are significantly less (p<0.05) than Dlx3+/+ littermates and the same 
growth pattern is maintained at E15.5.
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Figure 4.3. Oxyblot indicates increased relative abundance of protein carbonyl 
groups in Dlx3+/- placentas throughout gestation.  Wildtype (Dlx3+/+) and Dlx3 
heterozygous (Dlx3+/-) placentas were harvested at 3 different gestational time points, 
E10.5, E12.5, and E15.5.  Placental tissues were subjected to an Oxyblot assay to 
determine the abundance of protein carbonyl side chains which are indicative of 
oxidative stress.  Dlx3+/- placental tissues reveal an increased abundance of protein 
carbonyl groups throughout gestation in contrast to Dlx3+/+ (n=3/genotype and 
timepoint).  Actin was used as a lane loading control. 
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mouse model of preeclampsia 14.  Based on these findings, we chose to examine the 
potential effects of Tempol administration in our Dlx3+/- mouse model.  Beginning 5 
days prior to mating and throughout gestation, Dlx3+/- females (mated to Dlx3+/- 
males) received Tempol in their drinking water; control animals received water.  
Tempol was routinely accepted and well-tolerated by these animals with no evidence 
of dehydration seen in these animals during the experimental period.  Based upon 
these timed matings, animals were sacrificed at E12.5 and embryos and placental disks 
removed for analysis (Figure 4.4A-C).  Consistent with our initial studies, Dlx3+/- 
fetuses had reduced fetal weight and crown rump measurements (p<0.05) compared to 
wildtype littermates.  The addition of Tempol in the drinking water effectively rescued 
this IUGR phenotype.  Surprisingly, oral administration of Tempol revealed a subset 
of small but viable Dlx-/- animals at E12.5, fully 3 days beyond the normal timing of 
fetal demise of these animals (Figure 4.4A) 2.  These initial results using Tempol 
indicate the potential benefits of antioxidant therapy in rescuing the IUGR phenotype 
associated with a single allelic loss of Dlx3.  
These studies supported the hypothesis that fetal growth retardation in this 
model was a result of oxidative stress. To examine this hypothesis further, we 
examined ROS abundance and apoptosis within the placentas from our Tempol study. 
ROS abundance in Dlx3+/+and Dlx3+/- placental sections from both treatment groups 
was assessed by staining these sections with superoxide probe, DHE.  Our results 
reveal an increase (p<0.05) in the abundance of DHE stain observed in placental 
sections comparing Dlx3+/+ with Dlx3-/- receiving water, again correlated with the 
IUGR phenotype (Figure 4.5A).   The elevated level of ROS detected by this method 
in the Dlx3+/- placentas was rescued by administration of Tempol.  Tempol 
administration did not appear to reduce DHE staining in Dlx3+/+ placentas.  Similar 
results were obtained using TUNEL staining to detect apoptotic cells (Figure 4.5B).   
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Figure 4.4. Antioxidant therapy rescues the IUGR phenotype in Dlx3+/- mice. 
Dlx3 heterozygous (Dlx3+/-) females were pretreated with the superoxide dismutase 
mimetic, Tempol (2mM), in their drinking water five days prior to mating with Dlx3+/- 
males and continue throughout gestation.  Control Dlx3+/- were given control drinking 
water before mating and during gestation.  All animals were sacrificed at E12.5.  A. 
No gross morphological differences other than size were noted for the E12.5 Dlx3+/+ 
and +/- embryos (n≥10/genotype and treatment) between the control group (top row) 
and Tempol treated group (bottom row).   Tempol administration did reveal a subset of 
Dlx3-/- embryos at E12.5.  B.  Fetal weights (mg) indicate an IUGR phenotype with 
single allelic loss of Dlx3 in the water group (p<0.05).  Tempol supplementation 
ameliorates the IUGR phenotype in the Dlx3+/- animal.  No significant changes in fetal 
weight are observed in the Dlx3+/+ mouse despite antioxidant therapy.  C.  Embryo 
crown-rump measurements (mm) correlate with the IUGR phenotype displayed in the 
Dlx3+/- animals indicating decreased (p<0.05) embryo length measurements with loss 
of one Dlx3 allele.  Chronic Tempol administration increased (p<0.05) crown rump 
measurements in Dlx3+/- embryos.  No significant alterations were found in Dlx3+/+ 
animals with antioxidant therapy.   
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Increased TUNEL positive cells were detected (p<0.05) in the Dlx3+/- placentas 
compared to Dlx3+/+ animals receiving water.  This effect was again reversed in the 
Dlx3+/- animals receiving Tempol.  Addition of Tempol also reduced the number of 
apoptotic cells in placentas from Dlx3+/+ animals.  These results support the 
conclusion that loss of a single Dlx3 allele results in increased placental ROS 
accumulation and apoptosis, correlated with the IUGR phenotype.  These measures of 
oxidative stress were effectively reversed by antioxidant treatment. 
 
Loss of one Dlx3 allele results in vascular dysfunction within the placenta- One 
potential cause of oxidative stress within the developing placenta is altered 
vascularization and placental perfusion.  For example, in the BPH/5 mouse model of 
preeclampsia, maternal hypertension was associated with increased placental ROS 
accumulation, reduced fetal weights and defects in maternal spiral artery remodeling 
9,14,15.  We initially examined circulating concentration VEGF in maternal serum 
collected from Dlx3+/- and wildtype mice at E12.5.  Figure 4.6 depicts decreased 
(p<0.05) circulating VEGF in maternal serum in Dlx3+/- animal compared to wildtype 
control.  These findings suggest a shift in angiogenic potential in Dlx3+/- mice may be 
effecting vascularization of the mouse placenta. 
To examine this possibility, we took two approaches; 1) assessment of 
maternal placental vasculature using microCT imaging; and 2) assessment of maternal 
vascular volume using standard histological techniques augmented by the use of an 
Aperio Scanscope.   To examine placental vascularization using micro-CT imaging, 
we injected a micro-CT compound, Microfil (Flow Tech, Carver, MA) into pregnant 
Dlx3+/+ and Dlx3+/- mice at E12.5.  Further, to investigate the potential role of ROS 
stress on placental vascularization, we included our Tempol administration paradigm 
as outlined above.  Gravid uteri were harvested, injected with Mircofil and subjected  
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Figure 4.5. Chronic Tempol administration ameliorates ROS insult.  A.  A single 
loss of a Dlx3 allele resulted in significant (p<0.05) ROS accumulation in placental 
tissue as measured by dihydroethidum (DHE) stain.  Antioxidant therapy with Tempol 
effectively resolved (p<0.05) ROS abundance in the Dlx3+/- placenta.  No significant 
difference was noted in the Dlx3+/+ placentas with chronic Tempol supplementation.  
(n=6-8/genotype/treatment)  B.  Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) indicated an abundance of TUNEL positive cells in the placentas 
lacking one Dlx3 allele compared to littermate controls.   Tempol administration 
resulted in significantly less (p<0.05) TUNEL positive cells in the Dlx3+/+ and Dlx3+/- 
placentas.  (n=6/genotype/treatment) 
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Figure 4.6. Vascular endothelial growth factor (VEGF) is misregulated in the 
maternal serum of Dlx3+/- mice.  Loss of a single Dlx3 allele resulted in lower 
(p<0.05) maternal serum concentrations of VEGF compared to Dlx3+/+ mothers.  
VEGF was measured by a commercially available ELISA.  
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to micro-CT analysis.  Rendered images of placental vasculature were obtained and 
volume measurements were assessed using Microview (GE Healthcare, Piscataway, 
NJ) software.  Results revealed significant insights into Tempol antioxidant therapy 
effects on placental vasculature.  First, the volume of total placental Microfil tended 
(P<0.1) to be lower in Dlx3+/- mice compared to Dlx3+/+ animals treated with water.  
Further, administration of Tempol to the Dlx3+/- mice increased (p<0.05) total microfil 
volume; however, this same increase did not appear to be evident in the Dlx3+/+ mice 
(Figure 4.7A).  These differences were paralleled in the specific Microfil volume 
measurements associated with maternal spiral arteries (Figure 4.7B).  Maternal spiral 
artery branch points did not differ remarkably among treatments (Figure 4.7C).  It is 
important to note that these micro-CT imaging studies are considered preliminary at 
present since the sample size for the Dlx3+/+ mice is limited to four placentas in each 
treatment group.  We continue to collect and analyze these data as this project moves 
forward.  
In parallel, we used more traditional histological assessment of vascular 
parameters in these tissues using Masson’s trichrome staining (Figure 4.8).  
Identification of discrete compartments within the mouse placenta was discernable 
with H&E staining in these sections.  Initially, we quantitated total placental and 
labyrinth area in the Dlx3+/+ and Dlx3+/- mice receiving water or Tempol.  The 
proportion of labyrinth area (as a percent of total placental area) was not affected by 
genotype or antioxidant treatment (Figure 4.8A).  In contrast, maternal spiral artery 
cross-sectional area (as a percentage of total placental area) was reduced (p<0.05) in 
the Dlx3+/- mice compared to Dlx3+/+ mice receiving water (Figure 4.8B).  Addition of 
Tempol tended (p<0.1) to increase maternal spiral artery cross-sectional area in both 
genotypes.  Cross-sectional area of maternal veins within these placentas were 
unaffected by genotype or antioxidant treatment in this study (Figure 4.8C).    These  
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Figure 4.7. Micro-CT analysis indicates alterations in placental vascularization of 
the Dlx3+/- mouse model.  A.  Quantitation of placental microfil volume following 
microCT imaging indicates a trend (p<0.1) in decreased placental vascular volume 
with a single loss of a Dlx3 allele.  Chronic antioxidant supplementation resulted in 
resolution of the placental vascular volume in Dlx3+/- mice (p<0.05).  No significant 
change was observed in Dlx3+/+ placental volumes with antioxidant administration.  B.  
Volumetric measurements of the maternal spiral arteries indicate a tendency toward 
reduction (p<0.1) in total volume in the Dlx3+/- placentas compared with Dlx3+/+ 
placentas.  Antioxidant administration eliminates this difference (p<0.05) in maternal 
spiral artery volumes across Dlx3 genotypes.  No statistical difference was detected 
for maternal spiral artery volume measurements between treatment groups for the 
Dlx3+/+ placentas.  C.  Maternal spiral artery branch points in Dlx3+/+ and Dlx3+/- 
placentas were not different across genotype and antioxidant treatment.   
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Studies support the preliminary conclusion that loss of one Dlx3 allele clearly impacts 
maternal VEGF serum concentrations and this is correlated with alterations in 
maternal spiral artery volume as measured by micro-CT imaging and histological 
analysis.  These data support our working hypothesis that these changes in placental 
vasculature may underlie mechanisms regulating the ability of the Dlx3+/- placenta to 
manage oxidative stress during gestation leading to IURG in this model.  We continue 
to expand our histological analyses to include a number of new vascular markers to 
assess (for example) smooth muscle actin and expand our timeframe to beyond E12.5 
to better assess maternal spiral artery remodeling.  
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Figure 4.8. Loss of a single Dlx3 allele results in a reduction in cross-sectional 
area in maternal arteries.  Standard histological analysis using Masson’s trichrome 
and H&E staining was used to examine placental labyrinth and vasculature.  A.  Total 
placental labyrinth area was not different between in the wildtype (Dlx3+/+) and Dlx3 
heterozygous (Dlx3+/-) with and without chronic antioxidant supplementation.  B.  
Measurements of the total placental artery area indicated a decrease (p<0.05) in the 
Dlx3+/- placenta compared to Dlx3+/+.  Chronic supplementation of antioxidant during 
gestation increased the arterial area in both Dlx3+/- and Dlx3+/+ placentas.  C.  
Calculations of total placental venous area indicate no statistical difference between 
Dlx3+/- and Dlx3+/+ placentas.  Administration of antioxidant demonstrates no change 
in placental venous area in the Dlx3 mouse model.   
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Discussion 
 The role of Dlx3 in the developing placenta has a clear impact on not only fetal 
fitness 2, but also suitable placentation necessary for proper blood flow and nutrient 
exchange 1.  Our studies indicate conditional loss of Dlx3 in the epiblast of the 
developing embryo does not affect the ability of Dlx3-/flox  x Meox2CreSor to be born 
(Figure 4.1A).  Closer examination of histological sections of several Dlx3-/flox  x 
Meox2CreSor embryonic tissues including gonads, skin, and teeth, suggest abnormal 
patterns of growth and development compared to wildtype littermate controls (Figure 
4.1B).  More specifically, both male and female Dlx3-/flox  x Meox2CreSor mice display 
immature gonadal structure, acanthosis of the epidermis, and irregular enamel and 
dental layers in tooth structure.  However, there are important limitations to this study 
that need to be carefully considered.  Unlike the Dlx3-/- animal, Meox2CreSor animals 
do not display epiblast-specific Cre expression until ~ embryonic day (E) 6.0.  Thus, 
key developmental events associated with Dlx3 expression may have occurred prior to 
gene excision in the embryo.  Additionally, Cre expression in Meox2CreSor animals has 
been largely characterized as a mosaic, limiting the probability of Dlx3 excision in 
every cell within the epiblast.   The frequency of Dlx3 excision within the epiblast is 
increased in our studies based on the use of one floxed allele and one null allele. 
Despite these caveats, the Dlx3-/flox  x Meox2CreSor embryos display a predictable 
phenotype in hair, skin and teeth as have been previously described in patients with 
tricho-dento-osseus syndrome and during mouse development in many tissues that are 
known to express Dlx3 2.  More importantly, these studies indicate the midgestational 
embryonic lethality associated with Dlx3-/- mice may be associated with a maternal 
Dlx3 placental lesion despite defects within the embryo proper.  
This cohort of studies implies loss of one Dlx3 allele results in problems 
associated with fetal fitness and placental disruptions.  Analysis of Dlx3 heterozygous 
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(Dlx3+/-) embryos from matings between Dlx3+/- male and females mice resulted in 
altered growth kinetics in contrast to wildtype littermate controls (Figure 4.2).  
Specifically, at E12.5 Dlx3+/- embryos lag behind in embryonic weight gain compared 
to controls.  By E15.5 there is a decreased difference between embryonic weights of 
Dlx3+/- and wildtype littermate controls.  By E18.5, fetal weight is similar between the 
two genotypes (Data not shown).   In accord with these findings, assessment of Dlx3+/- 
placentas revealed an increase in protein carbonyl groups at E12.5, in contrast to 
wildtype placental controls (Figure 4.3).  Additional assessment of Dlx3+/- placentas 
found a statistically significant (p<0.05) increase in reactive oxygen species (ROS) 
(Figure 4.5A) and apoptotic cell types (Figure 4.5B), as measured by DHE and 
TUNEL assays, respectively.  Analysis of Dlx3+/-maternal serum revealed decreased 
(p<0.05) concentrations of a potent placental angiogenic factor, vascular endothelial 
growth factor (VEGF), in contrast to controls.   Together these findings imply reactive 
oxygen species stress within the Dlx3+/- placental development may have implications 
on placental cell types, placental angiogenic factors, and a potential direct correlation 
to embryo growth kinetics.   
Further investigation of Dlx3+/- placental vasculature using micro-CT analysis 
revealed loss of a single Dlx3 allele resulted in trends (p<0.1) toward decreased 
maternal spiral arteries volume (Figure 4.7B) in contrast to control placental 
vasculature.  In corroboration with these findings, Masson’s Trichrome staining 
revealed a decrease placental maternal artery area (p<0.05) in Dlx3+/- placentas 
compared to wildtype controls (Figure 4.8B).  Chronic administration of the 
superoxide dismutase mimetic Tempol, ameliorates the observed adverse effects in the 
Dlx3+/- mouse including altered embryonic growth kinetics (Figure 4.4A-C), 
abundance of ROS (Figure 4.5A), abundance of apoptotic cell types (Figure 4.5B), 
and decreased placental and maternal spiral artery volumes (Figure 4.7A, B).  
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Importantly, antioxidant therapy rescued a subset of Dlx3-/- embryos at E12.5, 3 days 
beyond their normal fetal demise 2.  The statistical trends observed in both the micro-
CT analysis and the Masson’s Trichrome staining are currently representations of 
preliminary evidence.  Further studies are necessary to add to the statistical relevance 
of each data set.  However even at this preliminary stage of data collection, these data 
indicate Dlx3+/- mice are sensitive to ROS stresses resulting in detrimental structural 
implications in the Dlx3+/- placenta and ultimately altered fetal growth kinetics.  
Moreover antioxidant therapy in the Dlx3 mouse has the ability to rescue the placental 
and embryonic phenotypes found in the Dlx3+/-. 
The Dlx3 mouse is not the only model of altered embryo growth kinetics and 
abnormal placentation.    The BPH/5 mouse model of preeclampsia also displays an 
intrauterine growth retardation (IUGR) phenotype and placental insufficiency.  More 
specifically, neonatal weights of BPH/5 embryos are significantly less than that of 
control mice 15; as early as E10.5, BPH/5 decidual vessels have narrowed lumens and 
a thickened arterial wall; by E12.5 BPH/5 placental labyrinth exhibits decreased 
vascularization compared to controls 9.  Moreover, BPH/5 and Dlx3+/- placentas 
indicate a similar susceptibility to ROS accumulation.  Similar to the Dlx3 mouse 
model, antioxidant therapy normalizes ROS levels in the BPH/5 placenta and 
increases fetal growth and survival rates 14.  However, antioxidant therapy in the 
BPH/5 model does not reveal the same extent of IUGR rescue as indicated by our 
studies in the Dlx3 mouse model, suggesting some portion of variable phenotype in 
these models as gestation progresses. 
The condition of pregnancy is deemed to be a state of oxidative stress arising from 
increased metabolic activity in placental mitochondria and reduced ROS scavenging 
potential by antioxidants 16.  Measurements of markers of oxidative stress in maternal 
blood and urine show that pregnancy is a condition of high oxidative stress due to the 
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high metabolic activity of the placenta and maternal metabolism17.  This condition is 
exacerbated in pregnancies complicated by preeclampsia, intrauterine growth 
restriction (IUGR), and diabetes as measured by increased markers of ROS and a 
decrease in antioxidant defense mechanisms 18.  For example, immunostaining of 
placental vascular endothelium revealed an increase in ROS production in pregnancies 
complicated by preeclampsia compared to control pregnancies 19.  Although an exact 
mechanism of increased placental ROS generation associated with preeclampsia has 
not been elucidated, one particular hypothesis arises from the placental vasculature 
associated with preeclampsia.  Pregnancies complicated by preeclampsia exhibit a 
failed remodeling of maternal spiral arteries 20 resulting in impaired placental 
perfusion leading to potential harmful effects on fetal growth kinetics 21.   
A mounting body of evidence points to a disrupted secretion and/or sequestering 
of proangiogenic growth factors, such as VEGF and placental growth factor (PGF), in 
abnormal placentation such as observed in preeclampsia.  VEGF is an endothelial-
specific mitogen that promotes angiogenesis.  The activities of VEGF are primarily 
mediated by two high-affinity cell surface receptor tyrosine kinases:  kinase insert 
domain region (KDR) and fms-like tyrosine kindase-1 22,23.  Soluble fms-like tyrosine 
kindase-1 (sFlt-1) is a naturally occurring antagonist of both VEGF and PGF, which is 
formed by alternative splicing of the pre-mRNA encoding VEGF-R1 (Flt-1).  sFlt-1 
lacks both the cytoplasmic and transmembrane domain and can bind to both 
circulating VEGF and PGF preventing interactions with endogenous receptors.  
Increased expression of sFlt-1 has been found in both the maternal serum 23 and 
placenta 24 of preeclamptic patients implicating altered expression of placental growth 
factors may one cause of impaired placentation observed in preeclampsia.  The BPH/5 
mouse model of preeclampsia also shows abnormal secretion of angiogenic factors 
such as VEGF and PGF, in addition to abnormal placental endothelial cell 
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morphology, as mentioned above 14.  Our studies indicate a similar disruption in 
relative VEGF concentration in maternal serum of Dlx3+/- animals compared to 
controls (Figure 4.6).  This current set of studies supports previous findings indicating 
altered vasculature in the Dlx3+/- placentas 1.  Together these studies indicate altered 
placental angiogenic secretion may correlate with abnormal placental vasculature.   
Antioxidants represent a potentially powerful defense from the onslaught of 
ROS-mediated placental effects.  Antioxidant therapy has been used as a way to 
combat ROS assault on placental vasculature.  Results from studies of 
supplementation of vitamin C and E during the second trimester of pregnancy 
decreased the biochemical incidence of ROS 25.  Further, gestational supplementation 
of vitamins C and E indicate a significant reduction in syncytiotrophoblast apoptosis 
associated with placental hypoxia-reoxygenation 26.  Recent evidence points to a 
critical gestational time frame for antioxidant therapy to effectively treat ROS stress in 
the placenta.  Myatt and colleagues have indicated antioxidant therapy is most 
effective when administered before conception and during early gestation 18.  The 
placenta is in a dynamic state of growth and differentiation throughout gestation with 
development of the placental vasculature and fetal development occurring in a highly 
regulated manner.  Stressors, particularly from ROS, to the placental at these key 
growth periods may impact placental development and augment the fetal growth 
trajectory.  Our studies corroborate previous findings in the BPH/5 mouse model, 
indicating administration of antioxidant therapy prior to and during presumptively 
critical periods of placental establishment and growth has positive outcomes.  Chronic 
supplementation of Tempol not only ameliorated the observed IUGR phentoype in the 
Dlx3+/- mouse model (Figure 4.4A-C), but also normalized placental ROS levels 
(Figure 4.5A, B) and vascularization defects (Figure 4.7A, B).  Altogether, these 
studies add to the beneficial theory of gestational antioxidant therapy.    
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 Proper placental perfusion is critical for fetal growth and development.  
Impaired placental angiogenic function in combination with placental endothelial cell 
dysfunction leads to placental insufficiency as observed in both the BPH/5 and Dlx3+/- 
mouse models.  Both models indicate an impaired fetal growth curve that maybe a 
direct repercussion of ROS mediated effects resulting in placental insufficiency.  Our 
studies clearly point to the possible benefits of antioxidant therapy on not only 
placental development but also fetal fitness throughout gestation.   
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CHAPTER FIVE 
 
SUMMARY AND DISCUSSION 
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The placenta of a developing fetus has several roles including an immune 
interface between mother and fetus, serving to transport nutrients and waste products, 
and serving as a source of many peptide and steroid hormones that influence fetal, 
placental and maternal metabolism and development.  The mammalian placenta is in a 
dynamic state of growth and differentiation throughout gestation; specifically human 
placentas show a 40-fold increase in fetal/placental weight ratio (a measure of 
placental efficiency) from weeks 6 to term.  This increased placental efficiency is 
achieved by both a 10-fold increase in the villous volume occupied by vasculature and 
an increase in trophoblast surface area from 0.08 to 12.5m2 and a decrease in mean 
trophoblast thickness from 18.9 to 4.1µm ultimately resulting in a decreased fetal-
maternal diffusion distance from 55.9 to 4.8µm 1. 
Each physical placental change is connected to highly organized growth phases 
involving branching events linked to angiogenesis, trophoblast differentiation, and 
syncytium formation; each step is governed by a complex gene profile carefully 
coordinated with placental specific angiogenic factors.  Disruption in the normal 
pattern of placental development will lead to altered placental function.  More 
specifically, the timing of these alterations during gestation and the extent of the 
disruption may cause critical implications on placental function leading to pregnancy 
complications.   
My central hypothesis implicates the necessity of the homeodomain-containing 
transcription factor, Distal-less (Dlx) 3, along with its gene profile, in proper murine 
placental development.  Initial studies of the Dlx3 mouse model have indicated a mid-
gestational lethality associated with complete loss of Dlx3 2.  Further studies have 
linked placental insufficiency in the Dlx3 mouse to the early fetal demise 3.  In the 
developing primate placenta, Dlx3 has been shown to activate the α subunit of the 
glycoprotein hormone gene by binding to the junctional regulatory elements found in 
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the promoter region 4.   Activation of the glycoprotein hormone a subunit gene is 
necessary for expression of chorionic gonadotropin (CG) in the placental, effectively 
resulting in early maintenance of pregnancy.  Loss of Dlx3 in choriocarcinoma cells 
results in decreased expression of the α subunit.  Immunostaining of human placental 
section obtained from 8 weeks gestation implicate the expression of Dlx3 in human 
cyto- and syncytiotrophoblasts at the time of peak CG production 5.  These studies 
support the theory that Dlx3 is involved in the molecular regulation of CG 
biosynthesis, indicating the novel role of Dlx3 in maintenance of early pregnancy.   
Investigation of molecular interacting partners of Dlx3 in a human placental 
cDNA library identified Smad6 as a binding partner through yeast two-hybrid analysis 
(Chapter 2) 3.  Smad proteins are a group of transcriptional regulators that are 
categorized into 3 subclasses: receptor-regulated Smads (R), common Smads (C), and 
inhibitory Smads (I).   The R-Smads acquire signals through two distinct pathways.  
Smad 1, 5, and 8 are regulated through the bone morphogenic pathway (BMP), while 
Smads 2 and 3 obtain signals through the transforming growth factor-β (TGF-β) 
pathway.  Both BMP and TGF-β activate the Smad pathway by interacting and 
phosphorylating specific R-Smads.  Phosphorylation of the R-Smads causes 
dissociation from the receptor and induces assembly of a complex with Smad4, a C-
Smad.  This heterodimeric complex then translocates to the nucleus and functions as a 
transcriptional comodulator by recruiting various coactivators and corepressors to the 
Smad DNA binding machinery 6.  The I-Smads, Smad6 and 7, function as potent 
antagonists by binding to either TGF-β or BMP receptors and blocking the 
phosphorylation of R-Smads or, in the case of Smad6, by binding to the 
phosphorylated Smad1 and preventing the formation of a complex with Smad4 7.  
Transcription of the I-Smads is stimulated by not only TGF-β family members 8 
indicating a possible negative feedback mechanism, but also epidermal growth factor 
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(EGF), phorbol ester -12-O-tetradecanoylphorbol 13-acetate (TPA), and interferon-γ 9.  
The findings imply the signaling governing Smad6, such as BMP and TGF-β, may 
also indirectly effect Dlx3 expression. 
Further immunostaining of trophoblast cells indentified Smad6 and Dlx3 co-
localized to the nuclear compartment 3.  Similarly, in human term placenta, Smad6 and 
Dlx3 were nuclear localized in both the cytotrophoblast and syncytial trophoblast cells 
within the microvilli 3.  This observation demonstrates that the interaction of Smad6 
and Dlx3 is not restricted to a temporal pattern in gestation; Dlx3 expression can be 
maintained within the trophoblast population until term in the human placenta.  The 
co-nuclear localization of Dlx3 and Smad6 implies Smad6 has the capability of 
modulating Dlx3 transcriptional expression in the placenta.  For example, Smad6 
disrupts the Dlx3-dependent gene expression of the placental specific promoter, 
Extraembryonic, spermatogenesis, homeobox-1 like protein (Esx-1) promoter 
(Chapter 2) 3.  The interaction between Dlx3 and Smad6 may play a role in the 
abnormal placental phenotype observed in the Dlx3 mouse model 3. 
Further assessment of the Dlx3 gene profile was investigated by conducting an 
Affymetrix microarray using RNA from E9.5 wildtype and Dlx3-/- placentas 10.  
Results identified 401 genes that were differentially expressed following the loss of 
Dlx3, including expression of matrix metalloproteinase (MMP-) 9, an extracellular 
matrix (ECM) remodeler.  Microarray analysis and subsequent q-PCR revealed loss of 
Dlx3 at E9.5 in the Dlx3-/- mouse placenta resulted in decreased expression of MMP-9 
10.  MMP-9 is part of a larger family of MMPs.  These molecules are mainly involved 
in extracellular matrix degradation (ECM).  Necessary for my studies are the essential 
role MMPs play in placental remodeling.  Degradation of ECM is critical to remodel 
the maternal vascular network from high resistance, low capacity structures to low 
resistance, high capacity vessels necessary for appropriate placental perfusion 11.  The 
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link between aberrant Dlx3 expression and MMP-9 transcript levels, as well as the 
placental abnormalities identified in the Dlx3 mouse, indicate the potential association 
of MMP-9 in the gene profile associated with the Dlx3 mouse model. 
 My studies indicate Dlx3 is capable of binding to the MMP-9 mouse and 
human promoters, as indicated by EMSA and ChIP assays, respectively.  Further 
characterization indicates a Dlx3 dose dependent transcriptional activation on the 
murine MMP-9 gene promoter.  Additional experiments linked loss of Dlx3, either by 
si-RNA knockdown in choriocarcinoma cells, or genetic loss as in Dlx3-/- placentas, to 
a significant decrease in MMP-9 activity as measured by zymography.  Moreover, the 
misregulation throughout gestation, of both MMP-9 and Dlx3 transcript levels, in the 
BPH/5 mouse model of preeclampsia indicate a potential interplay between these two 
molecules underlying the abnormal placental phenotype observed in this mouse model 
12. 
Abnormal placentation is not the only phenotype associated with preeclampsia.  
Numerous studies have found that preeclampsia also is associated with uteroplacental 
vascular insufficiency, altered intervillous hemodynamics, oxidative stress, anti-
angiogenic molecules and generalized maternal endothelial cell dysfunction 13. 
However, the exact cause(s) of the disease is still unknown.  Unfortunately, the 
disease state cannot be detected until it presents as maternal symptoms in late 
gestation.  Finding a potential biomarker for early detection of preeclampsia in the 
placental transcriptome would be beneficial and could possibly lead to the 
development of novel treatments.   
Many studies have focused on angiogenic factors as potential biomarkers of 
preeclampsia.  For example, a nested case-control study investigated the association 
between fms-like tyrosine kinase 1 (sFlt1), endoglin (ENG) and placental growth 
factor (PGF) and preeclampsia.  ELISA measurements indicated sFlt1 levels remained 
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unchanged between control and pregnancies complicated by preeclampsia.  However, 
ENG levels were higher (p<0.001) and PGF levels were lower (p<0.001) in 
pregnancies complicated by preeclampsia compared to controls 14.  Yet, this study 
does not correlate with other recent data that indicates sFlt1 levels are increased in 
preeclamptic patients compared to control 15.  The reason for such discrepancies may 
have to do with maternal factors including gestational age, diet, parity.  Regardless of 
the reason for the inconsistency, the conflicting reports in the literature only 
demonstrate the necessity of a reliable biomarker for preeclampsia.   
Recent findings have focused on microRNA’s (miRNAs), a family of small 
non-coding regulatory RNAs involved in human development and pathology, as 
effective biomarkers of human disease.  miRNAs have a critical role in 
posttranscriptional regulation of protein-coding genes and are present in bodily fluids 
making them easily accessible for identification.  Serum miRNA profiles have already 
been shown to change during physiological or pathological conditions as in 
pregnancy; moreover, these alterations in miRNA profiles correlate to pregnancy stage 
16.   Further, studies have characterized increased expression of specific placental 
miRNAs in pregnancies complicated by preeclampsia in contrast to controls 17.  Future 
studies should seek to examine the shared miRNA profile of the Dlx3 mouse model 
and other models of placental insufficiency, such as the BPH/5 mouse model.  These 
approaches would ultimately yield more precise information about the miRNA 
determinants found in abnormal placentation and result in a useful biomarker for 
placental insufficiency. 
 Important lessons are still to be learned from the Dlx3-/- placental microarray 
study.  As mentioned above, loss of Dlx3 resulted in the differential gene expression 
of 401 genes 10 indicating numerous direct and indirect Dlx3 interacting partners.  
Future studies should investigate the definitive relationship between Dlx3 and other 
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highly differentially expressed genes and their collective correlation to placental 
insufficiency. 
 A deeper investigation of the Dlx3 mouse model placental vasculature is 
necessary for complete understanding the effect Dlx3 haploinsufficiency has on the 
developing placenta.  Initial investigation of the Dlx3 mouse model using micro-
computed tomography (micro-CT) revealed abnormal placental vascularization in the 
Dlx3+/- mouse.  More specifically, Dlx3+/- placental and maternal spiral artery volumes 
tended an observed decrease (p<0.01) compared to wildtype controls.  As discussed in 
Chapter 4, these studies only represent preliminary evidence.  The volumetric 
measurements should be repeated on the Dlx3 mouse model for a better statistical 
representation of the data.   
Antioxidant therapy using the superoxide dismutase (SOD) mimetic 
ameliorated the observed placental and IUGR phenotype found in the Dlx3 mouse 
model.  These findings indicate the potential benefits of antioxidant therapy in cases of 
placental insufficiency.   
Additionally, future studies should use the refined spacial imaging resolution 
associated with 2-photon excited microscopy (2-PE).  Initial studies I undertook using 
a GFP-transgenic mouse model under the transcriptional control of a fetal endothelial 
cell promoter (Tie-2) resulted in marvelous images of the placental vasculature using 
2-PE.  However, numerous obstacles do exist for this imaging technique.   The 
vasculature of the placenta is a very complex network of fetal and maternal blood 
vessels in the murine labyrinth layer 18.  Studies have indicated the labyrinth layer in 
the Dlx3 mouse model exhibits a restricted growth pattern in contrast to wildtype 
controls 3 thereby identifying the labyrinth layer as potential instrumental factor 
underlying the observed IUGR phenotype.  Thus for the purposes of my studies, I will 
require a labeling tool to define fetal and maternal contributions to the labyrinth.   I 
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originally designed a congenic animal mating the Dlx3+/- x Tie-2 GFP mouse for the 
purposes of visualizing the fetal vasculature without exogenous addition of a 
fluororphore.   Maternal vasculature was to be labeled with addition of a designated 
fluorophore so subsequent imaging would allow assessment of both fetal and maternal 
vasculature in the mouse placenta.  Limitations on imaging capabilities restricted the 
progress of this project.  Currently those limitations are being resolved and future 
studies should take advantage of this congenic Dlx3+/- x Tie-2 GFP mouse model.  
Further investigation using 2-PE of Dlx3 placental vasculature in conjunction with 
gestational antioxidant therapy will expand on these initial studies.  Potential future 
findings will broaden our understanding of the placental insufficiency exhibited in this 
mouse model and the effect of antioxidant therapy on placental vasculature.   
 Dlx3 has multiple mechanisms of control in the placental as described in this 
dissertation.  In some instances, the impact of Dlx3 on placental function may be 
dependent on its interacting partners.  For example, Smad6 down-regulates Dlx3-
mediated transcription of the important placental angiogenic factor PGF in JEG3 cells 
10.  Additionally, the combined effects of Dlx3 and its interacting partners can have 
implications on a variety of placental functions including hormone production, 
vascular remodeling, and angiogenesis.  Alterations in the interplay of Dlx3 and its 
interacting partners may have detrimental effects leading to ROS-mediated placental 
insufficiency, IUGR, or preeclampsia.  Future studies should examine not only the 
singular role of Dlx3 in the placenta, but also the combined effects of Dlx3 and its 
interacting partners. 
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